Tobacco use: All cancers

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**20037**	**5998**	**30.7**	**3178**	**53.0**	**1617**	**50.9**	**726**	**4.2**	**509**	**3.0**	**242**	**1.4**	**1623**	**9.3**
	Age at baseline	18-19	2152	353	17.1	223	63.2	80	35.9	62	3.2	46	2.4	17	0.9	90	4.7
		20-24	6024	1533	26.3	918	59.9	486	52.9	252	4.8	142	2.8	86	1.7	474	9.0
		25-29	5571	1734	31.8	928	53.5	496	53.4	217	4.5	148	3.2	68	1.5	512	10.6
		30-34	3885	1441	37.6	700	48.6	341	48.7	137	4.1	110	3.3	55	1.7	352	10.4
		35+	2405	937	39.3	409	43.6	214	52.3	58	2.9	63	3.2	16	0.8	195	9.5
	Years since diagnosis	5-9	1000	216	25.7	81	37.5	29	35.8	28	3.4	17	2.1	9	1.1	37	4.5
		10-14	4897	1360	28.6	723	53.2	374	51.7	188	4.2	132	3.0	57	1.3	357	8.0
		15-19	7563	2158	29.0	1206	55.9	604	50.1	257	3.9	192	3.0	89	1.4	616	9.3
		20+	6577	2264	34.7	1168	51.6	610	52.2	253	4.7	168	3.2	87	1.6	613	11.1
	Age at diagnosis	<1	819	235	29.2	137	58.3	74	54.0	44	6.3	16	2.4	16	2.3	68	9.7
		1-4	4706	1140	24.5	704	61.8	364	51.7	159	4.0	109	2.8	63	1.6	382	9.5
		5-9	4868	1320	27.6	748	56.7	370	49.5	190	4.5	117	2.8	62	1.5	404	9.4
		10-14	5392	1784	34.0	942	52.8	464	49.3	208	4.4	156	3.4	63	1.4	432	9.1
		15-20	4252	1519	37.2	647	42.6	345	53.3	125	3.4	111	3.0	38	1.0	337	9.0
	Treatment	Surgery only	1655	577	35.6	315	54.6	169	53.7	61	4.2	48	3.3	27	1.9	150	10.3
		Chemotherapy, no radiation	6054	1986	33.6	1008	50.8	549	54.5	270	5.5	171	3.5	99	2.1	599	12.0
		Radiation, no chemotherapy	1785	504	28.9	261	51.8	114	43.7	54	3.3	43	2.7	23	1.4	123	7.5
		Chemotherapy and radiation	8510	2291	27.7	1216	53.1	610	50.2	270	3.6	196	2.7	75	1.0	612	8.1
		Unknown	2033	640	32.0	378	59.1	175	46.3	71	3.9	51	2.8	18	1.0	139	7.6
Males	**All cases**		**10688**	**3412**	**32.8**	**1871**	**54.8**	**931**	**49.8**	**708**	**7.8**	**503**	**5.7**	**225**	**2.6**	**1451**	**15.7**
	Age at baseline	18-19	1122	212	19.6	139	65.6	49	35.3	60	6.0	45	4.6	14	1.4	78	7.8
		20-24	3170	894	29.3	561	62.8	302	53.8	243	9.0	139	5.2	76	2.9	409	14.9
		25-29	3091	999	33.2	558	55.9	285	51.1	213	8.1	148	5.8	66	2.6	476	17.8
		30-34	2072	803	39.4	400	49.8	188	47.0	136	7.8	109	6.4	53	3.2	316	17.8
		35+	1233	504	41.3	213	42.3	107	50.2	56	5.6	62	6.3	16	1.6	172	16.5
	Years since diagnosis	5-9	552	127	27.6	48	37.8	15	31.3	27	6.1	17	3.9	9	2.1	36	8.2
		10-14	2640	752	29.6	414	55.1	215	51.9	182	7.7	130	5.6	53	2.3	322	13.7

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

Tobacco use: All cancers

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		15-19	3980	1231	31.5	722	58.7	358	49.6	250	7.3	189	5.7	80	2.4	544	15.7
		20+	3516	1302	37.3	687	52.8	343	49.9	249	8.7	167	6.0	83	3.0	549	18.6
	Age at diagnosis	<1	419	135	32.6	88	65.2	46	52.3	42	11.7	16	4.6	12	3.5	54	14.9
		1-4	2411	666	27.9	425	63.8	219	51.5	154	7.7	106	5.4	58	3.0	330	16.1
		5-9	2738	789	29.5	470	59.6	228	48.5	186	7.9	117	5.1	58	2.6	368	15.3
		10-14	2848	983	35.5	534	54.3	251	47.0	205	8.4	154	6.4	59	2.5	392	15.9
		15-20	2272	839	38.8	354	42.2	187	52.8	121	6.3	110	5.9	38	2.1	307	15.9
	Treatment	Surgery only	815	284	35.7	170	59.9	93	54.7	59	8.3	47	6.7	27	3.9	125	17.4
		Chemotherapy, no radiation	3219	1139	36.4	600	52.7	315	52.5	262	10.1	170	6.8	86	3.5	532	20.0
		Radiation, no chemotherapy	928	277	30.8	149	53.8	67	45.0	53	6.5	43	5.4	23	2.9	115	14.0
		Chemotherapy and radiation	4517	1307	29.8	704	53.9	350	49.7	265	6.8	193	5.1	71	1.9	556	14.1
		Unknown	1209	405	34.0	248	61.2	106	42.7	69	6.4	50	4.7	18	1.7	123	11.4
Females	**All cases**		**9349**	**2586**	**28.2**	**1307**	**50.5**	**686**	**52.5**	**18**	**0.2**	**6**	**0.1**	**17**	**0.2**	**172**	**2.1**
	Age at baseline	18-19	1030	141	14.3	84	59.6	31	36.9	2	0.2	1	0.1	3	0.3	12	1.3
		20-24	2854	639	23.0	357	55.9	184	51.5	9	0.4	3	0.1	10	0.4	65	2.6
		25-29	2480	735	30.2	370	50.3	211	57.0	4	0.2	_	_	2	0.1	36	1.7
		30-34	1813	638	35.5	300	47.0	153	51.0	1	0.1	1	0.1	2	0.1	36	2.2
		35+	1172	433	37.2	196	45.3	107	54.6	2	0.2	1	0.1	_	_	23	2.3
	Years since diagnosis	5-9	448	89	23.4	33	37.1	14	42.4	1	0.3	_	_	_	_	1	0.3
		10-14	2257	608	27.5	309	50.8	159	51.5	6	0.3	2	0.1	4	0.2	35	1.6
		15-19	3583	927	26.3	484	52.2	246	50.8	7	0.2	3	0.1	9	0.3	72	2.3
		20+	3061	962	31.7	481	50.0	267	55.5	4	0.2	1	0.0	4	0.2	64	2.5
	Age at diagnosis	<1	400	100	25.5	49	49.0	28	57.1	2	0.6	_	_	4	1.2	14	4.1
		1-4	2295	474	21.0	279	58.9	145	52.0	5	0.3	3	0.2	5	0.3	52	2.7
		5-9	2130	531	25.3	278	52.4	142	51.1	4	0.2	_	_	4	0.2	36	1.9
		10-14	2544	801	32.3	408	50.9	213	52.2	3	0.1	2	0.1	4	0.2	40	1.8
		15-20	1980	680	35.3	293	43.1	158	53.9	4	0.2	1	0.1	_	_	30	1.7
	Treatment	Surgery only	840	293	35.5	145	49.5	76	52.4	2	0.3	1	0.1	_	_	25	3.4

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

Tobacco use: All cancers

			All cases	Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
				N	%	N	%	N	%	N	%	N	%	N	%	N	%
		Chemotherapy, no radiation	2835	847	30.6	408	48.2	234	57.4	8	0.3	1	0.0	13	0.6	67	2.8
		Radiation, no chemotherapy	857	227	26.8	112	49.3	47	42.0	1	0.1	_	_	_	_	8	1.0
		Chemotherapy and radiation	3993	984	25.3	512	52.0	260	50.8	5	0.1	3	0.1	4	0.1	56	1.6
		Unknown	824	235	28.9	130	55.3	69	53.1	2	0.3	1	0.1	_	_	16	2.1

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

Tobacco use: All leukemias

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**5672**	**1545**	**27.7**	**903**	**58.4**	**449**	**49.7**	**198**	**4.1**	**146**	**3.1**	**61**	**1.3**	**444**	**9.2**
	Age at baseline	18-19	844	125	15.2	77	61.6	21	27.3	18	2.4	19	2.6	6	0.8	33	4.4
		20-24	1970	491	25.3	318	64.8	165	51.9	81	4.8	50	3.0	17	1.0	143	8.4
		25-29	1608	489	30.9	271	55.4	146	53.9	64	4.8	42	3.2	20	1.5	150	11.0
		30-34	847	303	36.3	175	57.8	81	46.3	27	4.0	27	4.1	13	2.0	92	13.4
		35+	403	137	34.5	62	45.3	36	58.1	8	2.6	8	2.6	5	1.7	26	8.4
	Years since diagnosis	5-9	251	53	24.4	23	43.4	11	47.8	3	1.4	5	2.4	2	1.0	7	3.3
		10-14	1289	321	25.4	191	59.5	92	48.2	49	4.1	40	3.4	14	1.2	95	8.0
		15-19	2283	596	26.4	357	59.9	169	47.3	87	4.5	60	3.2	24	1.3	171	8.8
		20+	1849	575	31.2	332	57.7	177	53.3	59	4.1	41	3.0	21	1.5	171	11.6
	Age at diagnosis	<1	93	15	16.5	6	40.0	3	50.0	2	2.7	1	1.4	3	3.9	3	3.9
		1-4	2049	469	23.0	304	64.8	150	49.3	64	3.8	54	3.3	18	1.1	152	9.0
		5-9	1547	429	28.1	259	60.4	123	47.5	63	4.7	35	2.7	15	1.1	123	9.1
		10-14	1296	411	32.4	232	56.4	113	48.7	46	4.1	31	2.8	16	1.4	107	9.5
		15-20	687	221	33.8	102	46.2	60	58.8	23	4.0	25	4.4	9	1.6	59	10.0
	Treatment	Surgery only	2	_	_	_	_	_	_	_	_	_	_	_	_	_	_
		Chemotherapy, no radiation	2306	729	32.2	382	52.4	211	55.2	85	4.7	56	3.2	35	2.0	212	11.6
		Radiation, no chemotherapy	3	_	_	_	_	_	_	_	_	1	33.3	_	_	_	_
		Chemotherapy and radiation	2777	662	24.2	411	62.1	185	45.0	97	3.9	76	3.2	22	0.9	191	7.7
		Unknown	584	154	26.6	110	71.4	53	48.2	16	3.1	13	2.5	4	0.8	41	7.8
Males	**All cases**		**2996**	**887**	**30.1**	**524**	**59.1**	**258**	**49.2**	**190**	**7.6**	**143**	**5.9**	**52**	**2.2**	**391**	**15.5**
	Age at baseline	18-19	454	74	16.8	47	63.5	14	29.8	17	4.3	18	4.6	4	1.0	27	6.8
		20-24	997	285	29.1	193	67.7	101	52.3	75	8.8	49	5.8	13	1.6	121	14.1
		25-29	870	280	32.7	156	55.7	82	52.6	64	8.8	42	6.1	18	2.6	144	19.7
		30-34	449	167	37.8	94	56.3	39	41.5	27	7.6	27	7.8	12	3.5	79	21.5
		35+	226	81	36.5	34	42.0	22	64.7	7	4.1	7	4.1	5	3.0	20	11.4
	Years since diagnosis	5-9	138	32	26.9	13	40.6	6	46.2	3	2.7	5	4.4	2	1.8	7	6.0
		10-14	694	181	26.7	106	58.6	53	50.0	46	7.3	40	6.5	10	1.7	82	13.3

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

Tobacco use: All leukemias

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		15-19	1170	341	29.4	215	63.0	101	47.0	83	8.4	58	6.0	21	2.2	152	15.2
		20+	994	333	33.7	190	57.1	98	51.6	58	7.6	40	5.4	19	2.6	150	18.8
	Age at diagnosis	<1	49	7	14.6	6	85.7	3	50.0	2	5.1	1	2.6	2	5.0	3	7.1
		1-4	1068	287	27.0	187	65.2	90	48.1	60	6.9	52	6.2	15	1.9	131	15.0
		5-9	823	229	28.3	142	62.0	68	47.9	61	8.7	35	5.1	13	1.9	112	15.8
		10-14	640	219	34.9	128	58.4	61	47.7	44	8.0	30	5.6	13	2.4	91	16.6
		15-20	416	145	36.7	61	42.1	36	59.0	23	6.6	25	7.3	9	2.7	54	15.2
	Treatment	Chemotherapy, no radiation	1161	388	34.1	205	52.8	111	54.1	79	8.7	55	6.3	28	3.3	183	20.0
		Radiation, no chemotherapy	2	_	_	_	_	_	_	_	_	1	50.0	_	_	_	_
		Chemotherapy and radiation	1489	403	27.6	249	61.8	119	47.8	96	7.4	75	5.9	20	1.6	172	13.2
		Unknown	344	96	28.2	70	72.9	28	40.0	15	4.9	12	4.0	4	1.3	36	11.5
Females	**All cases**		**2676**	**658**	**25.0**	**379**	**57.6**	**191**	**50.4**	**8**	**0.4**	**3**	**0.1**	**9**	**0.4**	**53**	**2.3**
	Age at baseline	18-19	390	51	13.4	30	58.8	7	23.3	1	0.3	1	0.3	2	0.6	6	1.7
		20-24	973	206	21.5	125	60.7	64	51.2	6	0.7	1	0.1	4	0.5	22	2.6
		25-29	738	209	28.7	115	55.0	64	55.7	_	_	_	_	2	0.3	6	1.0
		30-34	398	136	34.6	81	59.6	42	51.9	_	_	_	_	1	0.3	13	4.0
		35+	177	56	32.0	28	50.0	14	50.0	1	0.8	1	0.8	_	_	6	4.5
	Years since diagnosis	5-9	113	21	21.4	10	47.6	5	50.0	_	_	_	_	_	_	_	_
		10-14	595	140	23.9	85	60.7	39	45.9	3	0.5	_	_	4	0.7	13	2.3
		15-19	1113	255	23.2	142	55.7	68	47.9	4	0.4	2	0.2	3	0.3	19	2.0
		20+	855	242	28.4	142	58.7	79	55.6	1	0.2	1	0.2	2	0.3	21	3.1
	Age at diagnosis	<1	44	8	18.6	_	_	_	_	_	_	_	_	1	2.8	_	_
		1-4	981	182	18.7	117	64.3	60	51.3	4	0.5	2	0.3	3	0.4	21	2.6
		5-9	724	200	27.9	117	58.5	55	47.0	2	0.3	_	_	2	0.3	11	1.7
		10-14	656	192	29.9	104	54.2	52	50.0	2	0.4	1	0.2	3	0.5	16	2.8
		15-20	271	76	29.5	41	53.9	24	58.5	_	_	_	_	_	_	5	2.1
	Treatment	Surgery only	2	_	_	_	_	_	_	_	_	_	_	_	_	_	_
		Chemotherapy, no radiation	1145	341	30.3	177	51.9	100	56.5	6	0.7	1	0.1	7	0.8	29	3.2

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

Tobacco use: All leukemias

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		Radiation, no chemotherapy	1	_	_	_	_	_	_	_	_	_	_	_	_	_	_
		Chemotherapy and radiation	1288	259	20.4	162	62.5	66	40.7	1	0.1	1	0.1	2	0.2	19	1.6
		Unknown	240	58	24.3	40	69.0	25	62.5	1	0.5	1	0.5	_	_	5	2.3

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

Tobacco use: ALL

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**4705**	**1265**	**27.2**	**765**	**60.5**	**365**	**47.7**	**168**	**4.2**	**122**	**3.1**	**50**	**1.3**	**365**	**9.1**
	Age at baseline	18-19	730	112	15.7	71	63.4	19	26.8	17	2.6	17	2.6	6	0.9	31	4.8
		20-24	1693	426	25.5	279	65.5	143	51.3	70	4.8	44	3.1	15	1.1	120	8.2
		25-29	1338	407	30.7	232	57.0	118	50.9	57	5.1	38	3.5	16	1.5	121	10.7
		30-34	657	227	34.9	136	59.9	55	40.4	21	4.0	18	3.6	9	1.8	74	13.9
		35+	287	93	32.9	47	50.5	30	63.8	3	1.4	5	2.3	4	1.9	19	8.6
	Years since diagnosis	5-9	185	42	25.5	18	42.9	9	50.0	1	0.6	3	1.9	2	1.3	7	4.3
		10-14	1059	257	24.7	159	61.9	71	44.7	45	4.6	32	3.3	10	1.0	74	7.6
		15-19	1905	487	25.7	305	62.6	134	43.9	76	4.7	53	3.3	22	1.4	150	9.2
		20+	1556	479	30.9	283	59.1	151	53.4	46	3.8	34	2.9	16	1.4	134	10.9
	Age at diagnosis	<1	55	9	16.7	5	55.6	2	40.0	1	2.3	_	_	3	7.0	3	6.8
		1-4	1825	419	23.0	271	64.7	135	49.8	55	3.7	52	3.6	16	1.1	124	8.3
		5-9	1345	370	27.8	230	62.2	105	45.7	58	5.0	30	2.6	13	1.1	104	8.8
		10-14	1013	322	32.4	184	57.1	78	42.4	35	4.0	22	2.5	11	1.3	89	10.1
		15-20	467	145	32.2	75	51.7	45	60.0	19	4.8	18	4.6	7	1.8	45	11.1
	Treatment	Chemotherapy, no radiation	1796	564	31.9	305	54.1	166	54.4	67	4.9	44	3.3	28	2.1	164	11.8
		Radiation, no chemotherapy	3	_	_	_	_	_	_	_	_	1	33.3	_	_	_	_
		Chemotherapy and radiation	2416	564	23.6	360	63.8	152	42.2	88	4.1	66	3.1	18	0.9	168	7.8
		Unknown	490	137	28.2	100	73.0	47	47.0	13	2.9	11	2.5	4	0.9	33	7.3
Males	**All cases**		**2515**	**746**	**30.1**	**449**	**60.2**	**210**	**46.8**	**162**	**7.7**	**120**	**5.9**	**42**	**2.1**	**321**	**15.1**
	Age at baseline	18-19	397	68	17.7	44	64.7	12	27.3	16	4.6	16	4.7	4	1.2	25	7.2
		20-24	858	248	29.3	165	66.5	87	52.7	65	8.8	43	5.9	12	1.7	100	13.5
		25-29	736	238	32.6	137	57.6	67	48.9	57	9.2	38	6.5	14	2.4	116	18.7
		30-34	354	133	38.1	74	55.6	24	32.4	21	7.6	18	6.7	8	3.0	64	22.3
		35+	170	59	35.1	29	49.2	20	69.0	3	2.4	5	4.0	4	3.2	16	12.3
	Years since diagnosis	5-9	98	26	29.2	9	34.6	5	55.6	1	1.2	3	3.6	2	2.4	7	8.1
		10-14	584	146	25.7	88	60.3	42	47.7	42	8.0	32	6.2	6	1.2	63	12.2
		15-19	990	291	29.6	188	64.6	82	43.6	73	8.7	51	6.2	19	2.4	133	15.7

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

Tobacco use: ALL

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		20+	843	283	33.8	164	58.0	81	49.4	46	7.1	34	5.5	15	2.4	118	17.6
	Age at diagnosis	<1	31	6	20.0	5	83.3	2	40.0	1	4.0	_	_	2	8.3	3	11.5
		1-4	948	257	27.3	166	64.6	78	47.0	52	6.8	50	6.7	14	2.0	105	13.6
		5-9	727	199	27.8	125	62.8	57	45.6	56	8.9	30	4.9	11	1.8	94	14.9
		10-14	518	184	36.2	106	57.6	45	42.5	34	7.7	22	5.0	8	1.9	76	17.2
		15-20	291	100	35.5	47	47.0	28	59.6	19	7.9	18	7.5	7	3.0	43	17.1
	Treatment	Chemotherapy, no radiation	904	305	34.3	163	53.4	86	52.8	62	9.0	43	6.5	21	3.3	139	19.9
		Radiation, no chemotherapy	2	_	_	_	_	_	_	_	_	1	50.0	_	_	_	_
		Chemotherapy and radiation	1316	355	27.4	223	62.8	101	45.3	87	7.6	65	5.8	17	1.5	153	13.3
		Unknown	293	86	29.7	63	73.3	23	36.5	13	4.9	11	4.2	4	1.5	29	10.8
Females	**All cases**		**2190**	**519**	**23.9**	**316**	**60.9**	**155**	**49.1**	**6**	**0.3**	**2**	**0.1**	**8**	**0.4**	**44**	**2.3**
	Age at baseline	18-19	333	44	13.4	27	61.4	7	25.9	1	0.3	1	0.3	2	0.7	6	2.0
		20-24	835	178	21.5	114	64.0	56	49.1	5	0.7	1	0.1	3	0.4	20	2.7
		25-29	602	169	28.3	95	56.2	51	53.7	_	_	_	_	2	0.4	5	1.0
		30-34	303	94	31.2	62	66.0	31	50.0	_	_	_	_	1	0.4	10	4.1
		35+	117	34	29.6	18	52.9	10	55.6	_	_	_	_	_	_	3	3.3
	Years since diagnosis	5-9	87	16	21.1	9	56.3	4	44.4	_	_	_	_	_	_	_	_
		10-14	475	111	23.6	71	64.0	29	40.8	3	0.7	_	_	4	0.9	11	2.4
		15-19	915	196	21.5	117	59.7	52	44.4	3	0.4	2	0.3	3	0.4	17	2.2
		20+	713	196	27.6	119	60.7	70	58.8	_	_	_	_	1	0.2	16	2.8
	Age at diagnosis	<1	24	3	12.5	_	_	_	_	_	_	_	_	1	5.3	_	_
		1-4	877	162	18.5	105	64.8	57	54.3	3	0.4	2	0.3	2	0.3	19	2.6
		5-9	618	171	27.8	105	61.4	48	45.7	2	0.4	_	_	2	0.4	10	1.8
		10-14	495	138	28.5	78	56.5	33	42.3	1	0.2	_	_	3	0.7	13	2.9
		15-20	176	45	26.6	28	62.2	17	60.7	_	_	_	_	_	_	2	1.3
	Treatment	Chemotherapy, no radiation	892	259	29.5	142	54.8	80	56.3	5	0.7	1	0.1	7	1.0	25	3.6
		Radiation, no chemotherapy	1	_	_	_	_	_	_	_	_	_	_	_	_	_	_

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		Chemotherapy and radiation	1100	209	19.1	137	65.6	51	37.2	1	0.1	1	0.1	1	0.1	15	1.5
		Unknown	197	51	26.0	37	72.5	24	64.9	_	_	_	_	_	_	4	2.2

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

Tobacco use: AML

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**699**	**205**	**30.1**	**105**	**51.2**	**64**	**61.0**	**17**	**2.9**	**20**	**3.4**	**9**	**1.5**	**55**	**9.2**
	Age at baseline	18-19	89	9	10.3	4	44.4	1	25.0	_	_	2	2.5	_	_	2	2.4
		20-24	199	48	25.0	29	60.4	17	58.6	9	5.3	6	3.6	2	1.2	18	10.4
		25-29	201	71	36.2	35	49.3	26	74.3	3	1.8	4	2.5	4	2.4	19	11.3
		30-34	134	52	39.1	28	53.8	17	60.7	2	1.7	7	6.0	3	2.6	11	9.6
		35+	76	25	33.8	9	36.0	3	33.3	3	5.3	1	1.8	_	_	5	8.6
	Years since diagnosis	5-9	37	8	23.5	4	50.0	2	50.0	1	3.0	2	6.3	_	_	_	_
		10-14	166	49	30.1	27	55.1	17	63.0	3	1.9	8	5.2	3	1.9	15	9.6
		15-19	294	83	29.3	40	48.2	29	72.5	7	2.9	7	2.9	2	0.8	17	7.1
		20+	202	65	32.2	34	52.3	16	47.1	6	3.8	3	1.9	4	2.5	23	13.8
	Age at diagnosis	<1	35	6	17.6	1	16.7	1	100.0	1	3.4	1	3.4	_	_	_	_
		1-4	167	37	22.8	23	62.2	11	47.8	5	3.8	2	1.5	2	1.5	19	13.7
		5-9	149	45	30.4	23	51.1	13	56.5	2	1.6	4	3.2	2	1.6	14	10.8
		10-14	197	67	34.7	38	56.7	28	73.7	7	4.1	7	4.2	5	3.0	14	8.3
		15-20	151	50	34.5	20	40.0	11	55.0	2	1.5	6	4.7	_	_	8	6.2
	Treatment	Surgery only	2	_	_	_	_	_	_	_	_	_	_	_	_	_	_
		Chemotherapy, no radiation	406	134	33.8	64	47.8	35	54.7	13	3.7	11	3.2	6	1.8	37	10.6
		Chemotherapy and radiation	225	58	26.5	34	58.6	25	73.5	4	2.1	8	4.1	3	1.5	13	6.7
		Unknown	66	13	20.0	7	53.8	4	57.1	_	_	1	2.1	_	_	5	9.8
Males	**All cases**		**330**	**97**	**29.9**	**54**	**55.7**	**35**	**64.8**	**16**	**5.6**	**20**	**7.2**	**8**	**2.9**	**47**	**16.4**
	Age at baseline	18-19	45	4	9.1	2	50.0	1	50.0	_	_	2	5.0	_	_	2	4.8
		20-24	95	27	29.0	19	70.4	10	52.6	8	9.8	6	7.4	1	1.3	16	19.0
		25-29	90	35	39.3	17	48.6	14	82.4	3	4.1	4	5.7	4	5.6	18	24.0
		30-34	65	22	33.8	15	68.2	10	66.7	2	3.4	7	12.3	3	5.4	9	15.8
		35+	35	9	27.3	1	11.1	_	_	3	10.7	1	3.6	_	_	2	7.1
	Years since diagnosis	5-9	24	5	22.7	3	60.0	1	33.3	1	4.8	2	9.5	_	_	_	_
		10-14	74	26	35.6	15	57.7	9	60.0	3	4.3	8	11.9	3	4.4	13	19.1
		15-19	135	36	27.3	20	55.6	15	75.0	6	5.2	7	6.3	2	1.8	15	13.3

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

Tobacco use: AML

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		20+	97	30	30.9	16	53.3	10	62.5	6	7.8	3	3.9	3	4.0	19	22.6
	Age at diagnosis	<1	16	1	6.3	1	100.0	1	100.0	1	7.7	1	7.7	_	_	_	_
		1-4	86	23	27.1	14	60.9	8	57.1	4	5.8	2	2.9	1	1.5	17	23.0
		5-9	64	20	31.3	13	65.0	8	61.5	2	3.7	4	7.8	2	3.8	14	25.5
		10-14	81	28	35.0	16	57.1	12	75.0	7	9.3	7	9.7	5	6.9	11	15.3
		15-20	83	25	31.6	10	40.0	6	60.0	2	2.7	6	8.3	_	_	5	7.0
	Treatment	Chemotherapy, no radiation	194	64	33.7	33	51.6	19	57.6	12	7.2	11	6.8	6	3.8	33	19.8
		Chemotherapy and radiation	101	26	26.0	17	65.4	13	76.5	4	4.4	8	9.0	2	2.2	9	10.0
		Unknown	35	7	20.6	4	57.1	3	75.0	_	_	1	3.8	_	_	5	17.2
Females	**All cases**		**369**	**108**	**30.2**	**51**	**47.2**	**29**	**56.9**	**1**	**0.3**	**_**	**_**	**1**	**0.3**	**8**	**2.6**
	Age at baseline	18-19	44	5	11.6	2	40.0	_	_	_	_	_	_	_	_	_	_
		20-24	104	21	21.2	10	47.6	7	70.0	1	1.1	_	_	1	1.1	2	2.2
		25-29	111	36	33.6	18	50.0	12	66.7	_	_	_	_	_	_	1	1.1
		30-34	69	30	44.1	13	43.3	7	53.8	_	_	_	_	_	_	2	3.4
		35+	41	16	39.0	8	50.0	3	37.5	_	_	_	_	_	_	3	10.0
	Years since diagnosis	5-9	13	3	25.0	1	33.3	1	100.0	_	_	_	_	_	_	_	_
		10-14	92	23	25.6	12	52.2	8	66.7	_	_	_	_	_	_	2	2.3
		15-19	159	47	31.1	20	42.6	14	70.0	1	0.8	_	_	_	_	2	1.6
		20+	105	35	33.3	18	51.4	6	33.3	_	_	_	_	1	1.2	4	4.8
	Age at diagnosis	<1	19	5	27.8	_	_	_	_	_	_	_	_	_	_	_	_
		1-4	81	14	18.2	9	64.3	3	33.3	1	1.6	_	_	1	1.6	2	3.1
		5-9	85	25	29.8	10	40.0	5	50.0	_	_	_	_	_	_	_	_
		10-14	116	39	34.5	22	56.4	16	72.7	_	_	_	_	_	_	3	3.1
		15-20	68	25	37.9	10	40.0	5	50.0	_	_	_	_	_	_	3	5.1
	Treatment	Surgery only	2	_	_	_	_	_	_	_	_	_	_	_	_	_	_
		Chemotherapy, no radiation	212	70	33.8	31	44.3	16	51.6	1	0.6	_	_	_	_	4	2.2
		Chemotherapy and radiation	124	32	26.9	17	53.1	12	70.6	_	_	_	_	1	0.9	4	3.8
		Unknown	31	6	19.4	3	50.0	1	33.3	_	_	_	_	_	_	_	_

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

Tobacco use: All CNS

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**3545**	**866**	**25.4**	**445**	**51.4**	**238**	**53.5**	**88**	**2.9**	**69**	**2.3**	**42**	**1.4**	**239**	**7.8**
	Age at baseline	18-19	376	46	13.1	25	54.3	11	44.0	9	2.7	5	1.5	2	0.6	14	4.3
		20-24	1182	223	19.8	113	50.7	60	53.1	32	3.1	19	1.9	20	2.0	84	8.1
		25-29	1086	294	28.0	162	55.1	90	55.6	25	2.7	20	2.2	10	1.1	83	8.9
		30-34	625	204	33.2	99	48.5	50	50.5	17	3.1	17	3.2	10	1.9	43	7.8
		35+	276	99	36.5	46	46.5	27	58.7	5	2.2	8	3.5	_	_	15	6.5
	Years since diagnosis	5-9	175	33	24.8	15	45.5	5	33.3	5	3.7	1	0.8	1	0.8	7	5.3
		10-14	962	229	24.9	123	53.7	65	52.8	26	3.0	19	2.2	9	1.1	66	7.7
		15-19	1330	317	24.5	168	53.0	95	56.5	28	2.4	20	1.8	16	1.4	92	7.8
		20+	1078	287	26.9	139	48.4	73	52.5	29	3.2	29	3.2	16	1.8	74	8.1
	Age at diagnosis	<1	82	10	12.5	5	50.0	3	60.0	3	4.3	_	_	_	_	3	4.3
		1-4	725	127	18.0	73	57.5	39	53.4	20	3.3	17	2.8	15	2.5	50	8.1
		5-9	1204	255	21.7	123	48.2	70	56.9	31	2.9	15	1.4	13	1.2	82	7.7
		10-14	1054	312	30.8	161	51.6	77	47.8	21	2.3	23	2.6	13	1.5	73	7.9
		15-20	480	162	36.7	83	51.2	49	59.0	13	3.2	14	3.6	1	0.3	31	7.7
	Treatment	Surgery only	1073	368	35.0	205	55.7	113	55.1	37	3.9	31	3.3	17	1.8	101	10.6
		Chemotherapy, no radiation	245	61	26.0	27	44.3	19	70.4	8	4.3	2	1.1	2	1.1	19	10.1
		Radiation, no chemotherapy	949	203	22.0	103	50.7	43	41.7	22	2.6	16	1.9	14	1.7	62	7.2
		Chemotherapy and radiation	929	154	17.7	71	46.1	43	60.6	11	1.4	10	1.3	5	0.7	36	4.6
		Unknown	349	80	23.5	39	48.8	20	51.3	10	3.3	10	3.4	4	1.4	21	7.0
Males	**All cases**		**1926**	**481**	**26.0**	**263**	**54.7**	**142**	**54.0**	**86**	**5.2**	**67**	**4.2**	**41**	**2.6**	**211**	**12.7**
	Age at baseline	18-19	191	30	16.8	19	63.3	8	42.1	9	5.3	5	3.0	2	1.2	13	7.9
		20-24	634	125	20.9	65	52.0	34	52.3	31	5.7	18	3.4	20	3.8	73	13.2
		25-29	619	165	27.5	99	60.0	55	55.6	24	4.6	20	3.9	10	2.0	75	14.1
		30-34	333	110	33.7	57	51.8	31	54.4	17	6.0	16	5.9	9	3.3	37	12.9
		35+	149	51	34.9	23	45.1	14	60.9	5	4.3	8	7.1	_	_	13	10.9
	Years since diagnosis	5-9	101	21	27.3	9	42.9	2	22.2	5	6.5	1	1.4	1	1.4	6	7.9
		10-14	516	114	23.3	70	61.4	38	54.3	24	5.3	17	3.8	9	2.1	58	12.8

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

Tobacco use: All CNS

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		15-19	722	176	25.1	101	57.4	54	53.5	28	4.5	20	3.3	16	2.7	79	12.5
		20+	587	170	29.3	83	48.8	48	57.8	29	6.0	29	6.0	15	3.1	68	13.7
	Age at diagnosis	<1	49	6	12.5	3	50.0	2	66.7	3	7.3	_	_	_	_	3	7.3
		1-4	369	80	22.1	46	57.5	24	52.2	20	6.4	17	5.4	15	4.9	45	14.1
		5-9	675	151	23.2	80	53.0	45	56.3	31	5.3	15	2.6	13	2.3	73	12.4
		10-14	562	158	29.3	89	56.3	42	47.2	20	4.1	22	4.7	12	2.6	66	13.5
		15-20	271	86	34.8	45	52.3	29	64.4	12	5.5	13	6.3	1	0.5	24	11.2
	Treatment	Surgery only	544	187	35.3	114	61.0	62	54.4	36	7.6	31	6.6	17	3.7	81	16.9
		Chemotherapy, no radiation	135	36	28.1	17	47.2	14	82.4	8	7.9	2	2.0	2	2.1	17	16.7
		Radiation, no chemotherapy	501	110	22.9	59	53.6	26	44.1	21	4.8	16	3.8	14	3.3	58	13.2
		Chemotherapy and radiation	544	97	18.9	45	46.4	27	60.0	11	2.4	8	1.8	4	0.9	36	7.8
		Unknown	202	51	25.8	28	54.9	13	46.4	10	5.7	10	5.9	4	2.4	19	11.0
Females	**All cases**		**1619**	**385**	**24.6**	**182**	**47.3**	**96**	**52.7**	**2**	**0.1**	**2**	**0.1**	**1**	**0.1**	**28**	**2.0**
	Age at baseline	18-19	185	16	9.3	6	37.5	3	50.0	_	_	_	_	_	_	1	0.6
		20-24	548	98	18.5	48	49.0	26	54.2	1	0.2	1	0.2	_	_	11	2.3
		25-29	467	129	28.5	63	48.8	35	55.6	1	0.2	_	_	_	_	8	2.0
		30-34	292	94	32.5	42	44.7	19	45.2	_	_	1	0.4	1	0.4	6	2.3
		35+	127	48	38.4	23	47.9	13	56.5	_	_	_	_	_	_	2	1.8
	Years since diagnosis	5-9	74	12	21.4	6	50.0	3	50.0	_	_	_	_	_	_	1	1.8
		10-14	446	115	26.7	53	46.1	27	50.9	2	0.5	2	0.5	_	_	8	2.0
		15-19	608	141	23.7	67	47.5	41	61.2	_	_	_	_	_	_	13	2.4
		20+	491	117	24.1	56	47.9	25	44.6	_	_	_	_	1	0.2	6	1.4
	Age at diagnosis	<1	33	4	12.5	2	50.0	1	50.0	_	_	_	_	_	_	_	_
		1-4	356	47	13.7	27	57.4	15	55.6	_	_	_	_	_	_	5	1.7
		5-9	529	104	20.0	43	41.3	25	58.1	_	_	_	_	_	_	9	1.9
		10-14	492	154	32.4	72	46.8	35	48.6	1	0.2	1	0.2	1	0.2	7	1.6
		15-20	209	76	39.0	38	50.0	20	52.6	1	0.5	1	0.5	_	_	7	3.7
	Treatment	Surgery only	529	181	34.8	91	50.3	51	56.0	1	0.2	_	_	_	_	20	4.2

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

Tobacco use: All CNS

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		Chemotherapy, no radiation	110	25	23.4	10	40.0	5	50.0	_	_	_	_	_	_	2	2.3
		Radiation, no chemotherapy	448	93	21.1	44	47.3	17	38.6	1	0.2	_	_	_	_	4	1.0
		Chemotherapy and radiation	385	57	16.0	26	45.6	16	61.5	_	_	2	0.6	1	0.3	_	_
		Unknown	147	29	20.4	11	37.9	7	63.6	_	_	_	_	_	_	2	1.6

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

Tobacco use: Astrocytomas

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**2166**	**570**	**27.2**	**301**	**52.8**	**155**	**51.5**	**61**	**3.3**	**42**	**2.3**	**29**	**1.6**	**153**	**8.1**
	Age at baseline	18-19	215	34	16.7	19	55.9	8	42.1	8	4.2	4	2.1	2	1.1	9	4.7
		20-24	715	157	23.0	80	51.0	44	55.0	21	3.4	11	1.8	16	2.6	59	9.3
		25-29	665	193	30.0	110	57.0	54	49.1	20	3.5	11	2.0	6	1.1	54	9.5
		30-34	387	124	32.6	64	51.6	34	53.1	12	3.6	12	3.6	5	1.5	22	6.4
		35+	184	62	34.1	28	45.2	15	53.6	_	_	4	2.6	_	_	9	5.7
	Years since diagnosis	5-9	97	22	31.4	8	36.4	2	25.0	3	4.2	_	_	1	1.4	5	7.0
		10-14	570	141	25.7	79	56.0	36	45.6	21	4.1	11	2.2	6	1.2	40	7.9
		15-19	780	203	26.5	109	53.7	62	56.9	18	2.6	11	1.6	12	1.8	55	7.8
		20+	719	204	28.8	105	51.5	55	52.4	19	3.1	20	3.3	10	1.7	53	8.6
	Age at diagnosis	<1	57	8	14.5	3	37.5	2	66.7	2	4.3	_	_	_	_	2	4.3
		1-4	464	98	21.6	58	59.2	30	51.7	15	3.8	12	3.1	14	3.6	36	9.0
		5-9	703	177	25.7	88	49.7	48	54.5	21	3.3	10	1.6	5	0.8	53	8.4
		10-14	637	193	31.3	106	54.9	49	46.2	16	2.9	13	2.4	9	1.7	47	8.3
		15-20	305	94	33.8	46	48.9	26	56.5	7	2.8	7	2.8	1	0.4	15	6.0
	Treatment	Surgery only	894	297	33.8	166	55.9	92	55.4	33	4.2	22	2.8	13	1.7	78	9.8
		Chemotherapy, no radiation	179	47	27.8	18	38.3	12	66.7	5	3.6	_	_	2	1.5	13	9.2
		Radiation, no chemotherapy	597	129	22.4	67	51.9	25	37.3	15	2.8	13	2.5	10	1.9	40	7.4
		Chemotherapy and radiation	272	41	16.4	19	46.3	12	63.2	3	1.3	3	1.4	1	0.4	9	3.9
		Unknown	224	56	25.7	31	55.4	14	45.2	5	2.6	4	2.1	3	1.6	13	6.7
Males	**All cases**		**1130**	**306**	**28.2**	**177**	**57.8**	**91**	**51.4**	**59**	**6.1**	**41**	**4.3**	**29**	**3.1**	**136**	**13.8**
	Age at baseline	18-19	109	22	21.2	14	63.6	6	42.9	8	8.1	4	4.0	2	2.1	9	9.4
		20-24	355	83	24.9	47	56.6	26	55.3	20	6.5	11	3.6	16	5.3	52	16.5
		25-29	372	106	29.4	66	62.3	32	48.5	19	6.0	11	3.5	6	2.0	49	15.1
		30-34	196	63	33.2	36	57.1	20	55.6	12	7.2	11	6.9	5	3.1	18	10.7
		35+	98	32	33.3	14	43.8	7	50.0	_	_	4	5.3	_	_	8	9.9
	Years since diagnosis	5-9	51	11	28.9	3	27.3	_	_	3	7.7	_	_	1	2.6	4	10.3
		10-14	301	73	25.7	51	69.9	25	49.0	19	7.2	10	3.9	6	2.4	37	14.1

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

Tobacco use: Astrocytomas

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		15-19	396	104	27.0	61	58.7	32	52.5	18	5.2	11	3.3	12	3.6	48	13.4
		20+	382	118	31.3	62	52.5	34	54.8	19	6.0	20	6.3	10	3.2	47	14.4
	Age at diagnosis	<1	35	5	14.7	2	40.0	2	100.0	2	7.1	_	_	_	_	2	6.9
		1-4	224	60	27.1	37	61.7	19	51.4	15	7.9	12	6.3	14	7.4	33	16.8
		5-9	377	100	27.5	55	55.0	28	50.9	21	6.3	10	3.1	5	1.5	47	13.9
		10-14	326	95	30.2	58	61.1	26	44.8	15	5.3	13	4.7	9	3.3	41	14.1
		15-20	168	46	30.5	25	54.3	16	64.0	6	4.5	6	4.8	1	0.8	13	9.8
	Treatment	Surgery only	449	147	33.6	92	62.6	50	54.3	32	8.1	22	5.7	13	3.4	65	16.3
		Chemotherapy, no radiation	102	28	29.5	11	39.3	9	81.8	5	6.3	_	_	2	2.6	12	14.6
		Radiation, no chemotherapy	305	73	25.2	42	57.5	17	40.5	14	5.3	13	5.1	10	3.9	38	14.1
		Chemotherapy and radiation	149	23	16.7	11	47.8	7	63.6	3	2.5	2	1.7	1	0.8	9	7.2
		Unknown	125	35	28.5	21	60.0	8	38.1	5	4.5	4	3.8	3	2.9	12	10.9
Females	**All cases**		**1036**	**264**	**26.2**	**124**	**47.0**	**64**	**51.6**	**2**	**0.2**	**1**	**0.1**	**_**	**_**	**17**	**1.9**
	Age at baseline	18-19	106	12	12.0	5	41.7	2	40.0	_	_	_	_	_	_	_	_
		20-24	360	74	21.2	33	44.6	18	54.5	1	0.3	_	_	_	_	7	2.2
		25-29	293	87	30.7	44	50.6	22	50.0	1	0.4	_	_	_	_	5	2.0
		30-34	191	61	32.1	28	45.9	14	50.0	_	_	1	0.6	_	_	4	2.3
		35+	86	30	34.9	14	46.7	8	57.1	_	_	_	_	_	_	1	1.3
	Years since diagnosis	5-9	46	11	34.4	5	45.5	2	40.0	_	_	_	_	_	_	1	3.1
		10-14	269	68	25.8	28	41.2	11	39.3	2	0.8	1	0.4	_	_	3	1.2
		15-19	384	99	26.1	48	48.5	30	62.5	_	_	_	_	_	_	7	2.0
		20+	337	86	25.9	43	50.0	21	48.8	_	_	_	_	_	_	6	2.1
	Age at diagnosis	<1	22	3	14.3	1	33.3	_	_	_	_	_	_	_	_	_	_
		1-4	240	38	16.3	21	55.3	11	52.4	_	_	_	_	_	_	3	1.5
		5-9	326	77	23.7	33	42.9	20	60.6	_	_	_	_	_	_	6	2.0
		10-14	311	98	32.5	48	49.0	23	47.9	1	0.4	_	_	_	_	6	2.2
		15-20	137	48	37.8	21	43.8	10	47.6	1	0.8	1	0.8	_	_	2	1.7
	Treatment	Surgery only	445	150	34.1	74	49.3	42	56.8	1	0.3	_	_	_	_	13	3.3

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

Tobacco use: Astrocytomas

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		Chemotherapy, no radiation	77	19	25.7	7	36.8	3	42.9	_	_	_	_	_	_	1	1.7
		Radiation, no chemotherapy	292	56	19.5	25	44.6	8	32.0	1	0.4	_	_	_	_	2	0.7
		Chemotherapy and radiation	123	18	16.1	8	44.4	5	62.5	_	_	1	1.0	_	_	_	_
		Unknown	99	21	22.1	10	47.6	6	60.0	_	_	_	_	_	_	1	1.2

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

Tobacco use: Medulloblastoma/PNET

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**794**	**132**	**17.4**	**66**	**50.0**	**39**	**59.1**	**13**	**1.9**	**13**	**2.0**	**7**	**1.1**	**41**	**6.1**
	Age at baseline	18-19	82	5	6.8	2	40.0	1	50.0	_	_	1	1.4	_	_	2	3.0
		20-24	292	30	10.9	11	36.7	7	63.6	8	3.2	4	1.6	1	0.4	12	4.8
		25-29	252	52	21.1	30	57.7	22	73.3	2	0.9	4	1.8	4	1.8	15	6.8
		30-34	131	31	24.2	17	54.8	6	35.3	1	0.9	1	0.9	2	1.9	10	9.3
		35+	37	14	38.9	6	42.9	3	50.0	2	8.3	3	12.5	_	_	2	8.7
	Years since diagnosis	5-9	32	4	17.4	1	25.0	1	100.0	_	_	_	_	_	_	_	_
		10-14	219	42	20.1	20	47.6	14	70.0	4	2.1	5	2.6	1	0.5	12	6.2
		15-19	326	49	15.7	27	55.1	15	55.6	4	1.4	5	1.8	3	1.1	16	5.8
		20+	217	37	17.1	18	48.6	9	50.0	5	2.8	3	1.7	3	1.7	13	7.3
	Age at diagnosis	<1	9	1	11.1	1	100.0	1	100.0	1	11.1	_	_	_	_	1	12.5
		1-4	161	10	6.5	5	50.0	3	60.0	2	1.5	2	1.5	_	_	6	4.5
		5-9	342	47	14.2	23	48.9	16	69.6	8	2.7	3	1.0	4	1.4	18	6.1
		10-14	220	52	24.9	27	51.9	13	48.1	1	0.5	5	2.7	3	1.6	10	5.4
		15-20	62	22	39.3	10	45.5	6	60.0	1	2.0	3	6.3	_	_	6	12.0
	Treatment	Surgery only	8	2	25.0	2	100.0	_	_	_	_	_	_	_	_	_	_
		Chemotherapy, no radiation	35	7	20.0	5	71.4	4	80.0	2	7.7	2	7.7	_	_	4	16.0
		Radiation, no chemotherapy	161	25	15.8	17	68.0	9	52.9	1	0.7	1	0.7	2	1.4	6	4.1
		Chemotherapy and radiation	529	89	17.8	40	44.9	24	60.0	8	1.8	7	1.6	4	0.9	24	5.4
		Unknown	61	9	15.3	2	22.2	2	100.0	2	4.0	3	5.9	1	2.1	7	13.7
Males	**All cases**		**484**	**86**	**18.6**	**42**	**48.8**	**27**	**64.3**	**13**	**3.2**	**12**	**3.0**	**6**	**1.5**	**40**	**9.9**
	Age at baseline	18-19	47	3	7.3	1	33.3	_	_	_	_	1	2.6	_	_	2	5.4
		20-24	185	21	12.0	6	28.6	4	66.7	8	5.1	3	2.0	1	0.7	11	7.1
		25-29	157	38	25.0	22	57.9	17	77.3	2	1.5	4	3.0	4	3.0	15	11.0
		30-34	73	16	22.2	9	56.3	4	44.4	1	1.6	1	1.6	1	1.7	10	15.9
		35+	22	8	36.4	4	50.0	2	50.0	2	15.4	3	21.4	_	_	2	15.4
	Years since diagnosis	5-9	21	4	26.7	1	25.0	1	100.0	_	_	_	_	_	_	_	_
		10-14	128	22	18.3	9	40.9	7	77.8	4	3.6	4	3.7	1	1.0	11	10.0

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

Tobacco use: Medulloblastoma/PNET

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		15-19	205	37	18.7	21	56.8	12	57.1	4	2.3	5	2.9	3	1.8	16	9.3
		20+	130	23	17.8	11	47.8	7	63.6	5	4.7	3	2.8	2	1.9	13	11.9
	Age at diagnosis	<1	5	_	_	_	_	_	_	1	20.0	_	_	_	_	1	25.0
		1-4	97	8	8.5	3	37.5	2	66.7	2	2.4	2	2.4	_	_	6	7.3
		5-9	219	34	16.2	17	50.0	12	70.6	8	4.3	3	1.7	4	2.2	17	9.2
		10-14	126	29	24.4	14	48.3	8	57.1	1	1.0	4	3.8	2	2.0	10	9.5
		15-20	37	15	44.1	8	53.3	5	62.5	1	3.7	3	11.5	_	_	6	21.4
	Treatment	Surgery only	5	2	40.0	2	100.0	_	_	_	_	_	_	_	_	_	_
		Chemotherapy, no radiation	20	5	25.0	3	60.0	3	100.0	2	14.3	2	14.3	_	_	4	30.8
		Radiation, no chemotherapy	91	13	14.8	9	69.2	6	66.7	1	1.3	1	1.3	2	2.6	6	7.6
		Chemotherapy and radiation	330	60	19.2	26	43.3	16	61.5	8	2.9	6	2.2	3	1.1	24	8.6
		Unknown	38	6	16.7	2	33.3	2	100.0	2	6.9	3	10.0	1	3.6	6	20.0
Females	**All cases**		**310**	**46**	**15.4**	**24**	**52.2**	**12**	**50.0**	_	_	**1**	**0.4**	**1**	**0.4**	**1**	**0.4**
	Age at baseline	18-19	35	2	6.1	1	50.0	1	100.0	_	_	_	_	_	_	_	_
		20-24	107	9	8.9	5	55.6	3	60.0	_	_	1	1.1	_	_	1	1.1
		25-29	95	14	14.9	8	57.1	5	62.5	_	_	_	_	_	_	_	_
		30-34	58	15	26.8	8	53.3	2	25.0	_	_	_	_	1	2.1	_	_
		35+	15	6	42.9	2	33.3	1	50.0	_	_	_	_	_	_	_	_
	Years since diagnosis	5-9	11	_	_	_	_	_	_	_	_	_	_	_	_	_	_
		10-14	91	20	22.5	11	55.0	7	63.6	_	_	1	1.2	_	_	1	1.2
		15-19	121	12	10.5	6	50.0	3	50.0	_	_	_	_	_	_	_	_
		20+	87	14	16.1	7	50.0	2	28.6	_	_	_	_	1	1.4	_	_
	Age at diagnosis	<1	4	1	25.0	1	100.0	1	100.0	_	_	_	_	_	_	_	_
		1-4	64	2	3.3	2	100.0	1	50.0	_	_	_	_	_	_	_	_
		5-9	123	13	10.7	6	46.2	4	66.7	_	_	_	_	_	_	1	0.9
		10-14	94	23	25.6	13	56.5	5	38.5	_	_	1	1.2	1	1.2	_	_
		15-20	25	7	31.8	2	28.6	1	50.0	_	_	_	_	_	_	_	_
	Treatment	Surgery only	3	_	_	_	_	_	_	_	_	_	_	_	_	_	_

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		Chemotherapy, no radiation	15	2	13.3	2	100.0	1	50.0	_	_	_	_	_	_	_	_
		Radiation, no chemotherapy	70	12	17.1	8	66.7	3	37.5	_	_	_	_	_	_	_	_
		Chemotherapy and radiation	199	29	15.5	14	48.3	8	57.1	_	_	1	0.6	1	0.6	_	_
		Unknown	23	3	13.0	_	_	_	_	_	_	_	_	_	_	1	4.8

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

Tobacco use: Hodgkin

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**3050**	**1108**	**37.0**	**498**	**44.9**	**251**	**50.4**	**105**	**3.9**	**84**	**3.1**	**24**	**0.9**	**240**	**8.8**
	Age at baseline	18-19	61	13	22.4	9	69.2	4	44.4	3	5.5	1	1.8	1	1.8	6	10.3
		20-24	375	112	31.7	64	57.1	34	53.1	17	5.2	6	1.9	4	1.3	28	8.6
		25-29	798	267	34.0	131	49.1	69	52.7	33	4.6	26	3.6	4	0.6	71	9.9
		30-34	951	367	39.2	161	43.9	75	46.6	33	3.9	26	3.1	11	1.3	78	9.0
		35+	865	349	40.6	133	38.1	69	51.9	19	2.5	25	3.3	4	0.5	57	7.5
	Years since diagnosis	5-9	206	51	27.3	15	29.4	8	53.3	7	3.9	1	0.6	2	1.1	7	3.9
		10-14	921	302	33.6	139	46.0	76	54.7	28	3.3	20	2.4	8	1.0	83	9.7
		15-19	1008	367	36.8	176	48.0	88	50.0	34	3.8	33	3.7	7	0.8	89	9.8
		20+	915	388	42.7	168	43.3	79	47.0	36	4.5	30	3.8	7	0.9	61	7.7
	Age at diagnosis	1-4	66	22	33.3	18	81.8	10	55.6	2	3.6	_	_	1	1.9	8	14.3
		5-9	381	133	35.6	81	60.9	34	42.0	22	6.5	14	4.3	4	1.3	30	9.0
		10-14	1115	403	36.8	198	49.1	102	51.5	52	5.3	37	3.8	9	0.9	90	9.1
		15-20	1488	550	37.7	201	36.5	105	52.2	29	2.2	33	2.5	10	0.8	112	8.3
	Treatment	Surgery only	2	_	_	_	_	_	_	_	_	_	_	_	_	_	_
		Chemotherapy, no radiation	358	133	37.9	62	46.6	35	56.5	10	3.3	10	3.4	3	1.0	30	10.0
		Radiation, no chemotherapy	642	238	37.5	119	50.0	55	46.2	25	4.2	22	3.7	7	1.2	47	7.8
		Chemotherapy and radiation	1726	602	35.6	251	41.7	132	52.6	63	4.1	46	3.1	12	0.8	137	8.9
		Unknown	322	135	42.7	66	48.9	29	43.9	7	2.4	6	2.1	2	0.7	26	9.0
Males	**All cases**		**1588**	**602**	**38.9**	**288**	**47.8**	**136**	**47.2**	**101**	**7.3**	**84**	**6.2**	**24**	**1.8**	**220**	**15.9**
	Age at baseline	18-19	48	10	21.7	8	80.0	4	50.0	3	7.0	1	2.3	1	2.3	6	13.0
		20-24	239	84	37.7	50	59.5	23	46.0	17	8.3	6	3.1	4	2.1	26	13.0
		25-29	445	150	34.5	74	49.3	36	48.6	31	7.8	26	6.6	4	1.1	67	17.0
		30-34	482	197	41.5	95	48.2	43	45.3	32	7.6	26	6.3	11	2.7	70	16.4
		35+	374	161	43.5	61	37.9	30	49.2	18	5.7	25	8.0	4	1.3	51	15.8
	Years since diagnosis	5-9	111	30	30.9	11	36.7	4	36.4	6	6.5	1	1.1	2	2.2	7	7.6
		10-14	472	163	35.6	79	48.5	45	57.0	28	6.6	20	4.8	8	2.0	79	18.5
		15-19	537	202	38.0	103	51.0	47	45.6	32	6.9	33	7.3	7	1.6	78	16.6

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

Tobacco use: Hodgkin

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		20+	468	207	44.7	95	45.9	40	42.1	35	8.8	30	7.7	7	1.8	56	14.1
	Age at diagnosis	1-4	48	17	35.4	14	82.4	7	50.0	2	5.0	_	_	1	2.6	7	17.5
		5-9	276	102	37.6	65	63.7	26	40.0	21	8.5	14	5.9	4	1.7	28	11.6
		10-14	578	219	38.8	112	51.1	51	45.5	52	10.3	37	7.6	9	1.9	81	16.1
		15-20	686	264	39.7	97	36.7	52	53.6	26	4.4	33	5.6	10	1.7	104	17.2
	Treatment	Surgery only	2	_	_	_	_	_	_	_	_	_	_	_	_	_	_
		Chemotherapy, no radiation	183	68	38.2	36	52.9	17	47.2	9	5.8	10	6.8	3	2.1	26	17.3
		Radiation, no chemotherapy	328	134	41.7	71	53.0	34	47.9	25	8.5	22	7.5	7	2.5	46	15.5
		Chemotherapy and radiation	885	324	37.5	139	42.9	72	51.8	60	7.9	46	6.2	12	1.7	125	16.2
		Unknown	190	76	41.1	42	55.3	13	31.0	7	4.2	6	3.6	2	1.2	23	13.7
Females	**All cases**		**1462**	**506**	**35.1**	**210**	**41.5**	**115**	**54.8**	**4**	**0.3**	**_**	**_**	**_**	**_**	**20**	**1.5**
	Age at baseline	18-19	13	3	25.0	1	33.3	_	_	_	_	_	_	_	_	_	_
		20-24	136	28	21.5	14	50.0	11	78.6	_	_	_	_	_	_	2	1.6
		25-29	353	117	33.4	57	48.7	33	57.9	2	0.6	_	_	_	_	4	1.2
		30-34	469	170	36.8	66	38.8	32	48.5	1	0.2	_	_	_	_	8	1.8
		35+	491	188	38.4	72	38.3	39	54.2	1	0.2	_	_	_	_	6	1.4
	Years since diagnosis	5-9	95	21	23.3	4	19.0	4	100.0	1	1.1	_	_	_	_	_	_
		10-14	449	139	31.5	60	43.2	31	51.7	_	_	_	_	_	_	4	0.9
		15-19	471	165	35.3	73	44.2	41	56.2	2	0.5	_	_	_	_	11	2.5
		20+	447	181	40.7	73	40.3	39	53.4	1	0.3	_	_	_	_	5	1.3
	Age at diagnosis	1-4	18	5	27.8	4	80.0	3	75.0	_	_	_	_	_	_	1	6.3
		5-9	105	31	30.1	16	51.6	8	50.0	1	1.1	_	_	_	_	2	2.2
		10-14	537	184	34.8	86	46.7	51	59.3	_	_	_	_	_	_	9	1.8
		15-20	802	286	36.1	104	36.4	53	51.0	3	0.4	_	_	_	_	8	1.1
	Treatment	Chemotherapy, no radiation	175	65	37.6	26	40.0	18	69.2	1	0.7	_	_	_	_	4	2.6
		Radiation, no chemotherapy	314	104	33.2	48	46.2	21	43.8	_	_	_	_	_	_	1	0.3
		Chemotherapy and radiation	841	278	33.7	112	40.3	60	53.6	3	0.4	_	_	_	_	12	1.6
		Unknown	132	59	45.0	24	40.7	16	66.7	_	_	_	_	_	_	3	2.5

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

Tobacco use: NHL

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**1905**	**658**	**35.2**	**342**	**52.0**	**182**	**53.2**	**123**	**7.5**	**77**	**4.8**	**35**	**2.2**	**201**	**12.1**
	Age at baseline	18-19	132	20	15.7	14	70.0	9	64.3	11	9.0	8	6.7	5	4.2	7	5.7
		20-24	469	137	30.0	86	62.8	43	50.0	28	6.8	17	4.2	13	3.2	46	11.0
		25-29	572	202	36.0	107	53.0	57	53.3	41	8.4	28	5.8	8	1.7	61	12.2
		30-34	483	200	41.8	95	47.5	51	53.7	36	8.7	19	4.7	8	2.0	52	12.5
		35+	249	99	40.1	40	40.4	22	55.0	7	3.6	5	2.6	1	0.5	35	16.9
	Years since diagnosis	5-9	74	15	22.7	4	26.7	_	_	_	_	3	5.0	1	1.7	4	6.6
		10-14	542	164	31.1	91	55.5	50	54.9	41	8.3	28	5.7	10	2.1	44	8.9
		15-19	717	238	33.7	129	54.2	71	55.0	41	6.6	25	4.1	14	2.3	71	11.2
		20+	572	241	42.4	118	49.0	61	51.7	41	9.0	21	4.7	10	2.3	82	17.2
	Age at diagnosis	<1	2	_	_	_	_	_	_	1	50.0	_	_	_	_	_	_
		1-4	228	71	31.3	36	50.7	20	55.6	21	10.4	9	4.5	7	3.5	30	14.7
		5-9	573	183	32.5	116	63.4	63	54.3	36	7.4	23	4.9	18	3.8	63	12.5
		10-14	668	253	38.7	131	51.8	62	47.3	45	7.9	33	5.8	8	1.4	68	11.7
		15-20	434	151	35.7	59	39.1	37	62.7	20	5.3	12	3.3	2	0.6	40	10.7
	Treatment	Surgery only	12	6	54.5	2	33.3	2	100.0	1	11.1	_	_	_	_	2	22.2
		Chemotherapy, no radiation	965	351	37.3	170	48.4	103	60.6	77	9.8	49	6.3	21	2.7	110	13.6
		Radiation, no chemotherapy	37	12	33.3	5	41.7	3	60.0	1	3.1	_	_	1	3.0	2	5.9
		Chemotherapy and radiation	684	220	32.5	122	55.5	60	49.2	35	5.7	19	3.1	8	1.3	68	10.9
		Unknown	207	69	33.7	43	62.3	14	32.6	9	4.9	9	4.9	5	2.8	19	10.2
Males	**All cases**		**1291**	**473**	**37.5**	**257**	**54.3**	**136**	**52.9**	**123**	**11.3**	**77**	**7.2**	**33**	**3.2**	**193**	**17.3**
	Age at baseline	18-19	97	16	17.2	11	68.8	6	54.5	11	12.5	8	9.4	5	5.8	7	7.9
		20-24	304	95	32.2	65	68.4	37	56.9	28	10.9	17	6.7	11	4.4	43	16.3
		25-29	407	146	36.6	83	56.8	44	53.0	41	11.9	28	8.2	8	2.4	59	16.5
		30-34	319	141	44.9	71	50.4	36	50.7	36	13.6	19	7.3	8	3.2	50	18.9
		35+	164	75	46.3	27	36.0	13	48.1	7	5.4	5	3.9	1	0.8	34	23.9
	Years since diagnosis	5-9	56	10	19.2	4	40.0	_	_	_	_	3	6.4	1	2.2	4	8.3
		10-14	367	114	32.1	69	60.5	37	53.6	41	12.6	28	8.8	10	3.2	40	12.2

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

Tobacco use: NHL

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		15-19	476	171	36.5	97	56.7	56	57.7	41	10.4	25	6.4	12	3.1	70	17.1
		20+	392	178	45.9	87	48.9	43	49.4	41	13.0	21	6.9	10	3.3	79	23.8
	Age at diagnosis	<1	1	_	_	_	_	_	_	1	100.0	_	_	_	_	_	_
		1-4	154	49	32.0	24	49.0	15	62.5	21	15.7	9	6.8	7	5.3	28	20.6
		5-9	393	131	34.1	90	68.7	51	56.7	36	10.9	23	7.3	16	5.1	61	17.8
		10-14	459	185	41.2	100	54.1	45	45.0	45	11.8	33	8.6	8	2.1	64	16.2
		15-20	284	108	39.1	43	39.8	25	58.1	20	8.3	12	5.2	2	0.9	40	16.6
	Treatment	Surgery only	11	5	50.0	1	20.0	1	100.0	1	12.5	_	_	_	_	2	25.0
		Chemotherapy, no radiation	648	258	41.0	132	51.2	78	59.1	77	14.8	49	9.6	19	3.8	106	19.6
		Radiation, no chemotherapy	27	9	34.6	3	33.3	1	33.3	1	4.3	_	_	1	4.2	1	4.0
		Chemotherapy and radiation	456	149	33.1	89	59.7	43	48.3	35	8.7	19	4.8	8	2.0	66	16.1
		Unknown	149	52	35.4	32	61.5	13	40.6	9	6.9	9	7.0	5	4.0	18	13.7
Females	**All cases**		**614**	**185**	**30.5**	**85**	**45.9**	**46**	**54.1**	_	_	_	_	**2**	**0.4**	**8**	**1.5**
	Age at baseline	18-19	35	4	11.8	3	75.0	3	100.0	_	_	_	_	_	_	_	_
		20-24	165	42	26.1	21	50.0	6	28.6	_	_	_	_	2	1.3	3	1.9
		25-29	165	56	34.6	24	42.9	13	54.2	_	_	_	_	_	_	2	1.4
		30-34	164	59	36.0	24	40.7	15	62.5	_	_	_	_	_	_	2	1.3
		35+	85	24	28.2	13	54.2	9	69.2	_	_	_	_	_	_	1	1.5
	Years since diagnosis	5-9	18	5	35.7	_	_	_	_	_	_	_	_	_	_	_	_
		10-14	175	50	28.9	22	44.0	13	59.1	_	_	_	_	_	_	4	2.4
		15-19	241	67	28.0	32	47.8	15	46.9	_	_	_	_	2	0.9	1	0.4
		20+	180	63	35.0	31	49.2	18	58.1	_	_	_	_	_	_	3	2.1
	Age at diagnosis	<1	1	_	_	_	_	_	_	_	_	_	_	_	_	_	_
		1-4	74	22	29.7	12	54.5	5	41.7	_	_	_	_	_	_	2	2.9
		5-9	180	52	29.1	26	50.0	12	46.2	_	_	_	_	2	1.3	2	1.3
		10-14	209	68	33.2	31	45.6	17	54.8	_	_	_	_	_	_	4	2.2
		15-20	150	43	29.3	16	37.2	12	75.0	_	_	_	_	_	_	_	_
	Treatment	Surgery only	1	1	100.0	1	100.0	1	100.0	_	_	_	_	_	_	_	_

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		Chemotherapy, no radiation	317	93	29.9	38	40.9	25	65.8	_	_	_	_	2	0.7	4	1.5
		Radiation, no chemotherapy	10	3	30.0	2	66.7	2	100.0	_	_	_	_	_	_	1	11.1
		Chemotherapy and radiation	228	71	31.4	33	46.5	17	51.5	_	_	_	_	_	_	2	0.9
		Unknown	58	17	29.3	11	64.7	1	9.1	_	_	_	_	_	_	1	1.8

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

Tobacco use: Wilms

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**1445**	**423**	**29.7**	**262**	**61.9**	**141**	**53.8**	**54**	**4.4**	**28**	**2.3**	**22**	**1.8**	**143**	**11.3**
	Age at baseline	18-19	305	73	24.6	51	69.9	20	39.2	11	4.0	7	2.5	3	1.1	14	5.1
		20-24	670	181	27.3	116	64.1	64	55.2	33	5.6	11	1.9	13	2.3	64	10.7
		25-29	374	134	36.5	77	57.5	44	57.1	10	3.3	9	3.0	6	2.0	57	17.9
		30-34	77	28	36.4	15	53.6	12	80.0	_	_	_	_	_	_	7	11.9
		35+	19	7	36.8	3	42.9	1	33.3	_	_	1	6.3	_	_	1	6.7
	Years since diagnosis	5-9	11	4	50.0	2	50.0	1	50.0	_	_	_	_	_	_	1	12.5
		10-14	170	40	24.1	25	62.5	10	40.0	7	4.5	2	1.3	3	2.0	7	4.5
		15-19	661	165	25.4	117	70.9	60	51.3	19	3.3	15	2.6	11	1.9	63	10.6
		20+	603	214	35.8	118	55.1	70	59.3	28	5.6	11	2.3	8	1.6	72	14.1
	Age at diagnosis	<1	149	51	34.2	29	56.9	15	51.7	11	8.8	5	4.1	3	2.5	16	12.6
		1-4	825	238	29.3	151	63.4	81	53.6	30	4.3	13	1.9	14	2.0	83	11.5
		5-9	390	102	26.6	62	60.8	32	51.6	13	3.8	9	2.7	4	1.2	40	11.5
		10-14	58	23	40.4	14	60.9	9	64.3	_	_	1	2.0	1	2.0	2	4.1
		15-20	23	9	45.0	6	66.7	4	66.7	_	_	_	_	_	_	2	11.1
	Treatment	Surgery only	15	6	42.9	4	66.7	3	75.0	2	16.7	_	_	_	_	1	7.7
		Chemotherapy, no radiation	507	150	29.9	88	58.7	46	52.3	21	5.2	12	3.0	9	2.3	62	14.8
		Radiation, no chemotherapy	4	_	_	_	_	_	_	_	_	_	_	_	_	1	25.0
		Chemotherapy and radiation	781	224	29.3	138	61.6	73	52.9	23	3.4	12	1.8	11	1.6	69	9.8
		Unknown	138	43	31.2	32	74.4	19	59.4	8	6.3	4	3.1	2	1.6	10	7.9
Males	**All cases**		**616**	**205**	**33.7**	**134**	**65.4**	**67**	**50.0**	**53**	**10.2**	**28**	**5.5**	**18**	**3.6**	**114**	**21.0**
	Age at baseline	18-19	126	38	30.9	28	73.7	9	32.1	11	9.7	7	6.1	2	1.8	11	9.6
		20-24	285	95	33.6	66	69.5	37	56.1	33	13.4	11	4.7	10	4.3	51	20.1
		25-29	165	57	35.2	33	57.9	16	48.5	9	6.9	9	7.0	6	4.7	46	31.7
		30-34	32	13	40.6	7	53.8	5	71.4	_	_	_	_	_	_	6	24.0
		35+	8	2	25.0	_	_	_	_	_	_	1	16.7	_	_	_	_
	Years since diagnosis	5-9	4	2	100.0	1	50.0	_	_	_	_	_	_	_	_	1	50.0
		10-14	59	18	32.1	11	61.1	3	27.3	7	13.5	2	4.0	3	6.0	6	11.8

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

Tobacco use: Wilms

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		15-19	280	76	27.3	62	81.6	34	54.8	19	8.1	15	6.3	7	3.0	49	19.0
		20+	273	109	40.1	60	55.0	30	50.0	27	11.8	11	5.1	8	3.7	58	24.9
	Age at diagnosis	<1	70	31	44.3	19	61.3	8	42.1	11	17.7	5	8.5	1	1.7	10	16.4
		1-4	356	120	34.1	79	65.8	43	54.4	29	9.7	13	4.4	12	4.1	68	21.5
		5-9	161	45	28.3	30	66.7	13	43.3	13	9.6	9	6.9	4	3.1	32	22.2
		10-14	20	6	30.0	4	66.7	2	50.0	_	_	1	5.6	1	5.9	2	11.8
		15-20	9	3	42.9	2	66.7	1	50.0	_	_	_	_	_	_	2	40.0
	Treatment	Surgery only	8	3	37.5	3	100.0	2	66.7	2	28.6	_	_	_	_	1	12.5
		Chemotherapy, no radiation	222	74	33.6	48	64.9	22	45.8	21	11.8	12	6.9	6	3.5	48	25.4
		Chemotherapy and radiation	316	102	32.9	63	61.8	30	47.6	22	8.2	12	4.6	10	3.8	57	20.1
		Unknown	70	26	37.1	20	76.9	13	65.0	8	12.3	4	6.3	2	3.2	8	12.5
Females	**All cases**		**829**	**218**	**26.8**	**128**	**58.7**	**74**	**57.8**	**1**	**0.1**	**_**	**_**	**4**	**0.6**	**29**	**4.0**
	Age at baseline	18-19	179	35	20.1	23	65.7	11	47.8	_	_	_	_	1	0.6	3	1.9
		20-24	385	86	22.7	50	58.1	27	54.0	_	_	_	_	3	0.9	13	3.8
		25-29	209	77	37.6	44	57.1	28	63.6	1	0.6	_	_	_	_	11	6.4
		30-34	45	15	33.3	8	53.3	7	87.5	_	_	_	_	_	_	1	2.9
		35+	11	5	45.5	3	60.0	1	33.3	_	_	_	_	_	_	1	10.0
	Years since diagnosis	5-9	7	2	33.3	1	50.0	1	100.0	_	_	_	_	_	_	_	_
		10-14	111	22	20.0	14	63.6	7	50.0	_	_	_	_	_	_	1	1.0
		15-19	381	89	23.9	55	61.8	26	47.3	_	_	_	_	4	1.2	14	4.2
		20+	330	105	32.2	58	55.2	40	69.0	1	0.4	_	_	_	_	14	5.1
	Age at diagnosis	<1	79	20	25.3	10	50.0	7	70.0	_	_	_	_	2	3.2	6	9.1
		1-4	469	118	25.7	72	61.0	38	52.8	1	0.2	_	_	2	0.5	15	3.7
		5-9	229	57	25.3	32	56.1	19	59.4	_	_	_	_	_	_	8	3.9
		10-14	38	17	45.9	10	58.8	7	70.0	_	_	_	_	_	_	_	_
		15-20	14	6	46.2	4	66.7	3	75.0	_	_	_	_	_	_	_	_
	Treatment	Surgery only	7	3	50.0	1	33.3	1	100.0	_	_	_	_	_	_	_	_
		Chemotherapy, no radiation	285	76	27.0	40	52.6	24	60.0	_	_	_	_	3	1.3	14	6.1

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		Radiation, no chemotherapy	4	_	_	_	_	_	_	_	_	_	_	_	_	1	25.0
		Chemotherapy and radiation	465	122	26.8	75	61.5	43	57.3	1	0.2	_	_	1	0.2	12	2.9
		Unknown	68	17	25.0	12	70.6	6	50.0	_	_	_	_	_	_	2	3.2

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

Tobacco use: Neuroblastoma

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**997**	**294**	**30.3**	**169**	**57.5**	**91**	**53.8**	**34**	**4.0**	**27**	**3.2**	**18**	**2.2**	**83**	**9.6**
	Age at baseline	18-19	237	51	22.5	33	64.7	13	39.4	5	2.4	2	1.0	_	_	10	4.7
		20-24	544	168	31.6	98	58.3	57	58.2	23	4.9	18	3.9	14	3.0	51	10.7
		25-29	172	60	35.7	30	50.0	18	60.0	4	3.0	4	3.1	3	2.3	16	11.9
		30-34	36	10	27.8	4	40.0	1	25.0	2	6.9	3	10.0	1	3.4	5	16.1
		35+	8	5	62.5	4	80.0	2	50.0	_	_	_	_	_	_	1	14.3
	Years since diagnosis	5-9	8	1	25.0	_	_	_	_	_	_	_	_	_	_	_	_
		10-14	54	11	22.0	5	45.5	3	60.0	1	2.1	1	2.1	_	_	1	2.2
		15-19	390	99	26.2	57	57.6	29	50.9	8	2.3	12	3.6	3	0.9	25	7.2
		20+	545	183	34.0	107	58.5	59	55.1	25	5.5	14	3.1	15	3.3	57	12.3
	Age at diagnosis	<1	435	140	32.9	87	62.1	47	54.0	25	6.6	10	2.7	10	2.7	44	11.7
		1-4	414	106	26.0	60	56.6	33	55.0	6	1.7	10	2.9	6	1.7	29	8.1
		5-9	101	32	33.0	14	43.8	7	50.0	2	2.3	6	6.9	2	2.4	7	8.0
		10-14	28	10	38.5	5	50.0	2	40.0	_	_	_	_	_	_	2	8.7
		15-20	19	6	40.0	3	50.0	2	66.7	1	7.7	1	7.7	_	_	1	7.7
	Treatment	Surgery only	280	89	32.7	45	50.6	23	51.1	9	3.9	10	4.4	6	2.7	29	12.3
		Chemotherapy, no radiation	243	82	34.6	49	59.8	29	59.2	13	6.4	9	4.5	7	3.5	31	14.9
		Radiation, no chemotherapy	75	22	29.3	15	68.2	3	20.0	5	6.9	3	4.5	1	1.4	7	10.1
		Chemotherapy and radiation	306	69	23.4	42	60.9	27	64.3	5	2.0	4	1.6	4	1.6	11	4.2
		Unknown	93	32	34.8	18	56.3	9	50.0	2	2.2	1	1.1	_	_	5	5.6
Males	**All cases**		**474**	**157**	**34.1**	**103**	**65.6**	**59**	**57.3**	**32**	**8.1**	**26**	**6.7**	**17**	**4.5**	**68**	**16.9**
	Age at baseline	18-19	104	27	27.3	19	70.4	8	42.1	4	4.4	2	2.2	_	_	8	8.7
		20-24	275	90	33.6	58	64.4	36	62.1	22	9.6	17	7.5	13	5.9	43	18.4
		25-29	78	33	43.4	22	66.7	14	63.6	4	6.5	4	7.0	3	5.1	13	21.3
		30-34	14	6	42.9	3	50.0	1	33.3	2	18.2	3	25.0	1	9.1	4	30.8
		35+	3	1	33.3	1	100.0	_	_	_	_	_	_	_	_	_	_
	Years since diagnosis	5-9	2	_	_	_	_	_	_	_	_	_	_	_	_	_	_
		10-14	25	8	38.1	3	37.5	2	66.7	1	4.8	1	4.8	_	_	1	5.0

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

Tobacco use: Neuroblastoma

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		15-19	181	52	29.7	33	63.5	19	57.6	7	4.5	11	7.1	3	2.0	19	11.8
		20+	266	97	36.9	67	69.1	38	56.7	24	11.1	14	6.6	14	6.7	48	21.7
	Age at diagnosis	<1	224	83	37.6	55	66.3	31	56.4	23	12.0	10	5.4	9	5.0	37	19.3
		1-4	182	45	25.3	32	71.1	19	59.4	6	4.1	9	6.2	6	4.1	23	15.0
		5-9	50	20	43.5	11	55.0	7	63.6	2	4.8	6	14.0	2	4.9	6	13.6
		10-14	12	7	70.0	4	57.1	1	25.0	_	_	_	_	_	_	2	20.0
		15-20	6	2	40.0	1	50.0	1	100.0	1	20.0	1	20.0	_	_	_	_
	Treatment	Surgery only	133	43	33.3	27	62.8	16	59.3	8	7.3	9	8.3	6	5.7	25	21.9
		Chemotherapy, no radiation	115	45	39.8	30	66.7	21	70.0	12	12.6	9	9.6	6	6.7	27	27.0
		Radiation, no chemotherapy	33	13	39.4	9	69.2	2	22.2	5	16.7	3	12.0	1	3.7	6	22.2
		Chemotherapy and radiation	148	37	26.4	22	59.5	13	59.1	5	4.3	4	3.4	4	3.5	7	5.9
		Unknown	45	19	42.2	15	78.9	7	46.7	2	4.5	1	2.3	_	_	3	7.0
Females	**All cases**		**523**	**137**	**26.8**	**66**	**48.2**	**32**	**48.5**	**2**	**0.4**	**1**	**0.2**	**1**	**0.2**	**15**	**3.3**
	Age at baseline	18-19	133	24	18.8	14	58.3	5	35.7	1	0.8	_	_	_	_	2	1.7
		20-24	269	78	29.5	40	51.3	21	52.5	1	0.4	1	0.4	1	0.4	8	3.3
		25-29	94	27	29.3	8	29.6	4	50.0	_	_	_	_	_	_	3	4.1
		30-34	22	4	18.2	1	25.0	_	_	_	_	_	_	_	_	1	5.6
		35+	5	4	80.0	3	75.0	2	66.7	_	_	_	_	_	_	1	25.0
	Years since diagnosis	5-9	6	1	33.3	_	_	_	_	_	_	_	_	_	_	_	_
		10-14	29	3	10.3	2	66.7	1	50.0	_	_	_	_	_	_	_	_
		15-19	209	47	23.2	24	51.1	10	41.7	1	0.5	1	0.5	_	_	6	3.2
		20+	279	86	31.2	40	46.5	21	52.5	1	0.4	_	_	1	0.4	9	3.7
	Age at diagnosis	<1	211	57	27.8	32	56.1	16	50.0	2	1.1	_	_	1	0.5	7	3.8
		1-4	232	61	26.6	28	45.9	14	50.0	_	_	1	0.5	_	_	6	2.9
		5-9	51	12	23.5	3	25.0	_	_	_	_	_	_	_	_	1	2.3
		10-14	16	3	18.8	1	33.3	1	100.0	_	_	_	_	_	_	_	_
		15-20	13	4	40.0	2	50.0	1	50.0	_	_	_	_	_	_	1	11.1
	Treatment	Surgery only	147	46	32.2	18	39.1	7	38.9	1	0.8	1	0.8	_	_	4	3.3

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

Tobacco use: Neuroblastoma

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		Chemotherapy, no radiation	128	37	29.8	19	51.4	8	42.1	1	0.9	_	_	1	0.9	4	3.7
		Radiation, no chemotherapy	42	9	21.4	6	66.7	1	16.7	_	_	_	_	_	_	1	2.4
		Chemotherapy and radiation	158	32	20.6	20	62.5	14	70.0	_	_	_	_	_	_	4	2.9
		Unknown	48	13	27.7	3	23.1	2	66.7	_	_	_	_	_	_	2	4.3

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

Tobacco use: STS

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**1419**	**444**	**31.8**	**237**	**53.4**	**118**	**49.8**	**42**	**3.2**	**23**	**1.8**	**12**	**0.9**	**107**	**8.2**
	Age at baseline	18-19	125	18	14.5	12	66.7	2	16.7	2	1.7	3	2.6	_	_	2	1.7
		20-24	425	120	29.3	68	56.7	35	51.5	18	4.7	9	2.4	4	1.0	29	7.6
		25-29	393	123	31.6	64	52.0	33	51.6	12	3.4	3	0.8	3	0.9	33	9.1
		30-34	299	114	38.5	51	44.7	28	54.9	8	2.9	6	2.2	4	1.5	29	10.5
		35+	177	69	39.2	42	60.9	20	47.6	2	1.2	2	1.2	1	0.6	14	8.2
	Years since diagnosis	5-9	88	18	21.4	7	38.9	2	28.6	2	2.4	1	1.2	_	_	3	3.7
		10-14	314	93	30.4	46	49.5	25	54.3	6	2.0	6	2.1	4	1.4	17	5.9
		15-19	501	146	29.7	85	58.2	35	41.2	16	3.5	8	1.8	4	0.9	43	9.2
		20+	516	187	36.4	99	52.9	56	56.6	18	3.9	8	1.8	4	0.9	44	9.3
	Age at diagnosis	<1	56	17	30.4	10	58.8	6	60.0	2	4.0	_	_	_	_	1	2.0
		1-4	341	97	28.7	59	60.8	30	50.8	13	4.3	5	1.7	1	0.3	23	7.5
		5-9	350	103	30.2	46	44.7	22	47.8	14	4.4	8	2.5	4	1.3	28	8.8
		10-14	343	109	32.5	63	57.8	32	50.8	8	2.5	6	1.9	4	1.3	30	9.4
		15-20	329	118	36.3	59	50.0	28	47.5	5	1.6	4	1.3	3	1.0	25	8.0
	Treatment	Surgery only	152	62	40.8	32	51.6	18	56.3	6	4.1	5	3.5	2	1.4	8	5.7
		Chemotherapy, no radiation	281	95	34.4	46	48.4	22	47.8	10	3.9	8	3.2	3	1.2	33	12.8
		Radiation, no chemotherapy	59	23	39.0	14	60.9	7	50.0	1	1.8	1	1.8	_	_	4	7.1
		Chemotherapy and radiation	766	204	27.3	110	53.9	54	49.1	20	2.9	6	0.9	7	1.0	53	7.5
		Unknown	161	60	37.5	35	58.3	17	48.6	5	3.3	3	2.0	_	_	9	6.0
Males	**All cases**		**759**	**246**	**32.9**	**129**	**52.4**	**63**	**48.8**	**42**	**6.1**	**23**	**3.4**	**12**	**1.8**	**103**	**14.8**
	Age at baseline	18-19	66	11	16.7	6	54.5	_	_	2	3.2	3	4.9	_	_	2	3.3
		20-24	242	76	32.5	43	56.6	21	48.8	18	8.2	9	4.2	4	1.9	26	12.0
		25-29	208	69	33.5	37	53.6	18	48.6	12	6.3	3	1.6	3	1.7	33	17.2
		30-34	159	57	36.3	24	42.1	14	58.3	8	5.6	6	4.3	4	2.9	29	19.9
		35+	84	33	39.3	19	57.6	10	52.6	2	2.6	2	2.7	1	1.3	13	16.0
	Years since diagnosis	5-9	40	9	24.3	3	33.3	1	33.3	2	5.6	1	2.8	_	_	3	8.8
		10-14	170	46	27.7	22	47.8	12	54.5	6	3.8	6	3.8	4	2.6	17	10.9

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		15-19	268	88	33.3	48	54.5	20	41.7	16	6.5	8	3.3	4	1.7	41	16.7
		20+	281	103	36.8	56	54.4	30	53.6	18	7.2	8	3.3	4	1.6	42	16.1
	Age at diagnosis	<1	25	7	28.0	5	71.4	2	40.0	2	8.0	_	_	_	_	_	_
		1-4	198	63	32.0	41	65.1	20	48.8	13	7.3	5	2.9	1	0.6	21	11.6
		5-9	196	63	32.6	26	41.3	11	42.3	14	8.0	8	4.6	4	2.3	28	15.7
		10-14	183	52	29.4	29	55.8	16	55.2	8	4.9	6	3.7	4	2.6	29	17.8
		15-20	157	61	39.4	28	45.9	14	50.0	5	3.4	4	2.7	3	2.1	25	16.7
	Treatment	Surgery only	69	29	42.0	16	55.2	8	50.0	6	8.8	5	7.6	2	3.1	8	12.5
		Chemotherapy, no radiation	166	58	35.4	27	46.6	12	44.4	10	6.6	8	5.3	3	2.1	32	21.1
		Radiation, no chemotherapy	28	8	28.6	5	62.5	3	60.0	1	3.8	1	4.0	_	_	4	15.4
		Chemotherapy and radiation	401	116	29.6	64	55.2	32	50.0	20	5.6	6	1.7	7	2.0	50	13.6
		Unknown	95	35	37.2	17	48.6	8	47.1	5	5.7	3	3.5	_	_	9	10.3
Females	**All cases**		**660**	**198**	**30.6**	**108**	**54.5**	**55**	**50.9**	_	_	_	_	_	_	**4**	**0.7**
	Age at baseline	18-19	59	7	12.1	6	85.7	2	33.3	_	_	_	_	_	_	_	_
		20-24	183	44	25.0	25	56.8	14	56.0	_	_	_	_	_	_	3	1.8
		25-29	185	54	29.5	27	50.0	15	55.6	_	_	_	_	_	_	_	_
		30-34	140	57	41.0	27	47.4	14	51.9	_	_	_	_	_	_	_	_
		35+	93	36	39.1	23	63.9	10	43.5	_	_	_	_	_	_	1	1.1
	Years since diagnosis	5-9	48	9	19.1	4	44.4	1	25.0	_	_	_	_	_	_	_	_
		10-14	144	47	33.6	24	51.1	13	54.2	_	_	_	_	_	_	_	_
		15-19	233	58	25.6	37	63.8	15	40.5	_	_	_	_	_	_	2	0.9
		20+	235	84	35.9	43	51.2	26	60.5	_	_	_	_	_	_	2	0.9
	Age at diagnosis	<1	31	10	32.3	5	50.0	4	80.0	_	_	_	_	_	_	1	4.0
		1-4	143	34	24.1	18	52.9	10	55.6	_	_	_	_	_	_	2	1.6
		5-9	154	40	27.0	20	50.0	11	55.0	_	_	_	_	_	_	_	_
		10-14	160	57	36.1	34	59.6	16	47.1	_	_	_	_	_	_	1	0.6
		15-20	172	57	33.5	31	54.4	14	45.2	_	_	_	_	_	_	_	_
	Treatment	Surgery only	83	33	39.8	16	48.5	10	62.5	_	_	_	_	_	_	_	_

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		Chemotherapy, no radiation	115	37	33.0	19	51.4	10	52.6	_	_	_	_	_	_	1	1.0
		Radiation, no chemotherapy	31	15	48.4	9	60.0	4	44.4	_	_	_	_	_	_	_	_
		Chemotherapy and radiation	365	88	24.7	46	52.3	22	47.8	_	_	_	_	_	_	3	0.9
		Unknown	66	25	37.9	18	72.0	9	50.0	_	_	_	_	_	_	_	_

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

Tobacco use: All bone

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**2004**	**660**	**34.4**	**322**	**48.8**	**147**	**45.7**	**82**	**4.7**	**55**	**3.2**	**28**	**1.7**	**166**	**9.5**
	Age at baseline	18-19	72	7	11.7	2	28.6	_	_	3	5.3	1	1.8	_	_	4	6.9
		20-24	389	101	28.8	55	54.5	28	50.9	20	6.0	12	3.7	1	0.3	29	8.6
		25-29	568	165	30.5	86	52.1	39	45.3	28	5.6	16	3.3	14	2.9	41	8.1
		30-34	567	215	38.5	100	46.5	43	43.0	14	2.8	12	2.5	8	1.6	46	9.2
		35+	408	172	42.5	79	45.9	37	46.8	17	5.0	14	4.1	5	1.5	46	13.1
	Years since diagnosis	5-9	187	41	29.1	15	36.6	2	13.3	11	8.0	6	4.4	3	2.2	8	5.9
		10-14	645	200	32.1	103	51.5	53	51.5	30	5.1	16	2.8	9	1.6	44	7.4
		15-19	673	230	34.8	117	50.9	57	48.7	24	4.1	19	3.3	10	1.7	62	10.4
		20+	499	189	38.4	87	46.0	35	40.2	17	4.1	14	3.4	6	1.5	52	12.1
	Age at diagnosis	<1	2	2	100.0	_	_	_	_	_	_	_	_	_	_	1	50.0
		1-4	58	10	18.5	3	30.0	1	33.3	3	6.3	1	2.1	1	2.2	7	14.0
		5-9	322	83	26.3	47	56.6	19	40.4	9	3.2	7	2.5	2	0.7	31	10.7
		10-14	830	263	33.1	138	52.5	67	48.6	36	5.0	25	3.5	12	1.7	60	8.2
		15-20	792	302	40.3	134	44.4	60	44.8	34	5.0	22	3.3	13	2.0	67	9.9
	Treatment	Surgery only	119	46	39.0	27	58.7	10	37.0	6	5.5	2	1.9	2	1.9	9	8.3
		Chemotherapy, no radiation	1149	385	35.0	184	47.8	84	45.7	46	4.7	25	2.6	19	2.0	102	10.2
		Radiation, no chemotherapy	16	6	42.9	5	83.3	3	60.0	_	_	_	_	_	_	_	_
		Chemotherapy and radiation	541	156	30.6	71	45.5	36	50.7	16	3.5	23	5.0	6	1.3	47	10.1
		Unknown	179	67	38.7	35	52.2	14	40.0	14	8.6	5	3.1	1	0.6	8	4.9
Males	**All cases**		**1038**	**361**	**36.6**	**173**	**47.9**	**70**	**40.5**	**81**	**9.3**	**55**	**6.5**	**28**	**3.4**	**151**	**17.0**
	Age at baseline	18-19	36	6	18.8	1	16.7	_	_	3	10.0	1	3.3	_	_	4	12.9
		20-24	194	44	25.6	21	47.7	13	61.9	19	12.0	12	7.8	1	0.7	26	16.4
		25-29	299	99	35.4	54	54.5	20	37.0	28	11.0	16	6.6	14	5.8	39	15.1
		30-34	284	112	40.3	49	43.8	19	38.8	14	5.8	12	5.2	8	3.4	41	16.7
		35+	225	100	44.6	48	48.0	18	37.5	17	9.1	14	7.8	5	2.9	41	21.2
	Years since diagnosis	5-9	100	23	30.7	7	30.4	2	28.6	11	15.1	6	8.3	3	4.3	8	11.4
		10-14	337	108	33.6	54	50.0	25	46.3	29	9.8	16	5.6	9	3.2	39	13.1

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

Tobacco use: All bone

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		15-19	346	125	37.0	63	50.4	27	42.9	24	8.0	19	6.6	10	3.5	56	18.4
		20+	255	105	41.7	49	46.7	16	32.7	17	8.3	14	7.1	6	3.1	48	22.4
	Age at diagnosis	<1	1	1	100.0	_	_	_	_	_	_	_	_	_	_	1	100.0
		1-4	36	5	14.7	2	40.0	1	50.0	3	10.3	1	3.6	1	3.7	7	22.6
		5-9	164	48	29.6	26	54.2	7	26.9	8	5.7	7	5.1	2	1.5	28	18.8
		10-14	394	137	36.1	68	49.6	33	48.5	36	10.6	25	7.7	12	3.7	57	16.7
		15-20	443	170	41.5	77	45.3	29	37.7	34	9.4	22	6.3	13	3.8	58	15.9
	Treatment	Surgery only	48	17	36.2	9	52.9	4	44.4	6	13.3	2	4.9	2	4.9	8	18.2
		Chemotherapy, no radiation	589	212	37.8	105	49.5	40	38.1	46	9.4	25	5.3	19	4.1	93	18.5
		Radiation, no chemotherapy	9	3	37.5	2	66.7	1	50.0	_	_	_	_	_	_	_	_
		Chemotherapy and radiation	278	79	30.5	33	41.8	14	42.4	16	7.0	23	10.3	6	2.8	43	18.8
		Unknown	114	50	45.0	24	48.0	11	45.8	13	12.6	5	5.1	1	1.0	7	6.9
Females	**All cases**		**966**	**299**	**32.2**	**149**	**49.8**	**77**	**51.7**	**1**	**0.1**	**_**	**_**	**_**	**_**	**15**	**1.7**
	Age at baseline	18-19	36	1	3.6	1	100.0	_	_	_	_	_	_	_	_	_	_
		20-24	195	57	31.8	34	59.6	15	44.1	1	0.6	_	_	_	_	3	1.7
		25-29	269	66	25.3	32	48.5	19	59.4	_	_	_	_	_	_	2	0.8
		30-34	283	103	36.7	51	49.5	24	47.1	_	_	_	_	_	_	5	2.0
		35+	183	72	39.8	31	43.1	19	61.3	_	_	_	_	_	_	5	3.1
	Years since diagnosis	5-9	87	18	27.3	8	44.4	_	_	_	_	_	_	_	_	_	_
		10-14	308	92	30.5	49	53.3	28	57.1	1	0.3	_	_	_	_	5	1.7
		15-19	327	105	32.6	54	51.4	30	55.6	_	_	_	_	_	_	6	2.1
		20+	244	84	35.0	38	45.2	19	50.0	_	_	_	_	_	_	4	1.9
	Age at diagnosis	<1	1	1	100.0	_	_	_	_	_	_	_	_	_	_	_	_
		1-4	22	5	25.0	1	20.0	_	_	_	_	_	_	_	_	_	_
		5-9	158	35	22.7	21	60.0	12	57.1	1	0.7	_	_	_	_	3	2.1
		10-14	436	126	30.3	70	55.6	34	48.6	_	_	_	_	_	_	3	0.8
		15-20	349	132	38.9	57	43.2	31	54.4	_	_	_	_	_	_	9	2.9
	Treatment	Surgery only	71	29	40.8	18	62.1	6	33.3	_	_	_	_	_	_	1	1.6

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

Tobacco use: All bone

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		Chemotherapy, no radiation	560	173	32.0	79	45.7	44	55.7	_	_	_	_	_	_	9	1.8
		Radiation, no chemotherapy	7	3	50.0	3	100.0	2	66.7	_	_	_	_	_	_	_	_
		Chemotherapy and radiation	263	77	30.7	38	49.4	22	57.9	_	_	_	_	_	_	4	1.7
		Unknown	65	17	27.4	11	64.7	3	27.3	1	1.7	_	_	_	_	1	1.7

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

Tobacco use: Ewings

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**677**	**203**	**31.7**	**94**	**46.3**	**46**	**48.9**	**26**	**4.4**	**29**	**4.9**	**12**	**2.1**	**58**	**9.7**
	Age at baseline	18-19	36	3	10.7	1	33.3	_	_	2	7.1	1	3.6	_	_	1	3.6
		20-24	170	37	24.0	21	56.8	10	47.6	7	4.7	9	6.0	_	_	13	8.9
		25-29	204	62	32.0	33	53.2	16	48.5	8	4.4	8	4.5	8	4.4	15	8.2
		30-34	164	60	37.0	25	41.7	12	48.0	4	2.8	7	4.9	2	1.4	17	11.7
		35+	103	41	39.8	14	34.1	8	57.1	5	5.6	4	4.6	2	2.3	12	13.0
	Years since diagnosis	5-9	72	13	24.1	3	23.1	2	66.7	6	11.5	4	7.7	1	2.0	3	6.0
		10-14	222	62	29.4	32	51.6	15	46.9	7	3.5	11	5.6	2	1.0	15	7.6
		15-19	219	74	34.4	35	47.3	21	60.0	9	4.5	9	4.5	6	3.0	25	12.4
		20+	164	54	33.5	24	44.4	8	33.3	4	2.9	5	3.6	3	2.2	15	10.3
	Age at diagnosis	1-4	33	5	17.2	3	60.0	1	33.3	1	3.7	1	3.7	1	3.8	4	14.8
		5-9	154	39	25.8	23	59.0	7	30.4	1	0.7	3	2.1	2	1.4	11	7.7
		10-14	272	79	30.7	39	49.4	20	51.3	13	5.3	15	6.3	4	1.7	24	9.8
		15-20	218	80	39.2	29	36.3	18	62.1	11	6.0	10	5.5	5	2.7	19	10.4
	Treatment	Surgery only	1	_	_	_	_	_	_	_	_	_	_	_	_	_	_
		Chemotherapy, no radiation	191	63	33.9	29	46.0	17	58.6	7	4.2	7	4.2	5	3.0	20	11.7
		Radiation, no chemotherapy	2	_	_	_	_	_	_	_	_	_	_	_	_	_	_
		Chemotherapy and radiation	428	121	30.3	56	46.3	27	48.2	15	4.0	20	5.4	6	1.6	36	9.6
		Unknown	55	19	35.8	9	47.4	2	22.2	4	8.2	2	4.3	1	2.1	2	4.2
Males	**All cases**		**359**	**117**	**34.6**	**52**	**44.4**	**22**	**42.3**	**26**	**8.5**	**29**	**9.6**	**12**	**4.1**	**53**	**17.3**
	Age at baseline	18-19	20	3	17.6	1	33.3	_	_	2	11.8	1	5.9	_	_	1	5.9
		20-24	88	17	21.5	8	47.1	4	50.0	7	9.3	9	12.0	_	_	12	16.7
		25-29	105	39	39.8	22	56.4	8	36.4	8	9.2	8	9.3	8	9.3	14	15.7
		30-34	90	32	36.4	14	43.8	6	42.9	4	5.0	7	8.8	2	2.6	15	19.0
		35+	56	26	46.4	7	26.9	4	57.1	5	10.4	4	8.9	2	4.4	11	22.0
	Years since diagnosis	5-9	42	11	32.4	3	27.3	2	66.7	6	18.8	4	12.5	1	3.3	3	10.0
		10-14	111	32	31.1	14	43.8	3	21.4	7	7.4	11	11.8	2	2.2	13	14.0
		15-19	120	43	37.1	23	53.5	13	56.5	9	8.3	9	8.4	6	5.7	23	21.3

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

Tobacco use: Ewings

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		20+	86	31	36.5	12	38.7	4	33.3	4	5.6	5	7.0	3	4.3	14	18.4
	Age at diagnosis	1-4	20	3	16.7	2	66.7	1	50.0	1	6.3	1	6.3	1	6.7	4	25.0
		5-9	78	21	27.3	11	52.4	2	18.2	1	1.4	3	4.2	2	2.9	9	12.7
		10-14	144	49	35.8	25	51.0	12	48.0	13	10.2	15	12.2	4	3.4	24	18.8
		15-20	117	44	41.5	14	31.8	7	50.0	11	11.7	10	10.8	5	5.4	16	17.4
	Treatment	Chemotherapy, no radiation	101	36	36.7	19	52.8	10	52.6	7	8.0	7	8.0	5	5.7	19	20.9
		Radiation, no chemotherapy	1	_	_	_	_	_	_	_	_	_	_	_	_	_	_
		Chemotherapy and radiation	223	64	31.1	25	39.1	10	40.0	15	8.0	20	10.8	6	3.4	32	17.2
		Unknown	34	17	51.5	8	47.1	2	25.0	4	13.3	2	7.1	1	3.6	2	6.9
Females	**All cases**		**318**	**86**	**28.4**	**42**	**48.8**	**24**	**57.1**	_	_	_	_	_	_	**5**	**1.7**
	Age at baseline	18-19	16	_	_	_	_	_	_	_	_	_	_	_	_	_	_
		20-24	82	20	26.7	13	65.0	6	46.2	_	_	_	_	_	_	1	1.4
		25-29	99	23	24.0	11	47.8	8	72.7	_	_	_	_	_	_	1	1.1
		30-34	74	28	37.8	11	39.3	6	54.5	_	_	_	_	_	_	2	3.0
		35+	47	15	31.9	7	46.7	4	57.1	_	_	_	_	_	_	1	2.4
	Years since diagnosis	5-9	30	2	10.0	_	_	_	_	_	_	_	_	_	_	_	_
		10-14	111	30	27.8	18	60.0	12	66.7	_	_	_	_	_	_	2	1.9
		15-19	99	31	31.3	12	38.7	8	66.7	_	_	_	_	_	_	2	2.1
		20+	78	23	30.3	12	52.2	4	33.3	_	_	_	_	_	_	1	1.4
	Age at diagnosis	1-4	13	2	18.2	1	50.0	_	_	_	_	_	_	_	_	_	_
		5-9	76	18	24.3	12	66.7	5	41.7	_	_	_	_	_	_	2	2.8
		10-14	128	30	25.0	14	46.7	8	57.1	_	_	_	_	_	_	_	_
		15-20	101	36	36.7	15	41.7	11	73.3	_	_	_	_	_	_	3	3.3
	Treatment	Surgery only	1	_	_	_	_	_	_	_	_	_	_	_	_	_	_
		Chemotherapy, no radiation	90	27	30.7	10	37.0	7	70.0	_	_	_	_	_	_	1	1.3
		Radiation, no chemotherapy	1	_	_	_	_	_	_	_	_	_	_	_	_	_	_
		Chemotherapy and radiation	205	57	29.4	31	54.4	17	54.8	_	_	_	_	_	_	4	2.1
		Unknown	21	2	10.0	1	50.0	_	_	_	_	_	_	_	_	_	_

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

Tobacco use: Osteosarcoma

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**1230**	**424**	**36.0**	**213**	**50.2**	**94**	**44.1**	**50**	**4.7**	**23**	**2.2**	**16**	**1.5**	**95**	**8.8**
	Age at baseline	18-19	30	4	15.4	1	25.0	_	_	_	_	_	_	_	_	2	8.0
		20-24	199	56	31.6	31	55.4	17	54.8	12	7.1	2	1.2	1	0.6	12	6.9
		25-29	344	99	30.3	51	51.5	21	41.2	18	5.9	7	2.4	6	2.0	23	7.6
		30-34	374	145	39.3	70	48.3	30	42.9	10	3.0	5	1.6	6	1.9	28	8.4
		35+	283	120	42.9	60	50.0	26	43.3	10	4.2	9	3.8	3	1.3	30	12.3
	Years since diagnosis	5-9	110	26	31.7	12	46.2	_	_	5	6.2	1	1.3	2	2.5	5	6.2
		10-14	390	126	33.2	64	50.8	36	56.3	21	5.8	5	1.4	7	2.0	26	7.1
		15-19	423	149	36.0	78	52.3	33	42.3	12	3.3	9	2.5	4	1.1	32	8.6
		20+	307	123	40.6	59	48.0	25	42.4	12	4.7	8	3.2	3	1.2	32	12.3
	Age at diagnosis	1-4	19	4	21.1	_	_	_	_	1	5.9	_	_	_	_	1	5.6
		5-9	151	42	28.4	23	54.8	12	52.2	6	4.7	3	2.4	_	_	16	11.8
		10-14	528	174	34.3	93	53.4	42	45.2	23	5.0	9	2.0	8	1.8	34	7.3
		15-20	532	204	40.5	97	47.5	40	41.2	20	4.3	11	2.4	8	1.8	44	9.5
	Treatment	Surgery only	86	35	41.2	22	62.9	10	45.5	2	2.5	1	1.3	2	2.6	5	6.5
		Chemotherapy, no radiation	937	314	35.1	152	48.4	65	42.8	37	4.6	18	2.3	14	1.8	78	9.6
		Radiation, no chemotherapy	10	5	55.6	4	80.0	2	50.0	_	_	_	_	_	_	_	_
		Chemotherapy and radiation	79	25	32.9	9	36.0	5	55.6	1	1.4	2	2.9	_	_	7	9.6
		Unknown	118	45	39.5	26	57.8	12	46.2	10	9.3	2	1.9	_	_	5	4.6
Males	**All cases**		**628**	**227**	**38.0**	**116**	**51.1**	**47**	**40.5**	**49**	**9.3**	**23**	**4.6**	**16**	**3.2**	**85**	**15.8**
	Age at baseline	18-19	12	3	27.3	_	_	_	_	_	_	_	_	_	_	2	20.0
		20-24	95	23	28.0	12	52.2	9	75.0	11	14.3	2	2.7	1	1.3	10	12.7
		25-29	183	58	33.9	32	55.2	12	37.5	18	11.4	7	4.7	6	4.1	22	13.9
		30-34	179	75	42.6	33	44.0	13	39.4	10	6.5	5	3.5	6	4.1	25	16.1
		35+	159	68	43.0	39	57.4	13	33.3	10	7.6	9	7.0	3	2.4	26	19.1
	Years since diagnosis	5-9	55	11	28.9	4	36.4	_	_	5	13.2	1	2.7	2	5.4	5	13.5
		10-14	208	71	35.3	38	53.5	22	57.9	20	10.8	5	2.8	7	3.9	23	12.2
		15-19	211	78	37.7	39	50.0	14	35.9	12	6.6	9	5.3	4	2.3	28	15.1

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

Tobacco use: Osteosarcoma

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		20+	154	67	44.1	35	52.2	11	31.4	12	9.8	8	6.8	3	2.7	29	23.0
	Age at diagnosis	1-4	12	1	8.3	_	_	_	_	1	10.0	_	_	_	_	1	9.1
		5-9	72	25	35.2	14	56.0	5	35.7	5	8.3	3	5.4	_	_	15	22.4
		10-14	240	85	36.6	43	50.6	21	48.8	23	11.2	9	4.6	8	4.1	31	15.1
		15-20	304	116	41.0	59	50.9	21	35.6	20	7.9	11	4.5	8	3.3	38	14.9
	Treatment	Surgery only	30	11	37.9	7	63.6	4	57.1	2	6.9	1	3.8	2	7.7	4	14.8
		Chemotherapy, no radiation	476	171	37.8	85	49.7	30	35.3	37	9.5	18	4.8	14	3.8	70	17.4
		Radiation, no chemotherapy	6	3	60.0	2	66.7	1	50.0	_	_	_	_	_	_	_	_
		Chemotherapy and radiation	40	12	31.6	6	50.0	3	50.0	1	2.9	2	6.5	_	_	7	20.0
		Unknown	76	30	40.5	16	53.3	9	56.3	9	13.0	2	2.9	_	_	4	5.8
Females	**All cases**		**602**	**197**	**33.9**	**97**	**49.2**	**47**	**48.5**	**1**	**0.2**	**_**	**_**	**_**	**_**	**10**	**1.8**
	Age at baseline	18-19	18	1	6.7	1	100.0	_	_	_	_	_	_	_	_	_	_
		20-24	104	33	34.7	19	57.6	8	42.1	1	1.1	_	_	_	_	2	2.1
		25-29	161	41	26.3	19	46.3	9	47.4	_	_	_	_	_	_	1	0.7
		30-34	195	70	36.3	37	52.9	17	45.9	_	_	_	_	_	_	3	1.7
		35+	124	52	42.6	21	40.4	13	61.9	_	_	_	_	_	_	4	3.7
	Years since diagnosis	5-9	55	15	34.1	8	53.3	_	_	_	_	_	_	_	_	_	_
		10-14	182	55	30.7	26	47.3	14	53.8	1	0.6	_	_	_	_	3	1.7
		15-19	212	71	34.3	39	54.9	19	48.7	_	_	_	_	_	_	4	2.1
		20+	153	56	37.1	24	42.9	14	58.3	_	_	_	_	_	_	3	2.2
	Age at diagnosis	1-4	7	3	42.9	_	_	_	_	_	_	_	_	_	_	_	_
		5-9	79	17	22.1	9	52.9	7	77.8	1	1.5	_	_	_	_	1	1.4
		10-14	288	89	32.2	50	56.2	21	42.0	_	_	_	_	_	_	3	1.2
		15-20	228	88	39.8	38	43.2	19	50.0	_	_	_	_	_	_	6	2.9
	Treatment	Surgery only	56	24	42.9	15	62.5	6	40.0	_	_	_	_	_	_	1	2.0
		Chemotherapy, no radiation	461	143	32.3	67	46.9	35	52.2	_	_	_	_	_	_	8	1.9
		Radiation, no chemotherapy	4	2	50.0	2	100.0	1	50.0	_	_	_	_	_	_	_	_

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

				Cigarette smoking						Other tobacco-product use (N.2/O.7) [3]							
				Ever smoked (N.1/O.1)		Current smoker (N.1d/O.3) [1]		Tried to quit (N.1e/O.6) [2]		Chewing tobacco		Snuff tobacco		Pipes		Cigars	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		Chemotherapy and radiation	39	13	34.2	3	23.1	2	66.7	_	_	_	_	_	_	_	_
		Unknown	42	15	37.5	10	66.7	3	30.0	1	2.6	_	_	_	_	1	2.6

CCSS data from the March 2026 data freeze.
Presented only for those age 18 years and older at baseline because tobacco questions did not appear on the expansion under-18 questionnaire.
[1] Percentage for Current Smoker uses participants who ever smoked as the denominator.
[2] Percentage for Tried to Quit uses current smokers as the denominator; for the expansion cohort, Tried to Quit is based on at least one quit attempt in the previous 12 months (O.6).
[3] Use of other tobacco products is based on 'Yes, regularly use' or 'Yes, occasionally use' among those who responded.
N=10 participants without baseline questionnaire data were excluded.

				General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**25725**	**2647**	**11.1**	**2989**	**17.2**	**3244**	**13.9**	**3327**	**13.6**	**2248**	**9.6**	**3113**	**13.4**
	Age at baseline	<18	5688	256	5.2	_	_	561	11.5	602	11.2	247	5.1	525	10.8
		18-19	2152	173	8.7	220	15.6	259	13.3	231	11.4	121	6.3	208	10.9
		20-24	6024	594	10.7	867	17.0	770	14.1	738	13.0	482	8.9	651	12.0
		25-29	5571	712	13.6	861	17.3	780	15.1	747	14.1	547	10.7	772	15.1
		30-34	3885	535	14.3	648	17.9	524	14.3	594	16.0	505	13.8	568	15.6
		35+	2405	377	16.2	393	17.2	350	15.2	415	17.8	346	15.1	389	16.9
	Years since diagnosis	5-9	2592	97	6.5	103	20.4	157	10.7	408	18.9	103	7.1	170	11.8
		10-14	8345	704	9.0	720	17.3	913	11.8	955	11.9	624	8.1	972	12.6
		15-19	8211	891	11.2	1108	16.6	1114	14.3	1014	12.9	765	9.9	1022	13.2
		20+	6577	955	14.8	1058	17.4	1060	16.7	950	14.8	756	11.9	949	15.0
	Age at diagnosis	<1	1933	132	7.1	102	15.3	247	13.3	209	11.1	87	4.7	175	9.5
		1-4	8297	676	8.7	643	16.2	1055	13.7	890	11.2	544	7.1	878	11.5
		5-9	5790	618	11.6	737	17.4	774	14.7	686	12.5	472	9.0	690	13.2
		10-14	5453	678	13.6	884	18.3	683	13.9	816	15.9	633	13.0	777	16.0
		15-20	4252	543	14.4	623	16.8	485	13.3	726	18.4	512	14.0	593	16.3
	Treatment	Surgery only	2169	195	9.3	253	17.1	280	13.5	238	11.4	163	7.9	216	10.5
		Chemotherapy, no radiation	8166	697	8.9	913	17.1	842	10.9	881	11.2	702	9.1	1009	13.1
		Radiation, no chemotherapy	2086	271	14.2	278	17.8	419	22.7	345	17.9	190	10.3	241	13.2
		Chemotherapy and radiation	10806	1190	12.3	1288	17.6	1374	14.4	1478	14.6	920	9.7	1361	14.4
		Unknown	2498	294	13.0	257	15.0	329	14.7	385	15.9	273	12.3	286	13.0
Males	**All cases**		**13753**	**1301**	**10.3**	**1458**	**16.1**	**1604**	**13.0**	**1489**	**11.4**	**1087**	**8.8**	**1379**	**11.3**
	Age at baseline	<18	3065	130	5.0	_	_	288	11.1	302	10.5	122	4.7	274	10.7
		18-19	1122	77	7.5	95	13.8	130	12.9	112	10.5	54	5.5	91	9.3
		20-24	3170	283	9.8	412	15.9	388	13.7	320	10.8	229	8.1	268	9.5
		25-29	3091	364	12.6	445	16.5	399	14.1	336	11.4	258	9.2	349	12.4
		30-34	2072	274	13.9	341	17.9	253	13.0	264	13.3	259	13.4	250	13.0
		35+	1233	173	14.5	165	14.2	146	12.4	155	13.0	165	14.0	147	12.6

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

				General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
	Years since diagnosis	5-9	1455	62	7.8	57	21.5	81	10.5	214	17.8	51	6.6	91	12.0
		10-14	4468	332	8.0	363	16.8	460	11.2	458	10.7	308	7.5	449	11.1
		15-19	4314	425	10.2	510	14.9	542	13.2	424	10.2	368	9.1	428	10.6
		20+	3516	482	14.0	528	16.5	521	15.3	393	11.5	360	10.6	411	12.2
	Age at diagnosis	<1	987	65	6.8	47	14.5	124	13.0	96	10.0	44	4.6	89	9.4
		1-4	4344	330	8.1	304	15.5	518	13.0	390	9.3	251	6.3	388	9.8
		5-9	3263	319	10.7	370	16.0	430	14.7	354	11.5	227	7.8	332	11.5
		10-14	2887	313	12.0	418	16.6	310	12.0	323	11.8	308	12.0	320	12.5
		15-20	2272	274	13.9	319	16.5	222	11.7	326	15.7	257	13.5	250	13.2
	Treatment	Surgery only	1070	97	9.4	117	16.4	153	15.1	108	10.6	64	6.3	85	8.4
		Chemotherapy, no radiation	4299	343	8.4	458	16.5	409	10.1	374	9.1	337	8.4	438	10.9
		Radiation, no chemotherapy	1086	138	14.1	140	17.5	200	21.1	160	15.9	78	8.3	102	10.9
		Chemotherapy and radiation	5825	574	11.2	597	15.9	677	13.4	650	11.9	445	8.9	595	11.9
		Unknown	1473	149	11.3	146	14.5	165	12.6	197	13.8	163	12.5	159	12.4
Females	**All cases**		**11972**	**1346**	**12.1**	**1531**	**18.3**	**1640**	**14.9**	**1838**	**16.1**	**1161**	**10.6**	**1734**	**15.8**
	Age at baseline	<18	2623	126	5.5	_	_	273	11.8	300	12.1	125	5.4	251	10.9
		18-19	1030	96	10.1	125	17.2	129	13.7	119	12.3	67	7.1	117	12.5
		20-24	2854	311	11.7	455	18.1	382	14.6	418	15.5	253	9.7	383	14.8
		25-29	2480	348	14.8	416	18.4	381	16.5	411	17.4	289	12.5	423	18.4
		30-34	1813	261	14.8	307	17.8	271	15.7	330	19.0	246	14.3	318	18.5
		35+	1172	204	17.9	228	20.3	204	18.1	260	22.8	181	16.1	242	21.5
	Years since diagnosis	5-9	1137	35	5.0	46	19.2	76	11.0	194	20.2	52	7.6	79	11.6
		10-14	3877	372	10.1	357	17.9	453	12.4	497	13.3	316	8.7	523	14.4
		15-19	3897	466	12.3	598	18.4	572	15.4	590	15.8	397	10.7	594	16.0
		20+	3061	473	15.8	530	18.4	539	18.2	557	18.7	396	13.4	538	18.2
	Age at diagnosis	<1	946	67	7.3	55	16.0	123	13.6	113	12.3	43	4.8	86	9.6
		1-4	3953	346	9.3	339	17.0	537	14.5	500	13.2	293	7.9	490	13.3
		5-9	2527	299	12.7	367	19.2	344	14.7	332	13.8	245	10.5	358	15.4

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

			All cases	General Health [1] N	General Health [1] %	Mental Health [2] N	Mental Health [2] %	Functional Impairment [3] N	Functional Impairment [3] %	Activity Limitation [4] N	Activity Limitation [4] %	Pain [5] N	Pain [5] %	Anxiety [6] N	Anxiety [6] %
		10-14	2566	365	15.4	466	20.1	373	16.0	493	20.4	325	14.1	457	19.8
		15-20	1980	269	14.9	304	17.0	263	15.0	400	21.6	255	14.5	343	19.5
	Treatment	Surgery only	1099	98	9.2	136	17.6	127	12.0	130	12.3	99	9.4	131	12.5
		Chemotherapy, no radiation	3867	354	9.6	455	17.7	433	11.8	507	13.6	365	9.9	571	15.5
		Radiation, no chemotherapy	1000	133	14.2	138	18.2	219	24.4	185	20.0	112	12.5	139	15.7
		Chemotherapy and radiation	4981	616	13.6	691	19.5	697	15.6	828	17.7	475	10.7	766	17.3
		Unknown	1025	145	15.5	111	15.7	164	17.7	188	18.9	110	12.0	127	13.9

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

Health Status Domains: All leukemias

				General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**7908**	**697**	**9.5**	**851**	**17.2**	**755**	**10.5**	**738**	**9.8**	**579**	**8.1**	**887**	**12.4**
	Age at baseline	<18	2236	82	4.3	_	_	161	8.5	193	9.0	88	4.7	192	10.2
		18-19	844	54	6.9	83	14.7	89	11.7	66	8.3	37	4.9	81	10.7
		20-24	1970	201	10.7	308	17.9	205	11.2	189	10.1	147	8.1	223	12.4
		25-29	1608	192	12.4	259	17.4	165	10.9	146	9.4	146	9.7	228	15.1
		30-34	847	106	12.9	140	17.4	92	11.5	92	11.3	106	13.2	108	13.6
		35+	403	62	15.7	61	15.8	43	11.1	52	13.4	55	14.1	55	14.2
	Years since diagnosis	5-9	981	35	5.9	27	20.3	42	7.1	124	14.1	46	7.9	61	10.6
		10-14	2637	192	7.6	187	17.5	210	8.4	221	8.6	165	6.7	277	11.3
		15-19	2441	237	9.9	332	16.3	267	11.5	215	9.3	191	8.3	294	12.8
		20+	1849	233	12.8	305	17.7	236	13.2	178	9.8	177	9.9	255	14.3
	Age at diagnosis	<1	242	19	8.2	7	10.1	46	19.8	28	12.2	9	4.0	12	5.3
		1-4	3735	258	7.4	302	17.2	381	11.1	298	8.3	193	5.6	396	11.6
		5-9	1931	191	10.7	247	18.0	156	8.9	172	9.3	146	8.4	239	13.8
		10-14	1313	145	12.1	204	17.5	104	8.7	139	11.1	145	12.3	162	13.8
		15-20	687	84	13.7	91	15.2	68	11.6	101	16.1	86	14.7	78	13.3
	Treatment	Surgery only	3	_	_	_	_	_	_	_	_	_	_	_	_
		Chemotherapy, no radiation	3383	278	8.6	347	17.4	320	10.0	262	8.0	214	6.7	389	12.2
		Radiation, no chemotherapy	4	_	_	_	_	_	_	_	_	_	_	_	_
		Chemotherapy and radiation	3775	338	9.9	428	17.4	360	10.9	395	11.1	297	9.0	415	12.6
		Unknown	743	81	12.0	76	15.1	75	11.2	81	11.2	68	10.3	83	12.7
Males	**All cases**		**4218**	**337**	**8.7**	**384**	**15.0**	**362**	**9.5**	**320**	**7.9**	**275**	**7.3**	**404**	**10.8**
	Age at baseline	<18	1222	43	4.3	_	_	88	8.8	104	8.9	47	4.7	111	11.1
		18-19	454	27	6.4	35	12.0	45	11.0	34	7.8	19	4.7	37	9.2
		20-24	997	87	9.2	134	16.0	91	9.9	73	7.7	65	7.1	80	8.8
		25-29	870	97	11.6	127	16.0	77	9.4	61	7.3	68	8.4	102	12.5
		30-34	449	52	12.0	65	15.4	38	8.9	29	6.7	50	11.7	51	12.1
		35+	226	31	14.1	23	10.6	23	10.6	19	8.8	26	11.8	23	10.6

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

Health Status Domains: All leukemias

				General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
	Years since diagnosis	5-9	557	23	7.3	15	22.1	27	8.7	76	15.2	24	7.8	38	12.5
		10-14	1415	89	6.6	88	15.7	106	7.9	103	7.5	82	6.2	139	10.6
		15-19	1252	106	8.7	131	12.9	114	9.6	79	6.6	87	7.4	112	9.5
		20+	994	119	12.2	150	16.4	115	12.0	62	6.4	82	8.5	115	12.0
	Age at diagnosis	<1	113	10	9.2	3	8.6	23	20.9	10	9.3	6	5.6	7	6.5
		1-4	1998	129	7.0	145	16.3	183	10.1	138	7.1	94	5.2	184	10.2
		5-9	1041	86	9.1	105	14.9	76	8.2	80	8.1	65	7.1	105	11.5
		10-14	650	65	11.1	76	13.4	46	7.8	45	7.2	63	10.8	64	11.1
		15-20	416	47	12.7	55	15.1	34	9.6	47	12.3	47	13.1	44	12.4
	Treatment	Surgery only	1	_	_	_	_	_	_	_	_	_	_	_	_
		Chemotherapy, no radiation	1694	130	8.0	161	16.6	164	10.3	113	6.9	94	5.9	155	9.8
		Radiation, no chemotherapy	3	_	_	_	_	_	_	_	_	_	_	_	_
		Chemotherapy and radiation	2076	165	9.0	185	14.4	170	9.5	179	9.1	142	8.0	197	11.1
		Unknown	444	42	10.4	38	12.6	28	7.0	28	6.5	39	9.9	52	13.4
Females	**All cases**		**3690**	**360**	**10.4**	**467**	**19.4**	**393**	**11.6**	**418**	**11.9**	**304**	**9.0**	**483**	**14.3**
	Age at baseline	<18	1014	39	4.4	_	_	73	8.3	89	9.2	41	4.7	81	9.2
		18-19	390	27	7.4	48	17.5	44	12.5	32	8.8	18	5.1	44	12.5
		20-24	973	114	12.3	174	19.8	114	12.6	116	12.6	82	9.2	143	15.9
		25-29	738	95	13.2	132	19.0	88	12.6	85	12.0	78	11.1	126	18.0
		30-34	398	54	14.0	75	19.6	54	14.4	63	16.6	56	14.9	57	15.2
		35+	177	31	17.7	38	22.4	20	11.8	33	19.2	29	17.1	32	18.8
	Years since diagnosis	5-9	424	12	4.3	12	18.5	15	5.4	48	12.7	22	8.1	23	8.5
		10-14	1222	103	8.8	99	19.5	104	9.0	118	10.0	83	7.2	138	12.0
		15-19	1189	131	11.3	201	19.8	153	13.5	136	12.1	104	9.2	182	16.1
		20+	855	114	13.5	155	19.0	121	14.6	116	13.9	95	11.5	140	16.9
	Age at diagnosis	<1	129	9	7.3	4	11.8	23	18.9	18	14.6	3	2.5	5	4.1
		1-4	1737	129	7.9	157	18.1	198	12.3	160	9.6	99	6.1	212	13.1
		5-9	890	105	12.6	142	21.2	80	9.7	92	10.8	81	9.9	134	16.4

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

Health Status Domains: All leukemias

			All cases	General Health [1] N	General Health [1] %	Mental Health [2] N	Mental Health [2] %	Functional Impairment [3] N	Functional Impairment [3] %	Activity Limitation [4] N	Activity Limitation [4] %	Pain [5] N	Pain [5] %	Anxiety [6] N	Anxiety [6] %
		10-14	663	80	13.0	128	21.3	58	9.7	94	15.0	82	13.9	98	16.5
		15-20	271	37	15.4	36	15.5	34	14.8	54	21.8	39	17.0	34	14.8
	Treatment	Surgery only	2	_	_	_	_	_	_	_	_	_	_	_	_
		Chemotherapy, no radiation	1689	148	9.2	186	18.2	156	9.8	149	9.1	120	7.5	234	14.7
		Radiation, no chemotherapy	1	_	_	_	_	_	_	_	_	_	_	_	_
		Chemotherapy and radiation	1699	173	11.0	243	20.6	190	12.5	216	13.6	155	10.3	218	14.5
		Unknown	299	39	14.3	38	18.8	47	17.3	53	18.2	29	10.8	31	11.6

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

Health Status Domains: ALL

				General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**6646**	**554**	**9.0**	**708**	**17.0**	**569**	**9.4**	**593**	**9.3**	**491**	**8.1**	**740**	**12.3**
	Age at baseline	<18	1941	68	4.1	_	_	115	7.0	163	8.7	82	5.0	171	10.5
		18-19	730	44	6.5	73	14.6	65	9.8	57	8.2	30	4.6	71	10.8
		20-24	1693	176	10.8	270	17.8	157	9.9	156	9.7	133	8.5	195	12.5
		25-29	1338	153	11.8	219	17.6	137	10.8	122	9.4	123	9.7	186	14.7
		30-34	657	77	12.1	109	17.4	70	11.2	66	10.5	85	13.6	86	13.8
		35+	287	36	12.8	37	13.5	25	9.0	29	10.4	38	13.7	31	11.3
	Years since diagnosis	5-9	844	28	5.3	22	20.0	37	7.0	103	13.4	40	7.7	53	10.3
		10-14	2222	146	6.9	146	16.7	155	7.4	185	8.5	142	6.8	234	11.3
		15-19	2024	194	9.8	283	16.5	190	9.9	162	8.4	159	8.3	248	13.0
		20+	1556	186	12.1	257	17.5	187	12.4	143	9.4	150	9.9	205	13.6
	Age at diagnosis	<1	134	10	7.9	4	9.1	23	18.5	18	14.3	7	5.7	6	4.9
		1-4	3322	228	7.4	271	17.0	292	9.6	261	8.1	176	5.8	352	11.6
		5-9	1696	160	10.1	222	18.5	133	8.6	147	9.1	126	8.2	211	13.8
		10-14	1027	106	11.2	148	16.1	80	8.5	99	10.2	117	12.7	124	13.5
		15-20	467	50	11.9	63	15.4	41	10.1	68	15.5	65	16.0	47	11.6
	Treatment	Chemotherapy, no radiation	2699	215	8.3	271	17.3	201	7.8	193	7.4	174	6.8	312	12.2
		Radiation, no chemotherapy	4	_	_	_	_	_	_	_	_	_	_	_	_
		Chemotherapy and radiation	3306	278	9.3	373	17.3	309	10.6	336	10.8	258	8.9	355	12.3
		Unknown	637	61	10.6	64	14.8	59	10.2	64	10.3	59	10.4	73	13.1
Males	**All cases**		**3576**	**268**	**8.2**	**328**	**15.1**	**264**	**8.2**	**259**	**7.5**	**244**	**7.6**	**347**	**10.9**
	Age at baseline	<18	1061	34	3.9	_	_	58	6.7	88	8.6	45	5.2	96	11.1
		18-19	397	23	6.3	34	13.1	31	8.7	32	8.4	16	4.6	34	9.7
		20-24	858	74	9.0	118	15.8	62	7.8	57	7.0	59	7.4	74	9.4
		25-29	736	78	11.0	110	16.3	68	9.8	53	7.4	59	8.5	85	12.3
		30-34	354	39	11.4	50	15.0	31	9.2	19	5.5	44	13.0	45	13.4
		35+	170	20	12.0	16	9.9	14	8.4	10	6.1	21	12.7	13	8.0
	Years since diagnosis	5-9	480	20	7.1	13	23.2	24	8.5	61	13.9	22	7.9	34	12.3

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

Health Status Domains: ALL

				General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	1201	65	5.7	71	15.1	75	6.6	90	7.7	74	6.6	119	10.6
		15-19	1052	88	8.6	115	13.3	75	7.6	61	6.1	75	7.6	100	10.2
		20+	843	95	11.5	129	16.5	90	11.0	47	5.7	73	8.9	94	11.5
	Age at diagnosis	<1	65	6	9.5	2	8.3	11	17.7	6	9.8	5	8.3	3	5.0
		1-4	1769	111	6.8	131	16.3	128	8.0	123	7.2	85	5.3	162	10.2
		5-9	924	72	8.5	96	15.4	64	7.7	65	7.4	59	7.2	99	12.1
		10-14	527	51	10.6	62	13.4	41	8.5	35	6.9	56	11.7	55	11.6
		15-20	291	28	10.6	37	14.3	20	7.8	30	10.9	39	15.1	28	10.9
	Treatment	Chemotherapy, no radiation	1349	100	7.7	127	16.6	96	7.5	82	6.2	80	6.2	126	9.9
		Radiation, no chemotherapy	3	_	_	_	_	_	_	_	_	_	_	_	_
		Chemotherapy and radiation	1839	137	8.4	169	14.7	146	9.2	156	8.9	129	8.1	175	11.1
		Unknown	385	31	8.9	32	12.3	22	6.3	21	5.6	35	10.2	46	13.8
Females	**All cases**		**3070**	**286**	**9.9**	**380**	**19.1**	**305**	**10.8**	**334**	**11.4**	**247**	**8.8**	**393**	**14.0**
	Age at baseline	<18	880	34	4.4	_	_	57	7.4	75	8.9	37	4.8	75	9.8
		18-19	333	21	6.7	39	16.2	34	11.2	25	8.0	14	4.6	37	12.2
		20-24	835	102	12.7	152	19.7	95	12.1	99	12.5	74	9.6	121	15.7
		25-29	602	75	12.8	109	19.1	69	12.0	69	11.9	64	11.2	101	17.6
		30-34	303	38	12.8	59	20.3	39	13.7	47	16.3	41	14.3	41	14.3
		35+	117	16	13.9	21	18.6	11	9.9	19	16.8	17	15.2	18	16.1
	Years since diagnosis	5-9	364	8	3.3	9	16.7	13	5.3	42	12.8	18	7.4	19	7.9
		10-14	1021	81	8.3	75	18.6	80	8.3	95	9.6	68	7.1	115	12.0
		15-19	972	106	11.1	168	19.9	115	12.5	101	11.0	84	9.1	148	16.1
		20+	713	91	12.9	128	18.7	97	14.1	96	13.8	77	11.2	111	16.1
	Age at diagnosis	<1	69	4	6.3	2	10.0	12	19.4	12	18.5	2	3.2	3	4.8
		1-4	1553	117	8.0	140	17.7	164	11.3	138	9.2	91	6.3	190	13.1
		5-9	772	88	12.1	126	22.0	69	9.7	82	11.1	67	9.4	112	15.8
		10-14	500	55	11.8	86	19.0	39	8.6	64	13.6	61	13.8	69	15.5
		15-20	176	22	14.0	26	17.2	21	14.0	38	23.3	26	17.4	19	12.8

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

			All cases	General Health [1] N	General Health [1] %	Mental Health [2] N	Mental Health [2] %	Functional Impairment [3] N	Functional Impairment [3] %	Activity Limitation [4] N	Activity Limitation [4] %	Pain [5] N	Pain [5] %	Anxiety [6] N	Anxiety [6] %
	Treatment	Chemotherapy, no radiation	1350	115	8.9	144	17.9	105	8.2	111	8.5	94	7.3	186	14.5
		Radiation, no chemotherapy	1	_	_	_	_	_	_	_	_	_	_	_	_
		Chemotherapy and radiation	1467	141	10.4	204	20.2	163	12.4	180	13.1	129	9.9	180	13.8
		Unknown	252	30	13.0	32	18.7	37	16.0	43	17.6	24	10.6	27	12.0

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

Health Status Domains: AML

				General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**930**	**104**	**11.9**	**103**	**17.4**	**151**	**17.6**	**107**	**12.1**	**61**	**7.1**	**108**	**12.6**
	Age at baseline	<18	231	11	5.3	_	_	41	19.9	23	10.6	4	2.0	20	9.9
		18-19	89	8	9.5	8	14.8	21	25.3	9	10.3	5	6.1	8	9.6
		20-24	199	20	10.9	30	20.3	41	22.5	25	13.2	9	5.0	20	11.0
		25-29	201	30	15.5	28	15.1	20	10.7	16	8.4	16	8.6	28	14.9
		30-34	134	18	13.7	21	16.0	16	12.1	19	14.4	15	11.4	16	12.4
		35+	76	17	23.0	16	21.9	12	17.1	15	21.1	12	16.4	16	21.9
	Years since diagnosis	5-9	85	6	11.5	4	20.0	5	10.2	14	19.4	3	6.1	7	14.3
		10-14	320	35	11.3	31	21.4	46	15.1	28	9.1	16	5.3	33	11.0
		15-19	323	33	10.6	36	14.8	63	20.3	40	12.9	23	7.4	32	10.3
		20+	202	30	15.0	32	17.5	37	18.9	25	12.7	19	9.7	36	18.2
	Age at diagnosis	<1	93	8	8.8	3	12.5	20	21.5	10	11.2	2	2.2	6	6.7
		1-4	315	18	6.0	20	16.9	77	26.1	27	8.9	8	2.7	32	10.8
		5-9	172	27	17.1	20	15.0	18	11.3	19	11.4	17	10.8	25	15.8
		10-14	199	30	16.2	38	21.1	16	8.7	27	13.9	18	9.8	22	12.1
		15-20	151	21	15.1	22	16.1	20	15.4	24	17.6	16	12.1	23	17.6
	Treatment	Surgery only	3	_	_	_	_	_	_	_	_	_	_	_	_
		Chemotherapy, no radiation	558	58	10.9	64	18.6	103	19.6	56	10.4	32	6.1	66	12.6
		Chemotherapy and radiation	296	35	12.8	32	16.3	37	13.8	37	13.3	22	8.4	37	14.1
		Unknown	73	11	16.2	7	14.0	11	17.2	14	20.0	7	10.4	5	7.4
Males	**All cases**		**456**	**47**	**11.1**	**36**	**13.3**	**80**	**19.3**	**39**	**9.0**	**18**	**4.4**	**41**	**10.0**
	Age at baseline	<18	126	7	6.4	_	_	27	24.8	11	9.3	1	0.9	14	13.0
		18-19	45	3	7.3	1	4.0	13	32.5	2	4.7	2	5.0	3	7.5
		20-24	95	9	10.5	12	18.8	24	28.2	10	10.9	4	4.8	4	4.8
		25-29	90	13	14.8	10	11.8	4	4.7	4	4.6	5	6.0	9	10.6
		30-34	65	9	14.1	8	12.7	7	10.9	7	10.9	3	4.7	3	4.8
		35+	35	6	18.2	5	15.2	5	16.1	5	16.1	3	9.1	8	24.2
	Years since diagnosis	5-9	50	2	8.0	2	18.2	3	12.5	9	20.9	1	4.2	3	12.5

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

Health Status Domains: AML

				General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	160	18	11.6	10	15.9	27	17.8	9	5.9	5	3.3	16	10.8
		15-19	149	13	8.9	10	9.0	31	21.5	10	6.9	7	4.8	6	4.1
		20+	97	14	14.6	14	16.5	19	20.2	11	11.7	5	5.4	16	16.8
	Age at diagnosis	<1	40	4	10.5	1	10.0	10	25.0	4	10.5	1	2.6	4	10.3
		1-4	172	10	6.0	8	13.1	49	30.2	9	5.4	3	1.9	16	9.9
		5-9	79	10	14.3	6	10.9	7	10.0	9	11.8	4	5.9	5	7.2
		10-14	82	12	16.2	8	11.3	4	5.5	6	7.6	5	6.8	5	6.9
		15-20	83	11	14.9	13	17.8	10	14.5	11	14.9	5	7.0	11	15.7
	Treatment	Surgery only	1	_	_	_	_	_	_	_	_	_	_	_	_
		Chemotherapy, no radiation	269	26	10.3	25	15.9	58	23.3	20	7.8	10	4.0	22	8.9
		Chemotherapy and radiation	146	16	12.2	8	9.5	19	14.6	14	10.1	6	4.8	15	11.9
		Unknown	40	5	13.5	3	10.3	3	8.8	5	13.5	2	5.6	4	10.8
Females	**All cases**		**474**	**57**	**12.6**	**67**	**20.8**	**71**	**15.9**	**68**	**15.0**	**43**	**9.7**	**67**	**15.1**
	Age at baseline	<18	105	4	4.1	_	_	14	14.4	12	12.2	3	3.1	6	6.3
		18-19	44	5	11.6	7	24.1	8	18.6	7	15.9	3	7.1	5	11.6
		20-24	104	11	11.2	18	21.4	17	17.5	15	15.3	5	5.2	16	16.5
		25-29	111	17	16.2	18	17.8	16	15.7	12	11.5	11	10.7	19	18.4
		30-34	69	9	13.4	13	19.1	9	13.2	12	17.6	12	17.6	13	19.4
		35+	41	11	26.8	11	27.5	7	17.9	10	25.0	9	22.5	8	20.0
	Years since diagnosis	5-9	35	4	14.8	2	22.2	2	8.0	5	17.2	2	8.0	4	16.0
		10-14	160	17	11.0	21	25.6	19	12.5	19	12.3	11	7.2	17	11.2
		15-19	174	20	12.0	26	19.5	32	19.2	30	18.1	16	9.8	26	15.8
		20+	105	16	15.4	18	18.4	18	17.6	14	13.6	14	13.6	20	19.4
	Age at diagnosis	<1	53	4	7.5	2	14.3	10	18.9	6	11.8	1	2.0	2	3.9
		1-4	143	8	6.0	12	21.1	28	21.1	18	13.4	5	3.7	16	11.9
		5-9	93	17	19.3	14	17.9	11	12.4	10	11.1	13	14.6	20	22.5
		10-14	117	18	16.2	30	27.5	12	10.9	21	18.3	13	11.7	17	15.5
		15-20	68	10	15.4	9	14.1	10	16.4	13	21.0	11	18.0	12	19.7

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

			All cases	General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
				N	%	N	%	N	%	N	%	N	%	N	%
	Treatment	Surgery only	2	_	_	_	_	_	_	_	_	_	_	_	_
		Chemotherapy, no radiation	289	32	11.6	39	20.7	45	16.2	36	12.9	22	7.9	44	15.9
		Chemotherapy and radiation	150	19	13.4	24	21.4	18	13.0	23	16.5	16	11.8	22	16.2
		Unknown	33	6	19.4	4	19.0	8	26.7	9	27.3	5	16.1	1	3.2

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

Health Status Domains: All CNS

				General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**4498**	**626**	**15.4**	**520**	**18.4**	**1278**	**31.8**	**888**	**21.3**	**414**	**10.4**	**512**	**12.9**
	Age at baseline	<18	953	82	10.8	_	_	230	30.4	211	24.7	64	8.5	115	15.4
		18-19	376	43	12.8	36	16.1	99	30.1	60	17.3	24	7.3	35	10.9
		20-24	1182	158	14.6	155	17.0	330	30.7	219	19.9	101	9.5	111	10.5
		25-29	1086	179	17.6	161	18.1	348	34.5	203	19.9	106	10.6	133	13.3
		30-34	625	114	18.9	114	20.6	181	30.5	134	22.6	82	13.9	79	13.4
		35+	276	50	19.2	54	21.7	90	34.9	61	23.2	37	14.2	39	15.1
	Years since diagnosis	5-9	464	25	10.7	16	18.4	67	29.5	109	31.3	22	9.7	30	13.5
		10-14	1540	195	13.8	128	16.6	368	26.2	272	18.9	119	8.5	185	13.3
		15-19	1416	193	14.2	199	18.3	431	32.0	254	18.8	132	9.9	171	12.9
		20+	1078	213	20.3	177	20.1	412	39.5	253	24.4	141	13.6	126	12.2
	Age at diagnosis	<1	219	20	10.1	4	8.9	89	45.4	58	28.0	14	7.3	25	13.2
		1-4	1323	159	13.1	87	16.4	395	32.8	277	22.2	112	9.4	151	12.8
		5-9	1407	211	16.5	172	18.1	416	32.7	262	20.0	126	9.9	141	11.2
		10-14	1069	162	16.8	183	20.2	272	28.3	196	19.8	112	11.7	139	14.6
		15-20	480	74	18.4	74	18.8	106	27.5	95	22.5	50	12.7	56	14.4
	Treatment	Surgery only	1275	142	11.6	179	18.6	222	18.3	154	12.7	106	8.8	147	12.2
		Chemotherapy, no radiation	355	30	9.0	32	17.2	91	27.4	61	18.0	25	7.6	45	13.6
		Radiation, no chemotherapy	1170	174	16.5	158	20.3	358	34.6	251	23.1	125	12.1	129	12.6
		Chemotherapy and radiation	1256	217	20.6	115	18.4	477	45.3	330	29.7	116	11.2	156	15.1
		Unknown	442	63	16.1	36	13.1	130	33.4	92	21.9	42	10.9	35	9.3
Males	**All cases**		**2455**	**308**	**14.1**	**253**	**16.9**	**669**	**30.9**	**445**	**19.6**	**184**	**8.5**	**224**	**10.5**
	Age at baseline	<18	529	39	9.3	_	_	130	31.2	110	23.3	34	8.3	53	13.0
		18-19	191	18	10.6	16	15.1	49	29.9	33	19.0	10	6.1	15	9.4
		20-24	634	79	14.0	71	15.3	171	30.4	107	18.2	44	7.9	44	7.9
		25-29	619	92	15.9	82	16.3	188	32.7	101	17.2	40	7.0	61	10.7
		30-34	333	56	17.6	61	21.3	93	29.9	69	22.1	41	13.2	36	11.7
		35+	149	24	17.0	23	17.0	38	27.7	25	17.6	15	10.8	15	10.9

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

Health Status Domains: All CNS

				General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
	Years since diagnosis	5-9	264	16	12.7	8	16.7	34	28.3	55	28.5	11	9.2	10	8.5
		10-14	832	88	11.7	58	14.6	209	27.9	149	19.3	57	7.7	79	10.7
		15-19	772	93	12.6	102	17.7	223	30.6	124	16.8	52	7.2	76	10.5
		20+	587	111	19.4	85	18.0	203	35.7	117	20.5	64	11.3	59	10.5
	Age at diagnosis	<1	128	10	8.5	2	8.3	51	43.6	33	26.6	8	7.0	17	14.8
		1-4	699	77	12.1	46	17.4	201	31.7	134	20.4	51	8.2	65	10.5
		5-9	786	114	16.1	81	15.8	231	32.9	140	19.2	56	8.0	67	9.7
		10-14	571	71	14.0	86	18.0	130	25.7	92	17.2	49	9.7	52	10.3
		15-20	271	36	16.4	38	18.0	56	27.1	46	19.9	20	9.5	23	11.1
	Treatment	Surgery only	650	72	11.6	79	16.7	123	20.1	75	12.2	42	6.9	59	9.7
		Chemotherapy, no radiation	191	12	6.7	15	15.2	49	27.5	31	17.1	11	6.2	19	10.7
		Radiation, no chemotherapy	616	86	15.9	80	20.0	168	31.8	117	20.7	45	8.5	52	9.9
		Chemotherapy and radiation	744	108	17.3	60	16.6	260	41.5	171	25.6	63	10.2	73	11.9
		Unknown	254	30	13.5	19	12.1	69	31.1	51	20.9	23	10.4	21	9.5
Females	**All cases**		**2043**	**318**	**17.0**	**267**	**20.0**	**609**	**32.8**	**443**	**23.3**	**230**	**12.5**	**288**	**15.8**
	Age at baseline	<18	424	43	12.6	_	_	100	29.5	101	26.4	30	8.8	62	18.5
		18-19	185	25	15.2	20	17.1	50	30.3	27	15.7	14	8.5	20	12.3
		20-24	548	79	15.3	84	18.7	159	31.1	112	21.9	57	11.2	67	13.4
		25-29	467	87	19.8	79	20.4	160	36.8	102	23.7	66	15.3	72	16.7
		30-34	292	58	20.3	53	19.9	88	31.1	65	23.1	41	14.7	43	15.4
		35+	127	26	21.8	31	27.2	52	43.0	36	29.8	22	18.2	24	20.0
	Years since diagnosis	5-9	200	9	8.4	8	20.5	33	30.8	54	34.8	11	10.3	20	19.2
		10-14	708	107	16.2	70	18.8	159	24.3	123	18.5	62	9.5	106	16.3
		15-19	644	100	16.1	97	18.9	208	33.6	130	21.2	80	13.1	95	15.7
		20+	491	102	21.3	92	22.4	209	44.1	136	29.1	77	16.4	67	14.3
	Age at diagnosis	<1	91	10	12.5	2	9.5	38	48.1	25	30.1	6	7.8	8	10.7
		1-4	624	82	14.3	41	15.4	194	34.0	143	24.3	61	10.8	86	15.4
		5-9	621	97	17.0	91	20.9	185	32.5	122	21.0	70	12.3	74	13.1

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

			All cases	General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
				N	%	N	%	N	%	N	%	N	%	N	%
		10-14	498	91	19.9	97	22.7	142	31.1	104	22.7	63	14.0	87	19.6
		15-20	209	38	20.8	36	19.7	50	27.9	49	25.7	30	16.4	33	18.0
	Treatment	Surgery only	625	70	11.6	100	20.5	99	16.4	79	13.2	64	10.7	88	14.7
		Chemotherapy, no radiation	164	18	11.5	17	19.5	42	27.3	30	19.1	14	9.1	26	16.8
		Radiation, no chemotherapy	554	88	17.2	78	20.6	190	37.5	134	25.7	80	15.8	77	15.6
		Chemotherapy and radiation	512	109	25.5	55	20.8	217	51.1	159	35.8	53	12.5	83	19.7
		Unknown	188	33	19.5	17	14.4	61	36.5	41	23.2	19	11.7	14	8.9

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

Health Status Domains: Astrocytomas

				General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**2694**	**371**	**15.1**	**339**	**18.9**	**730**	**29.9**	**531**	**21.1**	**259**	**10.7**	**326**	**13.6**
	Age at baseline	<18	528	45	10.3	_	_	124	28.6	116	23.9	33	7.7	73	17.2
		18-19	215	24	12.1	25	17.6	57	29.4	32	16.1	14	7.3	20	10.5
		20-24	715	100	15.2	107	18.5	185	28.3	131	19.7	70	10.7	74	11.5
		25-29	665	106	17.0	100	18.1	207	33.5	132	21.1	68	11.1	80	13.1
		30-34	387	67	17.9	70	20.1	100	27.2	81	22.0	51	14.1	48	13.3
		35+	184	29	16.9	37	21.8	57	33.1	39	22.3	23	13.1	31	17.9
	Years since diagnosis	5-9	238	13	10.1	10	20.0	37	29.4	53	29.1	14	11.3	16	13.2
		10-14	906	109	13.0	91	19.5	206	24.8	151	17.8	72	8.7	125	15.2
		15-19	831	114	14.3	113	16.8	229	28.9	160	20.0	81	10.3	98	12.6
		20+	719	135	19.4	125	20.7	258	37.3	167	24.2	92	13.4	87	12.7
	Age at diagnosis	<1	151	17	12.8	2	6.1	67	50.8	46	32.6	8	6.3	19	15.1
		1-4	802	94	12.6	60	16.4	218	29.5	166	21.7	73	10.0	95	13.0
		5-9	794	116	15.7	108	18.6	211	28.8	146	19.5	72	9.9	83	11.5
		10-14	642	102	17.2	122	21.7	169	28.5	113	18.7	76	13.0	89	15.2
		15-20	305	42	16.5	47	18.8	65	26.6	60	22.7	30	12.0	40	16.3
	Treatment	Surgery only	1049	118	11.6	145	17.8	168	16.8	127	12.6	89	8.9	121	12.1
		Chemotherapy, no radiation	255	23	9.6	24	18.0	69	29.2	43	17.8	15	6.4	33	14.0
		Radiation, no chemotherapy	730	113	17.4	103	21.0	238	37.1	173	25.5	82	12.8	93	14.8
		Chemotherapy and radiation	374	74	24.3	42	23.9	165	53.9	121	37.3	44	14.7	55	18.7
		Unknown	286	43	16.8	25	14.0	90	35.3	67	24.6	29	11.6	24	9.8
Males	**All cases**		**1409**	**178**	**14.0**	**155**	**17.0**	**370**	**29.5**	**255**	**19.5**	**110**	**8.8**	**135**	**10.9**
	Age at baseline	<18	279	22	9.6	_	_	71	31.0	59	23.0	18	8.1	35	15.8
		18-19	109	9	8.9	12	16.7	28	29.5	17	17.2	6	6.4	9	9.7
		20-24	355	46	14.5	42	15.6	89	28.1	61	18.7	28	8.8	26	8.3
		25-29	372	52	15.2	51	16.5	108	31.6	63	17.9	25	7.4	34	10.1
		30-34	196	34	18.2	35	20.3	51	28.2	39	21.5	23	12.8	19	10.6
		35+	98	15	16.5	15	17.0	23	25.8	16	17.2	10	11.0	12	13.5

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

				General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
	Years since diagnosis	5-9	126	7	10.6	3	11.5	17	27.0	24	25.0	7	11.5	5	8.2
		10-14	479	47	10.9	42	17.8	125	29.1	84	19.0	35	8.3	55	13.1
		15-19	422	53	13.2	52	15.6	107	27.1	72	18.0	29	7.3	39	9.9
		20+	382	71	19.2	58	18.4	121	33.1	75	20.3	39	10.7	36	10.0
	Age at diagnosis	<1	86	8	10.5	1	5.6	37	48.7	26	31.7	5	6.8	12	16.4
		1-4	404	44	11.7	32	18.0	102	27.3	77	20.0	31	8.4	40	10.9
		5-9	422	64	16.6	46	15.3	115	30.3	73	18.7	31	8.2	38	10.2
		10-14	329	42	14.1	52	18.3	83	28.0	52	16.8	32	10.8	28	9.5
		15-20	168	20	14.7	24	18.5	33	25.8	27	19.1	11	8.4	17	13.4
	Treatment	Surgery only	525	64	12.7	61	15.4	95	19.3	60	12.0	36	7.3	46	9.4
		Chemotherapy, no radiation	142	10	7.6	10	13.5	37	28.2	19	14.3	6	4.6	13	10.0
		Radiation, no chemotherapy	371	49	15.2	51	20.6	107	33.8	77	22.7	27	8.6	39	12.5
		Chemotherapy and radiation	212	35	20.5	19	19.8	83	48.0	60	32.4	23	13.7	24	14.7
		Unknown	159	20	14.2	14	14.3	48	34.3	39	25.5	18	12.8	13	9.4
Females	**All cases**		**1285**	**193**	**16.2**	**184**	**20.9**	**360**	**30.3**	**276**	**22.8**	**149**	**12.6**	**191**	**16.3**
	Age at baseline	<18	249	23	11.1	_	_	53	25.9	57	24.9	15	7.3	38	18.8
		18-19	106	15	15.3	13	18.6	29	29.3	15	15.0	8	8.2	11	11.3
		20-24	360	54	15.8	65	21.0	96	28.5	70	20.6	42	12.5	48	14.5
		25-29	293	54	19.4	49	20.1	99	35.9	69	25.1	43	15.7	46	16.8
		30-34	191	33	17.6	35	19.8	49	26.2	42	22.5	28	15.4	29	16.0
		35+	86	14	17.3	22	26.8	34	41.0	23	28.0	13	15.5	19	22.6
	Years since diagnosis	5-9	112	6	9.5	7	29.2	20	31.7	29	33.7	7	11.1	11	18.3
		10-14	427	62	15.3	49	21.2	81	20.2	67	16.5	37	9.2	70	17.5
		15-19	409	61	15.3	61	18.1	122	30.7	88	22.1	52	13.3	59	15.3
		20+	337	64	19.6	67	23.1	137	42.2	92	28.7	53	16.4	51	15.7
	Age at diagnosis	<1	65	9	15.8	1	6.7	30	53.6	20	33.9	3	5.5	7	13.2
		1-4	398	50	13.5	28	14.9	116	31.7	89	23.5	42	11.6	55	15.2
		5-9	372	52	14.8	62	22.1	96	27.3	73	20.4	41	11.7	45	13.0

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

Health Status Domains: Astrocytomas

			All cases	General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
				N	%	N	%	N	%	N	%	N	%	N	%
		10-14	313	60	20.3	70	25.2	86	29.0	61	20.8	44	15.2	61	21.1
		15-20	137	22	18.5	23	19.2	32	27.6	33	26.8	19	15.8	23	19.3
	Treatment	Surgery only	524	54	10.6	84	20.0	73	14.3	67	13.2	53	10.5	75	14.8
		Chemotherapy, no radiation	113	13	12.1	14	23.7	32	30.5	24	22.2	9	8.6	20	18.9
		Radiation, no chemotherapy	359	64	19.5	52	21.4	131	40.3	96	28.3	55	16.9	54	17.0
		Chemotherapy and radiation	162	39	29.3	23	28.8	82	61.7	61	43.9	21	16.0	31	23.7
		Unknown	127	23	20.0	11	13.6	42	36.5	28	23.5	11	10.0	11	10.3

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

Health Status Domains: Medulloblastoma/PNET

				General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**1040**	**159**	**17.4**	**99**	**17.5**	**365**	**39.9**	**228**	**23.8**	**83**	**9.1**	**111**	**12.3**
	Age at baseline	<18	246	24	13.6	_	_	69	39.0	63	30.0	18	10.2	24	13.6
		18-19	82	11	15.7	3	8.1	23	32.9	17	22.7	4	5.8	10	14.7
		20-24	292	37	14.1	26	13.1	107	40.4	54	19.9	16	6.1	21	8.1
		25-29	252	47	19.3	41	21.0	94	39.0	49	20.4	20	8.3	34	14.2
		30-34	131	29	22.8	24	22.6	55	43.7	35	28.2	19	15.1	18	14.2
		35+	37	11	30.6	5	16.7	17	48.6	10	27.8	6	16.7	4	11.1
	Years since diagnosis	5-9	124	8	16.3	1	9.1	20	40.8	35	39.3	5	10.0	6	12.2
		10-14	355	48	15.0	19	11.4	99	30.7	79	23.8	20	6.2	36	11.3
		15-19	344	48	14.5	48	20.2	133	40.5	60	18.5	29	9.0	44	13.7
		20+	217	55	25.5	31	20.4	113	52.8	54	25.5	29	13.6	25	11.7
	Age at diagnosis	<1	28	2	7.4	_	_	12	44.4	5	18.5	2	7.7	3	11.5
		1-4	298	43	15.9	17	18.3	123	45.6	73	26.1	22	8.3	34	12.9
		5-9	422	66	17.9	40	16.7	151	41.0	83	21.7	34	9.3	39	10.7
		10-14	230	38	18.9	33	17.9	66	33.0	49	23.3	17	8.4	27	13.4
		15-20	62	10	20.4	9	19.6	13	26.5	18	31.6	8	16.3	8	16.3
	Treatment	Surgery only	8	2	25.0	1	20.0	4	50.0	3	37.5	1	12.5	1	12.5
		Chemotherapy, no radiation	53	4	7.8	5	18.5	11	21.6	10	19.6	3	5.9	9	17.6
		Radiation, no chemotherapy	208	32	16.7	29	22.1	64	34.0	38	19.0	18	9.5	15	8.0
		Chemotherapy and radiation	694	112	18.8	62	17.2	265	44.2	166	26.6	56	9.4	82	13.8
		Unknown	77	9	13.4	2	4.7	21	31.3	11	14.9	5	7.6	4	6.3
Males	**All cases**		**631**	**95**	**17.2**	**61**	**18.5**	**210**	**38.0**	**131**	**22.3**	**49**	**8.9**	**58**	**10.6**
	Age at baseline	<18	147	11	10.3	_	_	39	36.1	36	28.1	10	9.3	9	8.4
		18-19	47	8	21.6	2	12.5	12	32.4	11	26.8	3	8.1	4	11.1
		20-24	185	25	15.2	21	17.2	65	39.2	32	18.4	12	7.3	15	9.1
		25-29	157	31	20.5	21	18.3	56	37.3	27	17.9	10	6.8	18	12.2
		30-34	73	14	19.7	14	24.6	28	39.4	20	28.2	11	15.5	10	14.1
		35+	22	6	27.3	3	15.8	10	47.6	5	22.7	3	13.6	2	9.1

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

Health Status Domains: Medulloblastoma/PNET

				General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
	Years since diagnosis	5-9	76	5	16.7	1	14.3	11	36.7	21	37.5	3	9.7	2	6.7
		10-14	208	28	15.2	12	13.3	54	29.0	46	23.7	10	5.4	16	8.6
		15-19	217	31	14.8	32	21.9	79	37.8	34	16.3	17	8.3	25	12.2
		20+	130	31	24.0	16	18.6	66	51.6	30	23.3	19	14.8	15	11.7
	Age at diagnosis	<1	16	2	12.5	_	_	8	50.0	4	25.0	2	12.5	3	18.8
		1-4	180	26	15.9	10	18.9	73	44.5	39	22.8	14	8.7	17	10.6
		5-9	266	40	17.3	26	17.8	89	38.5	54	22.1	21	9.1	21	9.2
		10-14	132	20	17.7	20	19.8	30	26.5	24	19.7	9	7.9	13	11.5
		15-20	37	7	24.1	5	18.5	10	34.5	10	29.4	3	10.3	4	13.8
	Treatment	Surgery only	5	2	40.0	1	33.3	2	40.0	2	40.0	1	20.0	1	20.0
		Chemotherapy, no radiation	27	2	7.4	3	21.4	8	29.6	7	25.9	2	7.4	5	18.5
		Radiation, no chemotherapy	116	22	20.8	18	26.5	33	32.0	23	20.7	11	10.5	7	6.7
		Chemotherapy and radiation	436	65	17.3	39	17.9	158	41.7	95	23.8	35	9.4	43	11.5
		Unknown	47	4	10.3	_	_	9	23.1	4	9.1	_	_	2	5.3
Females	**All cases**		**409**	**64**	**17.7**	**38**	**16.0**	**155**	**42.9**	**97**	**26.2**	**34**	**9.5**	**53**	**14.8**
	Age at baseline	<18	99	13	18.8	_	_	30	43.5	27	32.9	8	11.6	15	21.7
		18-19	35	3	9.1	1	4.8	11	33.3	6	17.6	1	3.1	6	18.8
		20-24	107	12	12.2	5	6.5	42	42.4	22	22.4	4	4.1	6	6.4
		25-29	95	16	17.4	20	25.0	38	41.8	22	24.7	10	10.9	16	17.4
		30-34	58	15	26.8	10	20.4	27	49.1	15	28.3	8	14.5	8	14.3
		35+	15	5	35.7	2	18.2	7	50.0	5	35.7	3	21.4	2	14.3
	Years since diagnosis	5-9	48	3	15.8	_	_	9	47.4	14	42.4	2	10.5	4	21.1
		10-14	147	20	14.7	7	9.2	45	32.8	33	23.9	10	7.3	20	14.8
		15-19	127	17	14.2	16	17.4	54	45.4	26	22.4	12	10.2	19	16.2
		20+	87	24	27.6	15	22.7	47	54.7	24	28.9	10	11.8	10	11.6
	Age at diagnosis	<1	12	_	_	_	_	4	36.4	1	9.1	_	_	_	_
		1-4	118	17	16.0	7	17.5	50	47.2	34	31.2	8	7.7	17	16.5
		5-9	156	26	19.0	14	14.9	62	45.3	29	20.9	13	9.5	18	13.2

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

			All cases	General Health [1] N	General Health [1] %	Mental Health [2] N	Mental Health [2] %	Functional Impairment [3] N	Functional Impairment [3] %	Activity Limitation [4] N	Activity Limitation [4] %	Pain [5] N	Pain [5] %	Anxiety [6] N	Anxiety [6] %
		10-14	98	18	20.5	13	15.7	36	41.4	25	28.4	8	9.1	14	15.9
		15-20	25	3	15.0	4	21.1	3	15.0	8	34.8	5	25.0	4	20.0
	Treatment	Surgery only	3	_	_	_	_	2	66.7	1	33.3	_	_	_	_
		Chemotherapy, no radiation	26	2	8.3	2	15.4	3	12.5	3	12.5	1	4.2	4	16.7
		Radiation, no chemotherapy	92	10	11.6	11	17.5	31	36.5	15	16.9	7	8.3	8	9.6
		Chemotherapy and radiation	258	47	21.3	23	16.1	107	48.4	71	31.7	21	9.5	39	17.6
		Unknown	30	5	17.9	2	11.8	12	42.9	7	23.3	5	18.5	2	7.7

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

Health Status Domains: Hodgkin

				General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**3111**	**409**	**14.4**	**472**	**17.3**	**206**	**7.4**	**366**	**12.4**	**195**	**7.1**	**484**	**17.6**
	Age at baseline	<18	61	5	10.4	_	_	1	2.1	5	8.5	4	8.7	7	14.9
		18-19	61	6	11.3	8	20.5	3	5.8	6	10.3	4	7.7	6	12.2
		20-24	375	31	10.0	39	13.0	14	4.8	34	10.1	15	5.1	42	14.3
		25-29	798	95	13.3	126	18.1	39	5.7	88	11.7	28	4.1	108	16.0
		30-34	951	132	14.8	162	18.4	75	8.6	115	12.7	72	8.3	169	19.5
		35+	865	140	16.8	137	16.7	74	9.0	118	14.1	72	8.8	152	18.6
	Years since diagnosis	5-9	242	15	11.2	22	20.0	5	4.1	32	15.5	8	6.7	21	17.5
		10-14	946	106	12.1	138	16.7	47	5.6	89	10.0	50	6.0	124	14.9
		15-19	1008	136	14.1	145	15.5	77	8.3	123	12.8	65	7.1	172	18.6
		20+	915	152	17.3	167	19.3	77	8.8	122	13.7	72	8.2	167	19.2
	Age at diagnosis	1-4	82	12	15.0	11	19.0	7	9.1	8	10.1	7	8.9	10	13.3
		5-9	421	48	12.1	56	16.4	27	6.9	35	8.6	23	6.0	62	16.2
		10-14	1120	145	14.0	193	19.0	68	6.7	127	11.9	60	6.0	180	17.9
		15-20	1488	204	15.3	212	16.1	104	8.0	196	14.0	105	8.2	232	18.1
	Treatment	Surgery only	2	_	_	1	50.0	_	_	_	_	_	_	_	_
		Chemotherapy, no radiation	364	47	13.5	52	15.7	22	6.5	37	10.7	19	5.6	58	17.2
		Radiation, no chemotherapy	652	78	12.6	95	15.7	36	6.3	69	11.5	37	6.5	88	15.4
		Chemotherapy and radiation	1765	239	15.0	281	18.4	123	7.8	219	13.0	112	7.2	288	18.5
		Unknown	328	45	15.8	43	15.8	25	8.8	41	13.1	27	9.7	50	17.9
Males	**All cases**		**1634**	**198**	**13.5**	**232**	**16.8**	**90**	**6.3**	**142**	**9.2**	**96**	**6.8**	**200**	**14.1**
	Age at baseline	<18	46	3	8.6	_	_	_	_	3	6.7	3	8.8	4	11.4
		18-19	48	5	11.6	7	21.2	2	4.8	4	8.9	4	9.5	5	12.8
		20-24	239	19	9.6	33	17.6	11	5.8	18	8.4	11	5.9	30	16.0
		25-29	445	48	12.2	62	16.4	19	5.1	38	9.1	14	3.8	44	11.8
		30-34	482	63	14.1	75	17.4	35	8.1	47	10.1	34	7.9	70	16.2
		35+	374	60	17.0	55	15.9	23	6.6	32	8.9	30	8.6	47	13.5
	Years since diagnosis	5-9	138	8	11.4	11	20.4	4	6.3	12	10.4	6	9.5	12	19.4

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

Health Status Domains: Hodgkin

				General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	491	50	11.2	74	18.3	19	4.4	38	8.2	27	6.4	48	11.4
		15-19	537	62	12.2	64	13.3	30	6.1	43	8.4	31	6.5	72	14.9
		20+	468	78	17.4	83	19.1	37	8.3	49	10.8	32	7.1	68	15.2
	Age at diagnosis	1-4	62	10	16.7	10	25.0	6	10.3	6	10.0	5	8.3	9	15.8
		5-9	305	35	12.3	41	16.8	20	7.2	24	8.1	18	6.6	41	15.0
		10-14	581	65	12.1	93	18.0	25	4.8	44	8.0	31	6.0	77	14.7
		15-20	686	88	15.0	88	15.3	39	6.9	68	10.7	42	7.5	73	13.1
	Treatment	Surgery only	2	_	_	1	50.0	_	_	_	_	_	_	_	_
		Chemotherapy, no radiation	187	26	14.8	28	17.3	12	7.1	13	7.4	6	3.6	26	15.5
		Radiation, no chemotherapy	336	40	12.7	49	15.9	20	6.7	31	9.8	24	8.0	39	13.2
		Chemotherapy and radiation	915	108	13.4	128	17.1	44	5.6	76	8.7	50	6.4	108	13.8
		Unknown	194	24	14.4	26	16.7	14	8.4	22	12.1	16	9.9	27	16.5
Females	**All cases**		**1477**	**211**	**15.3**	**240**	**17.7**	**116**	**8.6**	**224**	**15.9**	**99**	**7.4**	**284**	**21.3**
	Age at baseline	<18	15	2	15.4	_	_	1	7.7	2	14.3	1	8.3	3	25.0
		18-19	13	1	10.0	1	16.7	1	10.0	2	15.4	_	_	1	10.0
		20-24	136	12	10.6	6	5.3	3	2.9	16	13.0	4	3.8	12	11.3
		25-29	353	47	14.7	64	20.1	20	6.5	50	14.8	14	4.6	64	21.1
		30-34	469	69	15.4	87	19.5	40	9.2	68	15.3	38	8.8	99	22.8
		35+	491	80	16.7	82	17.3	51	10.8	86	18.0	42	9.0	105	22.4
	Years since diagnosis	5-9	104	7	10.9	11	19.6	1	1.7	20	21.7	2	3.5	9	15.5
		10-14	455	56	13.1	64	15.3	28	6.7	51	11.8	23	5.6	76	18.4
		15-19	471	74	16.3	81	17.9	47	10.7	80	17.8	34	7.8	100	22.7
		20+	447	74	17.1	84	19.5	40	9.3	73	16.8	40	9.4	99	23.3
	Age at diagnosis	1-4	20	2	10.0	1	5.6	1	5.3	2	10.5	2	10.5	1	5.6
		5-9	116	13	11.6	15	15.3	7	6.3	11	9.7	5	4.6	21	19.3
		10-14	539	80	16.0	100	20.0	43	8.8	83	16.2	29	6.0	103	21.3
		15-20	802	116	15.5	124	16.7	65	9.0	128	16.7	63	8.7	159	21.9
	Treatment	Chemotherapy, no radiation	177	21	12.2	24	14.2	10	6.0	24	14.0	13	7.7	32	18.8

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

			All cases	General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
				N	%	N	%	N	%	N	%	N	%	N	%
		Radiation, no chemotherapy	316	38	12.6	46	15.5	16	5.8	38	13.3	13	4.8	49	17.9
		Chemotherapy and radiation	850	131	16.6	153	19.7	79	10.1	143	17.4	62	8.0	180	23.2
		Unknown	134	21	17.9	17	14.7	11	9.5	19	14.5	11	9.4	23	19.8

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

Health Status Domains: NHL

				General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**2117**	**215**	**10.6**	**295**	**17.1**	**186**	**9.3**	**200**	**9.8**	**160**	**8.1**	**259**	**13.1**
	Age at baseline	<18	212	4	2.1	_	_	16	8.6	15	7.3	6	3.2	19	10.1
		18-19	132	5	4.2	14	15.7	5	4.2	15	12.1	4	3.6	10	9.0
		20-24	469	29	6.6	72	17.4	37	8.5	41	9.1	32	7.3	50	11.4
		25-29	572	76	13.8	99	19.0	51	9.4	54	9.9	49	9.1	83	15.5
		30-34	483	65	13.7	74	15.9	54	11.5	44	9.4	40	8.5	62	13.3
		35+	249	36	14.7	36	14.9	23	9.5	31	12.7	29	12.0	35	14.5
	Years since diagnosis	5-9	144	2	2.0	7	17.5	6	6.5	14	11.1	3	3.2	12	12.6
		10-14	671	47	7.3	92	19.0	46	7.2	56	8.7	41	6.5	85	13.5
		15-19	730	82	11.5	105	15.9	79	11.1	73	10.3	56	8.0	85	12.1
		20+	572	84	14.9	91	16.8	55	9.9	57	10.2	60	10.8	77	13.8
	Age at diagnosis	<1	15	_	_	_	_	1	7.1	1	6.7	1	7.7	1	7.1
		1-4	347	20	6.0	36	18.3	29	8.6	28	8.2	21	6.3	26	7.8
		5-9	649	61	9.8	92	17.9	47	7.7	55	8.8	39	6.4	78	12.8
		10-14	672	80	12.5	106	17.2	64	10.1	70	10.9	64	10.2	95	15.2
		15-20	434	54	13.2	61	15.3	45	11.2	46	11.1	35	8.8	59	14.8
	Treatment	Surgery only	16	1	7.1	2	20.0	3	21.4	2	13.3	2	14.3	_	_
		Chemotherapy, no radiation	1077	107	10.2	153	17.5	89	8.6	87	8.4	82	7.9	143	13.7
		Radiation, no chemotherapy	38	2	6.1	2	6.1	_	_	1	2.8	1	3.1	_	_
		Chemotherapy and radiation	767	84	11.7	104	16.7	75	10.6	86	11.7	54	7.8	88	12.8
		Unknown	219	21	9.9	34	18.3	19	9.0	24	11.1	21	10.0	28	13.6
Males	**All cases**		**1437**	**131**	**9.6**	**197**	**17.0**	**113**	**8.3**	**111**	**8.0**	**96**	**7.2**	**150**	**11.2**
	Age at baseline	<18	146	3	2.3	_	_	10	7.8	7	5.0	4	3.1	11	8.6
		18-19	97	3	3.3	8	11.8	2	2.3	9	10.0	2	2.4	7	8.6
		20-24	304	14	4.9	47	17.9	21	7.4	18	6.1	19	6.7	26	9.2
		25-29	407	49	12.5	70	19.1	35	9.0	33	8.4	30	7.9	50	13.1
		30-34	319	44	14.2	52	17.2	36	11.8	29	9.4	26	8.5	37	12.2
		35+	164	18	11.1	20	12.5	9	5.6	15	9.3	15	9.4	19	11.9

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

				General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
	Years since diagnosis	5-9	109	2	2.5	6	18.8	4	5.3	9	9.1	2	2.6	11	14.3
		10-14	456	28	6.4	58	18.0	26	6.0	26	5.9	21	5.0	47	11.2
		15-19	480	51	10.9	70	16.2	50	10.7	41	8.8	36	7.9	46	10.0
		20+	392	50	13.0	63	17.0	33	8.7	35	9.1	37	9.7	46	12.0
	Age at diagnosis	<1	5	_	_	_	_	_	_	_	_	1	25.0	_	_
		1-4	235	9	4.0	21	16.2	16	7.0	15	6.5	13	5.9	16	7.1
		5-9	451	38	8.8	65	18.6	32	7.5	34	7.9	23	5.4	43	10.2
		10-14	462	52	11.8	74	17.7	41	9.4	37	8.4	42	9.7	54	12.7
		15-20	284	32	12.1	37	14.3	24	9.2	25	9.1	17	6.6	37	14.3
	Treatment	Surgery only	13	_	_	1	11.1	2	18.2	2	16.7	2	18.2	_	_
		Chemotherapy, no radiation	728	67	9.5	105	18.1	55	7.9	49	7.0	47	6.8	81	11.6
		Radiation, no chemotherapy	28	1	4.2	1	4.2	_	_	1	3.7	1	4.2	_	_
		Chemotherapy and radiation	511	51	10.7	67	16.3	43	9.2	46	9.3	32	7.0	54	11.9
		Unknown	157	12	7.8	23	17.0	13	8.6	13	8.4	14	9.2	15	10.1
Females	**All cases**		**680**	**84**	**12.9**	**98**	**17.2**	**73**	**11.4**	**89**	**13.6**	**64**	**9.9**	**109**	**16.9**
	Age at baseline	<18	66	1	1.7	_	_	6	10.2	8	12.5	2	3.4	8	13.1
		18-19	35	2	6.7	6	28.6	3	10.0	6	17.6	2	6.7	3	10.0
		20-24	165	15	9.6	25	16.6	16	10.5	23	14.6	13	8.4	24	15.6
		25-29	165	27	17.0	29	18.8	16	10.3	21	13.4	19	12.2	33	21.3
		30-34	164	21	12.8	22	13.6	18	11.0	15	9.4	14	8.6	25	15.2
		35+	85	18	21.7	16	19.8	14	17.3	16	19.3	14	17.1	16	19.8
	Years since diagnosis	5-9	35	_	_	1	12.5	2	11.8	5	18.5	1	5.6	1	5.6
		10-14	215	19	9.1	34	21.0	20	9.7	30	14.4	20	9.7	38	18.2
		15-19	250	31	12.7	35	15.4	29	12.0	32	13.1	20	8.2	39	15.9
		20+	180	34	19.0	28	16.4	22	12.5	22	12.6	23	13.1	31	17.9
	Age at diagnosis	<1	10	_	_	_	_	1	10.0	1	10.0	_	_	1	10.0
		1-4	112	11	10.1	15	22.4	13	11.8	13	11.8	8	7.3	10	9.1
		5-9	198	23	12.1	27	16.4	15	8.1	21	10.8	16	8.5	35	18.7

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

			All cases	General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
				N	%	N	%	N	%	N	%	N	%	N	%
		10-14	210	28	14.1	32	16.3	23	11.7	33	16.4	22	11.2	41	20.8
		15-20	150	22	15.3	24	17.0	21	14.9	21	15.0	18	12.7	22	15.6
	Treatment	Surgery only	3	1	33.3	1	100.0	1	33.3	_	_	_	_	_	_
		Chemotherapy, no radiation	349	40	11.7	48	16.2	34	10.1	38	11.2	35	10.3	62	18.2
		Radiation, no chemotherapy	10	1	11.1	1	11.1	_	_	_	_	_	_	_	_
		Chemotherapy and radiation	256	33	13.8	37	17.5	32	13.6	40	16.5	22	9.3	34	14.4
		Unknown	62	9	15.3	11	21.6	6	10.3	11	17.7	7	12.3	13	22.4

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

				General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**2277**	**148**	**6.8**	**179**	**14.0**	**127**	**5.8**	**160**	**7.2**	**122**	**5.6**	**220**	**10.2**
	Age at baseline	<18	832	25	3.2	_	_	39	4.9	42	5.2	28	3.5	72	9.2
		18-19	305	22	7.4	32	15.2	17	5.7	24	8.2	19	6.4	31	10.5
		20-24	670	52	8.1	87	14.0	40	6.2	48	7.3	40	6.2	66	10.2
		25-29	374	41	11.4	48	13.7	28	7.7	41	11.2	28	7.8	43	12.3
		30-34	77	5	6.5	10	13.0	2	2.6	5	6.5	6	8.0	7	9.2
		35+	19	3	15.8	2	11.1	1	5.9	_	_	1	5.6	1	5.9
	Years since diagnosis	5-9	176	2	1.4	2	40.0	5	3.5	14	8.8	1	0.7	14	9.9
		10-14	739	28	3.9	15	12.5	42	5.8	44	6.1	33	4.6	74	10.4
		15-19	759	58	7.9	85	14.6	37	5.0	40	5.4	40	5.5	61	8.3
		20+	603	60	10.2	77	13.5	43	7.3	62	10.4	48	8.2	71	12.3
	Age at diagnosis	<1	331	21	6.6	25	18.9	17	5.4	18	5.6	13	4.0	26	8.2
		1-4	1396	89	6.6	94	12.9	76	5.6	103	7.6	82	6.1	131	9.8
		5-9	468	32	7.3	48	14.0	29	6.6	30	6.7	21	4.8	53	12.2
		10-14	59	5	9.1	7	12.7	3	5.5	8	13.8	5	9.1	7	12.7
		15-20	23	1	5.3	5	27.8	2	11.1	1	5.3	1	5.6	3	16.7
	Treatment	Surgery only	35	3	8.6	3	23.1	1	2.9	1	3.0	_	_	2	6.1
		Chemotherapy, no radiation	873	41	4.8	59	13.1	39	4.6	40	4.7	29	3.4	80	9.4
		Radiation, no chemotherapy	4	1	25.0	2	50.0	_	_	1	25.0	_	_	1	25.0
		Chemotherapy and radiation	1155	78	7.2	101	14.6	72	6.6	101	9.0	66	6.1	112	10.4
		Unknown	210	25	12.3	14	11.7	15	7.4	17	8.3	27	13.6	25	12.6
Males	**All cases**		**1019**	**59**	**6.0**	**65**	**12.4**	**56**	**5.7**	**50**	**5.1**	**49**	**5.1**	**80**	**8.3**
	Age at baseline	<18	403	15	3.9	_	_	15	3.9	15	3.9	9	2.4	32	8.4
		18-19	126	7	5.6	11	14.9	8	6.5	7	5.7	6	5.0	11	9.1
		20-24	285	23	8.3	33	12.8	22	8.0	17	6.1	19	7.0	27	9.9
		25-29	165	12	7.5	16	10.5	10	6.3	9	5.7	12	7.8	9	5.9
		30-34	32	2	6.3	5	15.6	1	3.1	2	6.3	3	9.7	1	3.2
		35+	8	_	_	_	_	_	_	_	_	_	_	_	_

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

				General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
	Years since diagnosis	5-9	79	1	1.6	1	100.0	2	3.3	4	5.8	_	_	8	13.1
		10-14	333	14	4.3	5	14.7	15	4.6	19	5.8	10	3.1	27	8.5
		15-19	334	24	7.3	32	13.7	19	5.8	9	2.8	17	5.2	22	6.7
		20+	273	20	7.4	27	10.6	20	7.5	18	6.7	22	8.5	23	8.9
	Age at diagnosis	<1	169	8	4.9	9	15.5	8	4.9	5	3.0	6	3.6	14	8.6
		1-4	628	36	5.9	33	10.9	31	5.1	29	4.7	30	5.0	42	7.0
		5-9	192	15	8.4	18	13.0	17	9.7	14	7.7	11	6.3	23	13.4
		10-14	21	_	_	2	11.1	_	_	2	9.5	2	11.1	_	_
		15-20	9	_	_	3	42.9	_	_	_	_	_	_	1	14.3
	Treatment	Surgery only	19	2	10.5	2	28.6	1	5.3	1	5.6	_	_	1	5.6
		Chemotherapy, no radiation	396	16	4.1	18	9.7	15	3.9	9	2.3	9	2.3	36	9.4
		Chemotherapy and radiation	499	30	6.3	35	12.8	33	7.0	30	6.2	27	5.8	33	7.1
		Unknown	105	11	10.9	10	17.2	7	7.1	10	9.7	13	13.3	10	10.2
Females	**All cases**		**1258**	**89**	**7.4**	**114**	**15.1**	**71**	**5.9**	**110**	**9.0**	**73**	**6.0**	**140**	**11.7**
	Age at baseline	<18	429	10	2.4	_	_	24	5.9	27	6.5	19	4.7	40	9.9
		18-19	179	15	8.7	21	15.4	9	5.1	17	9.9	13	7.5	20	11.6
		20-24	385	29	8.0	54	14.8	18	4.9	31	8.2	21	5.7	39	10.5
		25-29	209	29	14.4	32	16.2	18	8.8	32	15.5	16	7.9	34	17.3
		30-34	45	3	6.7	5	11.1	1	2.3	3	6.7	3	6.8	6	13.3
		35+	11	3	27.3	2	20.0	1	10.0	_	_	1	10.0	1	10.0
	Years since diagnosis	5-9	97	1	1.2	1	25.0	3	3.7	10	11.1	1	1.2	6	7.4
		10-14	406	14	3.5	10	11.6	27	6.8	25	6.3	23	5.8	47	12.0
		15-19	425	34	8.4	53	15.2	18	4.4	31	7.5	23	5.6	39	9.6
		20+	330	40	12.4	50	15.8	23	7.1	44	13.5	26	8.0	48	15.1
	Age at diagnosis	<1	162	13	8.4	16	21.6	9	5.9	13	8.2	7	4.5	12	7.8
		1-4	768	53	7.2	61	14.3	45	6.1	74	9.9	52	7.0	89	12.1
		5-9	276	17	6.5	30	14.6	12	4.5	16	6.0	10	3.8	30	11.4
		10-14	38	5	13.5	5	13.5	3	8.1	6	16.2	3	8.1	7	18.9

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

			All cases	General Health [1] N	General Health [1] %	Mental Health [2] N	Mental Health [2] %	Functional Impairment [3] N	Functional Impairment [3] %	Activity Limitation [4] N	Activity Limitation [4] %	Pain [5] N	Pain [5] %	Anxiety [6] N	Anxiety [6] %
		15-20	14	1	8.3	2	18.2	2	18.2	1	8.3	1	9.1	2	18.2
	Treatment	Surgery only	16	1	6.3	1	16.7	_	_	_	_	_	_	1	6.7
		Chemotherapy, no radiation	477	25	5.4	41	15.4	24	5.1	31	6.6	20	4.3	44	9.4
		Radiation, no chemotherapy	4	1	25.0	2	50.0	_	_	1	25.0	_	_	1	25.0
		Chemotherapy and radiation	656	48	7.8	66	15.8	39	6.3	71	11.2	39	6.3	79	12.9
		Unknown	105	14	13.6	4	6.5	8	7.8	7	6.9	14	13.9	15	14.9

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

Health Status Domains: Neuroblastoma

				General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**1954**	**148**	**8.0**	**128**	**15.1**	**179**	**9.8**	**195**	**10.6**	**113**	**6.2**	**193**	**10.7**
	Age at baseline	<18	957	41	4.7	_	_	78	8.9	77	8.6	39	4.5	81	9.3
		18-19	237	23	10.1	24	15.4	23	10.1	26	11.4	13	5.7	19	8.4
		20-24	544	58	11.0	84	17.2	57	11.1	63	12.1	41	8.0	70	13.6
		25-29	172	19	11.5	14	8.8	18	11.0	23	14.2	16	9.9	17	10.4
		30-34	36	4	11.1	5	13.9	1	2.9	5	14.7	3	8.8	5	15.2
		35+	8	3	37.5	1	14.3	2	25.0	1	12.5	1	12.5	1	12.5
	Years since diagnosis	5-9	160	1	1.1	_	_	10	11.1	17	15.3	3	3.4	7	7.9
		10-14	610	31	5.3	9	23.7	55	9.4	53	9.0	28	4.8	57	9.8
		15-19	639	54	8.6	45	15.1	61	9.9	62	10.0	43	6.9	57	9.3
		20+	545	62	11.5	74	14.5	53	10.1	63	12.0	39	7.4	72	13.7
	Age at diagnosis	<1	993	61	6.2	58	15.5	80	8.2	88	9.0	44	4.5	100	10.3
		1-4	764	75	10.5	50	14.5	84	12.0	86	12.1	55	7.8	79	11.4
		5-9	148	6	5.3	15	16.9	8	7.2	11	9.1	11	9.8	10	9.1
		10-14	30	2	8.0	3	13.0	4	17.4	5	19.2	1	4.3	2	8.3
		15-20	19	4	30.8	2	15.4	3	25.0	5	35.7	2	16.7	2	16.7
	Treatment	Surgery only	548	30	5.5	31	13.0	30	5.6	28	5.3	19	3.5	39	7.3
		Chemotherapy, no radiation	562	31	5.7	32	15.5	57	10.5	52	9.6	24	4.4	63	11.6
		Radiation, no chemotherapy	138	11	8.1	16	23.5	17	13.5	17	13.5	17	13.7	16	13.1
		Chemotherapy and radiation	532	61	13.3	41	16.0	63	14.0	76	16.0	41	9.0	61	13.5
		Unknown	174	15	9.4	8	10.4	12	7.4	22	12.9	12	7.5	14	8.9
Males	**All cases**		**953**	**72**	**8.1**	**56**	**14.6**	**81**	**9.2**	**84**	**9.4**	**46**	**5.2**	**78**	**9.0**
	Age at baseline	<18	479	19	4.3	_	_	30	6.9	35	7.8	16	3.7	39	9.0
		18-19	104	9	9.0	7	12.7	12	12.0	10	10.0	5	5.0	8	8.3
		20-24	275	31	11.8	38	15.8	27	10.6	26	10.0	16	6.3	25	9.8
		25-29	78	9	12.3	8	11.1	10	13.9	11	15.5	6	8.5	6	8.3
		30-34	14	3	21.4	3	21.4	1	7.7	2	15.4	2	15.4	_	_
		35+	3	1	33.3	_	_	1	33.3	_	_	1	33.3	_	_

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

Health Status Domains: Neuroblastoma

				General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
	Years since diagnosis	5-9	75	1	2.6	_	_	4	10.0	8	16.3	1	2.6	2	5.1
		10-14	304	15	5.1	4	30.8	21	7.3	25	8.5	13	4.5	29	10.1
		15-19	308	24	8.0	13	10.5	29	9.8	23	7.8	17	5.8	23	7.9
		20+	266	32	12.4	39	15.9	27	10.6	28	11.0	15	5.9	24	9.4
	Age at diagnosis	<1	516	33	6.5	29	15.3	38	7.5	45	8.9	20	4.0	46	9.2
		1-4	344	32	10.1	15	10.7	35	11.2	28	8.8	15	4.8	28	9.1
		5-9	74	4	7.5	10	25.0	5	10.0	7	13.0	10	19.6	4	8.0
		10-14	13	1	10.0	1	11.1	1	12.5	2	22.2	_	_	_	_
		15-20	6	2	50.0	1	25.0	2	50.0	2	40.0	1	25.0	_	_
	Treatment	Surgery only	263	14	5.4	15	13.8	18	7.0	14	5.4	6	2.3	16	6.2
		Chemotherapy, no radiation	279	15	5.6	14	14.6	25	9.3	21	7.8	11	4.1	26	9.8
		Radiation, no chemotherapy	62	8	12.9	8	25.8	7	12.7	9	16.4	4	7.4	7	13.2
		Chemotherapy and radiation	259	26	11.9	15	13.3	23	10.7	27	11.9	17	7.9	21	9.9
		Unknown	90	9	11.1	4	11.8	8	9.5	13	14.9	8	9.9	8	10.0
Females	**All cases**		**1001**	**76**	**8.0**	**72**	**15.6**	**98**	**10.4**	**111**	**11.6**	**67**	**7.1**	**115**	**12.2**
	Age at baseline	<18	478	22	5.0	_	_	48	11.0	42	9.4	23	5.2	42	9.6
		18-19	133	14	10.9	17	16.8	11	8.6	16	12.4	8	6.2	11	8.5
		20-24	269	27	10.3	46	18.5	30	11.6	37	14.3	25	9.6	45	17.4
		25-29	94	10	10.9	6	6.9	8	8.8	12	13.2	10	11.0	11	12.0
		30-34	22	1	4.5	2	9.1	_	_	3	14.3	1	4.8	5	25.0
		35+	5	2	40.0	1	20.0	1	20.0	1	20.0	_	_	1	20.0
	Years since diagnosis	5-9	85	_	_	_	_	6	12.0	9	14.5	2	4.0	5	10.0
		10-14	306	16	5.4	5	20.0	34	11.5	28	9.4	15	5.1	28	9.6
		15-19	331	30	9.2	32	18.4	32	9.9	39	12.1	26	8.0	34	10.4
		20+	279	30	10.8	35	13.3	26	9.6	35	12.9	24	8.8	48	17.6
	Age at diagnosis	<1	477	28	5.9	29	15.7	42	9.0	43	9.2	24	5.1	54	11.5
		1-4	420	43	10.9	35	17.0	49	12.6	58	14.7	40	10.2	51	13.1
		5-9	74	2	3.3	5	10.2	3	4.9	4	6.0	1	1.6	6	10.0

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

			All cases	General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
				N	%	N	%	N	%	N	%	N	%	N	%
		10-14	17	1	6.7	2	14.3	3	20.0	3	17.6	1	7.1	2	13.3
		15-20	13	2	22.2	1	11.1	1	12.5	3	33.3	1	12.5	2	25.0
	Treatment	Surgery only	285	16	5.7	16	12.3	12	4.3	14	5.1	13	4.7	23	8.3
		Chemotherapy, no radiation	283	16	5.8	18	16.4	32	11.6	31	11.3	13	4.7	37	13.3
		Radiation, no chemotherapy	76	3	4.1	8	21.6	10	14.1	8	11.3	13	18.6	9	13.0
		Chemotherapy and radiation	273	35	14.5	26	18.2	40	16.9	49	19.8	24	10.0	40	16.7
		Unknown	84	6	7.6	4	9.3	4	5.1	9	10.8	4	5.1	6	7.7

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

Health Status Domains: STS

				General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**1760**	**164**	**10.1**	**208**	**16.4**	**181**	**11.3**	**216**	**12.8**	**201**	**12.6**	**242**	**15.3**
	Age at baseline	<18	341	16	5.4	_	_	29	9.7	39	12.0	15	5.0	34	11.6
		18-19	125	16	13.9	16	17.8	15	13.3	19	15.7	14	12.6	19	17.3
		20-24	425	30	7.9	62	17.3	45	12.2	53	13.1	46	12.5	49	13.5
		25-29	393	47	12.6	60	16.6	43	11.9	45	11.9	52	14.3	63	17.3
		30-34	299	31	10.8	47	16.6	29	10.3	36	12.4	40	14.1	41	14.6
		35+	177	24	14.0	23	13.3	20	11.7	24	14.0	34	19.8	36	21.1
	Years since diagnosis	5-9	182	7	6.2	10	20.4	7	6.4	30	18.6	6	5.5	13	12.0
		10-14	521	38	7.9	49	17.6	53	11.2	53	10.6	44	9.2	72	15.2
		15-19	541	47	9.0	72	16.1	46	9.0	67	12.8	71	13.9	73	14.5
		20+	516	72	14.3	77	15.7	75	15.0	66	13.1	80	16.0	84	16.8
	Age at diagnosis	<1	124	10	8.3	8	17.8	14	11.6	15	12.4	6	5.1	10	8.6
		1-4	562	57	10.8	50	16.7	69	13.3	74	13.7	63	12.2	76	14.8
		5-9	397	35	9.4	55	17.2	41	11.3	41	10.7	43	11.7	52	14.2
		10-14	348	32	10.2	49	15.6	28	9.1	39	11.7	46	14.9	52	16.9
		15-20	329	30	10.3	46	15.9	29	10.2	47	15.0	43	15.1	52	18.4
	Treatment	Surgery only	171	9	5.6	23	16.2	13	8.2	22	13.4	14	8.9	18	11.5
		Chemotherapy, no radiation	361	28	8.1	34	13.2	25	7.3	34	9.7	36	10.5	48	14.1
		Radiation, no chemotherapy	63	2	3.5	3	5.6	5	9.1	3	5.3	7	12.7	6	11.1
		Chemotherapy and radiation	974	107	12.1	131	19.4	117	13.5	120	12.9	118	13.6	146	16.9
		Unknown	191	18	10.4	17	12.3	21	12.4	37	19.7	26	15.1	24	14.0
Males	**All cases**		**951**	**75**	**8.6**	**105**	**15.7**	**91**	**10.6**	**87**	**9.5**	**104**	**12.1**	**118**	**13.9**
	Age at baseline	<18	192	7	4.3	_	_	13	8.1	16	8.9	8	4.9	23	14.5
		18-19	66	8	13.1	9	20.9	9	15.0	11	16.9	7	11.9	8	13.8
		20-24	242	16	7.3	33	16.2	27	12.8	27	11.8	31	14.7	26	12.6
		25-29	208	23	11.7	31	16.4	21	10.8	14	6.9	20	10.2	28	14.3
		30-34	159	14	9.3	25	16.8	15	10.0	16	10.3	22	14.8	18	12.2
		35+	84	7	8.3	7	8.4	6	7.4	3	3.7	16	19.5	15	18.5

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

Health Status Domains: STS

				General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
	Years since diagnosis	5-9	100	5	8.5	5	23.8	4	7.3	16	19.0	2	3.6	6	10.9
		10-14	288	16	6.0	25	16.9	26	9.9	24	8.6	23	8.7	42	16.2
		15-19	282	20	7.4	38	16.2	24	9.1	26	9.5	39	14.7	32	12.3
		20+	281	34	12.3	37	14.0	37	13.5	21	7.6	40	14.6	38	13.9
	Age at diagnosis	<1	52	4	7.7	4	23.5	4	7.8	3	5.9	3	6.0	5	10.0
		1-4	331	33	10.8	29	17.0	39	12.9	35	11.0	38	12.6	41	13.8
		5-9	225	11	5.3	27	15.4	21	10.3	19	8.6	20	9.7	25	12.3
		10-14	186	12	7.1	25	14.9	17	10.2	16	9.1	23	13.9	27	16.4
		15-20	157	15	10.8	20	14.6	10	7.5	14	9.5	20	14.8	20	15.0
	Treatment	Surgery only	74	4	5.6	11	16.9	4	6.0	5	7.2	5	7.6	5	7.6
		Chemotherapy, no radiation	212	15	7.3	18	11.8	10	5.0	11	5.4	18	8.9	25	12.4
		Radiation, no chemotherapy	32	1	3.4	1	3.8	3	10.3	1	3.3	3	10.3	4	14.3
		Chemotherapy and radiation	524	50	10.6	66	19.0	64	13.8	51	10.2	63	13.5	73	15.9
		Unknown	109	5	5.2	9	11.7	10	10.6	19	17.8	15	15.6	11	11.6
Females	**All cases**		**809**	**89**	**11.9**	**103**	**17.2**	**90**	**12.2**	**129**	**16.6**	**97**	**13.2**	**124**	**16.8**
	Age at baseline	<18	149	9	6.7	_	_	16	11.7	23	15.9	7	5.1	11	8.1
		18-19	59	8	14.8	7	14.9	6	11.3	8	14.3	7	13.5	11	21.2
		20-24	183	14	8.7	29	18.7	18	11.4	26	14.8	15	9.6	23	14.6
		25-29	185	24	13.6	29	16.8	22	13.1	31	17.7	32	19.0	35	20.7
		30-34	140	17	12.6	22	16.4	14	10.6	20	14.8	18	13.4	23	17.3
		35+	93	17	19.5	16	17.8	14	15.6	21	23.1	18	20.0	21	23.3
	Years since diagnosis	5-9	82	2	3.7	5	17.9	3	5.5	14	18.2	4	7.5	7	13.2
		10-14	233	22	10.1	24	18.3	27	12.7	29	12.9	21	9.8	30	14.1
		15-19	259	27	10.8	34	15.9	22	8.9	41	16.4	32	13.1	41	16.9
		20+	235	38	16.9	40	17.7	38	16.9	45	19.8	40	17.7	46	20.3
	Age at diagnosis	<1	72	6	8.7	4	14.3	10	14.3	12	17.1	3	4.5	5	7.6
		1-4	231	24	10.9	21	16.4	30	13.8	39	17.4	25	11.6	35	16.2
		5-9	172	24	14.7	28	19.4	20	12.7	22	13.6	23	14.3	27	16.7

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

			All cases	General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
				N	%	N	%	N	%	N	%	N	%	N	%
		10-14	162	20	13.9	24	16.4	11	7.7	23	14.7	23	16.1	25	17.5
		15-20	172	15	9.9	26	17.0	19	12.7	33	19.9	23	15.3	32	21.5
	Treatment	Surgery only	97	5	5.6	12	15.6	9	9.9	17	17.9	9	9.8	13	14.4
		Chemotherapy, no radiation	149	13	9.2	16	15.2	15	10.6	23	15.6	18	12.9	23	16.4
		Radiation, no chemotherapy	31	1	3.6	2	7.1	2	7.7	2	7.4	4	15.4	2	7.7
		Chemotherapy and radiation	450	57	13.8	65	19.8	53	13.1	69	16.1	55	13.6	73	18.1
		Unknown	82	13	17.1	8	13.1	11	14.5	18	22.2	11	14.5	13	17.1

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

Health Status Domains: All bone

				General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**2100**	**240**	**12.9**	**336**	**19.1**	**332**	**18.1**	**564**	**29.0**	**464**	**25.4**	**316**	**17.3**
	Age at baseline	<18	96	1	1.8	_	_	7	12.5	20	25.3	3	5.5	5	9.1
		18-19	72	4	8.3	7	17.9	8	17.4	15	25.0	6	12.8	7	14.9
		20-24	389	35	11.6	60	20.7	42	14.3	91	26.8	60	20.4	40	13.7
		25-29	568	63	12.3	94	18.7	88	17.4	147	27.8	122	24.3	97	19.2
		30-34	567	78	14.4	96	18.0	90	16.7	163	30.1	156	29.3	97	18.1
		35+	408	59	14.8	79	20.1	97	24.4	128	32.2	117	29.8	70	17.6
	Years since diagnosis	5-9	243	10	9.9	19	23.8	15	16.9	68	39.8	14	15.6	12	13.3
		10-14	681	67	10.8	102	17.9	92	14.9	167	25.9	144	23.5	98	16.1
		15-19	677	84	12.9	125	19.9	116	17.9	180	28.0	167	26.1	109	17.0
		20+	499	79	16.2	90	18.8	109	22.4	149	30.5	139	28.9	97	19.9
	Age at diagnosis	<1	9	1	11.1	_	_	_	_	1	11.1	_	_	1	12.5
		1-4	88	6	7.5	13	27.7	14	17.5	16	19.8	11	13.9	9	11.3
		5-9	369	34	10.2	52	17.4	50	15.1	80	22.8	63	19.0	55	16.5
		10-14	842	107	14.3	139	19.1	140	18.9	232	29.6	200	27.4	140	19.1
		15-20	792	92	13.3	132	19.3	128	18.9	235	32.5	190	28.1	111	16.4
	Treatment	Surgery only	119	10	8.5	14	12.2	11	9.6	31	27.0	22	19.1	10	8.7
		Chemotherapy, no radiation	1191	135	12.3	204	19.5	199	18.3	308	27.9	273	25.4	183	16.9
		Radiation, no chemotherapy	17	3	23.1	2	15.4	3	21.4	3	20.0	3	21.4	1	7.1
		Chemotherapy and radiation	582	66	13.7	87	19.6	87	18.6	151	28.4	116	24.9	95	20.3
		Unknown	191	26	16.9	29	20.6	32	20.8	71	39.4	50	32.5	27	17.6
Males	**All cases**		**1086**	**121**	**12.8**	**166**	**18.8**	**142**	**15.3**	**250**	**25.0**	**237**	**25.7**	**125**	**13.5**
	Age at baseline	<18	48	1	4.2	_	_	2	8.3	12	31.6	1	4.2	1	4.2
		18-19	36	_	_	2	13.3	3	16.7	4	12.9	1	5.3	_	_
		20-24	194	14	9.4	23	16.7	18	12.6	34	20.4	24	16.7	10	6.9
		25-29	299	34	12.9	49	19.4	39	15.2	69	25.4	68	26.8	49	19.3
		30-34	284	40	14.9	55	20.8	34	12.5	70	25.6	81	30.5	37	13.9
		35+	225	32	14.6	37	17.2	46	21.1	61	28.0	62	28.8	28	12.9

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

Health Status Domains: All bone

				General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
	Years since diagnosis	5-9	133	6	11.8	11	26.8	2	4.7	34	37.0	5	11.4	4	9.1
		10-14	349	32	10.4	51	18.1	38	12.5	74	22.9	75	24.8	38	12.7
		15-19	349	45	13.4	60	18.8	53	15.8	79	23.6	89	26.7	45	13.6
		20+	255	38	15.3	44	18.3	49	19.7	63	25.3	68	28.0	38	15.3
	Age at diagnosis	<1	4	_	_	_	_	_	_	_	_	_	_	_	_
		1-4	47	4	9.1	5	17.2	7	15.9	5	11.4	5	11.6	3	6.8
		5-9	189	16	9.4	23	15.5	28	16.8	36	19.9	24	14.4	24	14.3
		10-14	403	47	13.5	61	18.2	50	14.5	85	22.8	98	28.9	46	13.6
		15-20	443	54	14.3	77	20.8	57	15.4	124	31.2	110	29.8	52	14.1
	Treatment	Surgery only	48	5	10.4	8	17.4	5	10.6	11	23.4	9	18.8	4	8.3
		Chemotherapy, no radiation	612	62	11.2	99	18.9	79	14.4	127	22.5	141	26.0	70	12.8
		Radiation, no chemotherapy	9	2	33.3	1	14.3	2	28.6	1	12.5	1	14.3	_	_
		Chemotherapy and radiation	297	36	15.1	41	18.8	40	17.3	70	26.2	51	22.3	36	15.7
		Unknown	120	16	16.7	17	19.3	16	16.5	41	36.3	35	36.5	15	15.8
Females	**All cases**		**1014**	**119**	**13.0**	**170**	**19.4**	**190**	**20.9**	**314**	**33.2**	**227**	**25.1**	**191**	**21.1**
	Age at baseline	<18	48	_	_	_	_	5	15.6	8	19.5	2	6.5	4	12.9
		18-19	36	4	14.3	5	20.8	5	17.9	11	37.9	5	17.9	7	25.0
		20-24	195	21	13.7	37	24.3	24	16.0	57	32.9	36	24.0	30	20.1
		25-29	269	29	11.6	45	18.0	49	19.6	78	30.5	54	21.7	48	19.2
		30-34	283	38	13.9	41	15.2	56	20.8	93	34.6	75	28.1	60	22.3
		35+	183	27	15.0	42	23.5	51	28.5	67	37.4	55	30.9	42	23.3
	Years since diagnosis	5-9	110	4	8.0	8	20.5	13	28.3	34	43.0	9	19.6	8	17.4
		10-14	332	35	11.1	51	17.6	54	17.3	93	29.0	69	22.1	60	19.4
		15-19	328	39	12.4	65	21.0	63	20.3	101	32.8	78	25.4	64	20.6
		20+	244	41	17.2	46	19.3	60	25.2	86	36.0	71	29.8	59	24.6
	Age at diagnosis	<1	5	1	20.0	_	_	_	_	1	20.0	_	_	1	25.0
		1-4	41	2	5.6	8	44.4	7	19.4	11	29.7	6	16.7	6	16.7
		5-9	180	18	11.0	29	19.3	22	13.4	44	25.9	39	23.8	31	18.8

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

Health Status Domains: All bone

			All cases	General Health [1] N	General Health [1] %	Mental Health [2] N	Mental Health [2] %	Functional Impairment [3] N	Functional Impairment [3] %	Activity Limitation [4] N	Activity Limitation [4] %	Pain [5] N	Pain [5] %	Anxiety [6] N	Anxiety [6] %
		10-14	439	60	15.1	78	19.8	90	22.8	147	35.9	102	26.1	94	23.9
		15-20	349	38	12.0	55	17.6	71	23.0	111	34.2	80	26.0	59	19.1
	Treatment	Surgery only	71	5	7.2	6	8.7	6	9.0	20	29.4	13	19.4	6	9.0
		Chemotherapy, no radiation	579	73	13.5	105	20.2	120	22.3	181	33.5	132	24.7	113	21.0
		Radiation, no chemotherapy	8	1	14.3	1	16.7	1	14.3	2	28.6	2	28.6	1	14.3
		Chemotherapy and radiation	285	30	12.3	46	20.3	47	19.7	81	30.7	65	27.4	59	24.8
		Unknown	71	10	17.2	12	22.6	16	28.1	30	44.8	15	25.9	12	20.7

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

Health Status Domains: Ewings

				General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**738**	**78**	**12.5**	**105**	**18.4**	**97**	**15.8**	**175**	**25.6**	**135**	**22.2**	**111**	**18.2**
	Age at baseline	<18	61	1	2.7	_	_	3	8.1	11	19.6	2	5.6	3	8.3
		18-19	36	4	21.1	4	26.7	2	10.5	6	20.7	4	21.1	4	21.1
		20-24	170	11	8.5	23	18.4	11	8.6	41	27.0	26	20.2	15	11.6
		25-29	204	27	14.8	30	17.1	36	20.3	47	25.1	37	21.1	35	20.1
		30-34	164	18	11.6	25	16.1	17	11.2	38	24.2	39	25.7	33	21.7
		35+	103	17	16.7	23	22.5	28	27.7	32	31.4	27	27.8	21	20.8
	Years since diagnosis	5-9	104	4	13.3	3	15.0	1	3.6	30	37.5	3	10.7	2	7.1
		10-14	247	18	8.2	30	16.0	28	13.0	50	21.7	45	21.0	36	16.9
		15-19	223	31	14.4	40	19.4	36	17.1	52	24.4	43	20.7	37	17.7
		20+	164	25	15.5	32	20.1	32	19.9	43	26.9	44	27.8	36	22.4
	Age at diagnosis	<1	5	_	_	_	_	_	_	_	_	_	_	1	25.0
		1-4	54	6	12.5	8	32.0	8	16.7	10	20.0	8	16.7	5	10.4
		5-9	183	12	7.5	25	17.9	16	9.9	36	20.3	28	17.5	28	17.5
		10-14	278	36	15.4	37	16.2	37	16.3	58	22.8	53	23.7	45	19.8
		15-20	218	24	13.5	35	19.7	36	20.8	71	36.0	46	26.7	32	18.6
	Treatment	Surgery only	1	_	_	_	_	_	_	1	100.0	_	_	_	_
		Chemotherapy, no radiation	210	20	10.0	33	18.3	24	12.1	32	16.0	30	15.3	23	11.6
		Radiation, no chemotherapy	2	_	_	_	_	_	_	_	_	_	_	_	_
		Chemotherapy and radiation	463	50	13.2	64	18.3	65	17.7	120	28.4	91	24.9	78	21.3
		Unknown	62	8	17.8	8	20.0	8	17.8	22	37.3	14	31.8	10	22.7
Males	**All cases**		**386**	**41**	**12.7**	**52**	**17.8**	**47**	**14.7**	**87**	**24.4**	**63**	**20.1**	**42**	**13.3**
	Age at baseline	<18	27	1	5.9	_	_	1	5.9	8	30.8	1	5.9	1	5.9
		18-19	20	_	_	2	40.0	1	12.5	4	23.5	1	12.5	_	_
		20-24	88	6	8.7	10	15.6	6	8.7	17	21.3	8	11.6	2	2.9
		25-29	105	13	14.1	15	17.6	15	17.0	22	23.7	17	19.8	20	23.3
		30-34	90	13	15.9	16	19.5	8	9.8	19	22.1	21	25.9	12	14.8
		35+	56	8	14.3	9	16.1	16	29.1	17	30.9	15	28.3	7	12.7

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

				General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
	Years since diagnosis	5-9	56	3	15.0	2	13.3	_	_	18	38.3	1	5.3	_	_
		10-14	121	8	8.0	15	17.9	9	9.2	22	20.2	17	17.5	10	10.3
		15-19	123	16	13.6	18	16.5	19	16.4	26	22.2	22	19.3	14	12.3
		20+	86	14	16.3	17	20.2	19	22.1	21	25.0	23	27.4	18	20.9
	Age at diagnosis	<1	2	_	_	_	_	_	_	_	_	_	_	_	_
		1-4	29	4	14.8	4	28.6	6	22.2	5	18.5	5	18.5	3	11.1
		5-9	91	6	7.4	12	17.6	9	11.1	18	20.0	9	11.3	13	16.3
		10-14	147	18	14.5	21	17.5	15	12.4	26	19.4	26	22.2	15	12.6
		15-20	117	13	14.4	15	16.7	17	19.3	38	36.5	23	26.1	11	12.5
	Treatment	Chemotherapy, no radiation	111	10	9.3	19	20.0	12	11.2	19	17.6	17	16.2	11	10.3
		Radiation, no chemotherapy	1	_	_	_	_	_	_	_	_	_	_	_	_
		Chemotherapy and radiation	237	27	14.4	29	16.9	31	16.9	57	26.8	37	20.4	27	14.9
		Unknown	37	4	14.3	4	16.7	4	14.3	11	31.4	9	33.3	4	14.8
Females	**All cases**		**352**	**37**	**12.3**	**53**	**18.9**	**50**	**16.9**	**88**	**27.0**	**72**	**24.5**	**69**	**23.4**
	Age at baseline	<18	34	_	_	_	_	2	10.0	3	10.0	1	5.3	2	10.5
		18-19	16	4	36.4	2	20.0	1	9.1	2	16.7	3	27.3	4	36.4
		20-24	82	5	8.2	13	21.3	5	8.5	24	33.3	18	30.0	13	21.7
		25-29	99	14	15.4	15	16.7	21	23.6	25	26.6	20	22.5	15	17.0
		30-34	74	5	6.8	9	12.3	9	12.9	19	26.8	18	25.4	21	29.6
		35+	47	9	19.6	14	30.4	12	26.1	15	31.9	12	27.3	14	30.4
	Years since diagnosis	5-9	48	1	10.0	1	20.0	1	11.1	12	36.4	2	22.2	2	22.2
		10-14	126	10	8.4	15	14.6	19	16.2	28	23.1	28	23.9	26	22.4
		15-19	100	15	15.3	22	22.7	17	18.1	26	27.1	21	22.3	23	24.2
		20+	78	11	14.7	15	20.0	13	17.3	22	28.9	21	28.4	18	24.0
	Age at diagnosis	<1	3	_	_	_	_	_	_	_	_	_	_	1	50.0
		1-4	25	2	9.5	4	36.4	2	9.5	5	21.7	3	14.3	2	9.5
		5-9	92	6	7.5	13	18.1	7	8.8	18	20.7	19	23.8	15	18.8
		10-14	131	18	16.4	16	14.7	22	20.8	32	26.7	27	25.2	30	27.8

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

			All cases	General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
				N	%	N	%	N	%	N	%	N	%	N	%
		15-20	101	11	12.5	20	22.7	19	22.4	33	35.5	23	27.4	21	25.0
	Treatment	Surgery only	1	_	_	_	_	_	_	1	100.0	_	_	_	_
		Chemotherapy, no radiation	99	10	10.6	14	16.5	12	13.0	13	14.1	13	14.3	12	13.2
		Radiation, no chemotherapy	1	_	_	_	_	_	_	_	_	_	_	_	_
		Chemotherapy and radiation	226	23	12.1	35	19.7	34	18.4	63	30.1	54	29.2	51	27.4
		Unknown	25	4	23.5	4	25.0	4	23.5	11	45.8	5	29.4	6	35.3

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

				General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**1259**	**151**	**13.3**	**219**	**19.9**	**221**	**19.6**	**370**	**31.8**	**318**	**28.4**	**190**	**16.9**
	Age at baseline	<18	29	_	_	_	_	3	21.4	7	38.9	_	_	1	7.1
		18-19	30	_	_	2	9.5	6	26.1	8	32.0	2	8.7	2	8.7
		20-24	199	21	13.8	35	23.8	28	19.2	48	28.6	33	22.8	24	16.7
		25-29	344	36	11.5	62	20.1	50	16.0	98	30.4	85	27.4	59	18.9
		30-34	374	57	15.8	68	19.3	69	19.1	120	33.5	113	31.9	59	16.6
		35+	283	37	13.5	52	19.3	65	23.7	89	32.6	85	31.0	45	16.4
	Years since diagnosis	5-9	132	5	7.6	15	26.3	13	23.2	38	45.2	10	17.5	10	17.5
		10-14	397	46	12.5	69	19.5	60	16.3	111	29.3	96	26.3	56	15.5
		15-19	423	52	12.8	81	20.5	76	18.6	122	30.4	121	30.0	68	16.8
		20+	307	48	16.1	54	18.4	72	24.2	99	33.0	91	30.8	56	18.7
	Age at diagnosis	1-4	25	_	_	4	22.2	4	16.7	4	17.4	2	8.7	2	8.3
		5-9	168	22	14.2	27	19.0	33	21.4	42	26.9	35	22.9	26	16.8
		10-14	534	68	14.0	96	20.3	97	20.0	167	33.4	142	29.7	91	19.1
		15-20	532	61	12.8	92	19.7	87	18.6	157	32.4	139	29.8	71	15.2
	Treatment	Surgery only	86	5	6.0	12	14.5	9	10.8	25	30.1	22	26.5	7	8.4
		Chemotherapy, no radiation	957	114	13.0	166	19.6	172	19.8	272	30.8	240	27.9	155	18.0
		Radiation, no chemotherapy	10	3	37.5	2	22.2	2	22.2	2	22.2	2	22.2	1	11.1
		Chemotherapy and radiation	83	14	20.9	19	29.7	17	25.8	23	31.1	21	32.8	11	17.2
		Unknown	123	15	14.4	20	20.6	21	20.2	48	41.7	33	31.4	16	15.4
Males	**All cases**		**648**	**74**	**13.0**	**109**	**19.9**	**89**	**15.8**	**157**	**26.6**	**169**	**30.2**	**78**	**14.0**
	Age at baseline	<18	20	_	_	_	_	1	16.7	4	36.4	_	_	_	_
		18-19	12	_	_	_	_	2	25.0	_	_	_	_	_	_
		20-24	95	7	10.1	13	20.0	10	15.6	17	22.4	15	23.4	7	10.9
		25-29	183	21	13.0	33	21.0	23	14.5	46	27.4	51	32.3	28	17.7
		30-34	179	25	14.5	37	21.9	25	14.3	49	28.3	58	33.9	22	12.9
		35+	159	21	13.7	26	17.4	28	18.3	41	26.8	45	29.6	21	13.8
	Years since diagnosis	5-9	74	2	6.7	9	36.0	1	4.3	16	38.1	3	12.5	4	16.7

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

				General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	209	22	11.5	34	18.6	28	14.9	51	26.0	56	29.9	25	13.5
		15-19	211	29	14.3	41	20.8	33	16.0	51	25.1	67	32.8	29	14.3
		20+	154	21	14.3	25	17.5	27	18.2	39	26.0	43	29.9	20	13.6
	Age at diagnosis	1-4	14	_	_	1	8.3	_	_	_	_	_	_	_	_
		5-9	84	10	13.3	11	16.4	18	24.3	17	22.1	15	20.5	10	13.5
		10-14	246	27	12.5	39	18.8	33	15.3	57	24.9	70	32.9	30	14.2
		15-20	304	37	13.9	58	22.1	38	14.5	83	30.5	84	32.2	38	14.6
	Treatment	Surgery only	30	3	10.0	6	20.7	5	16.7	9	31.0	9	30.0	3	10.0
		Chemotherapy, no radiation	489	52	11.8	79	18.8	67	15.5	108	24.3	124	29.0	58	13.6
		Radiation, no chemotherapy	6	2	50.0	1	20.0	1	20.0	1	20.0	1	20.0	_	_
		Chemotherapy and radiation	44	7	20.6	11	33.3	6	18.2	10	26.3	11	34.4	6	18.8
		Unknown	79	10	15.6	12	20.0	10	15.4	29	39.2	24	36.9	11	17.2
Females	**All cases**		**611**	**77**	**13.6**	**110**	**19.9**	**132**	**23.4**	**213**	**37.2**	**149**	**26.6**	**112**	**19.9**
	Age at baseline	<18	9	_	_	_	_	2	25.0	3	42.9	_	_	1	12.5
		18-19	18	_	_	2	15.4	4	26.7	8	53.3	2	13.3	2	13.3
		20-24	104	14	16.9	22	26.8	18	22.0	31	33.7	18	22.2	17	21.3
		25-29	161	15	9.9	29	19.1	27	17.6	52	33.8	34	22.4	31	20.1
		30-34	195	32	17.1	31	16.8	44	23.7	71	38.4	55	30.1	37	20.0
		35+	124	16	13.1	26	21.5	37	30.6	48	40.0	40	32.8	24	19.7
	Years since diagnosis	5-9	58	3	8.3	6	18.8	12	36.4	22	52.4	7	21.2	6	18.2
		10-14	188	24	13.5	35	20.5	32	17.9	60	32.8	40	22.5	31	17.5
		15-19	212	23	11.4	40	20.1	43	21.2	71	35.9	54	27.1	39	19.3
		20+	153	27	17.9	29	19.3	45	30.0	60	40.0	48	31.8	36	23.7
	Age at diagnosis	1-4	11	_	_	3	50.0	4	36.4	4	40.0	2	18.2	2	18.2
		5-9	84	12	15.0	16	21.3	15	18.8	25	31.6	20	25.0	16	19.8
		10-14	288	41	15.3	57	21.5	64	23.8	110	40.6	72	27.2	61	22.9
		15-20	228	24	11.5	34	16.5	49	23.9	74	34.7	55	26.8	33	16.0
	Treatment	Surgery only	56	2	3.7	6	11.1	4	7.5	16	29.6	13	24.5	4	7.5

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

			All cases	General Health [1]		Mental Health [2]		Functional Impairment [3]		Activity Limitation [4]		Pain [5]		Anxiety [6]	
				N	%	N	%	N	%	N	%	N	%	N	%
		Chemotherapy, no radiation	468	62	14.2	87	20.4	105	24.1	164	37.4	116	26.9	97	22.3
		Radiation, no chemotherapy	4	1	25.0	1	25.0	1	25.0	1	25.0	1	25.0	1	25.0
		Chemotherapy and radiation	39	7	21.2	8	25.8	11	33.3	13	36.1	10	31.3	5	15.6
		Unknown	44	5	12.5	8	21.6	11	28.2	19	46.3	9	22.5	5	12.5

CCSS data from the March 2026 data freeze.
Health status definitions adapted from Hudson et al., JAMA 2003;290:1583-1592.
[1] General Health: self-reported fair/poor health (Original: N.15; Expansion: O.21).
[2] Mental Health (age >=18): adverse if any BSI-18 T-score >=63 (Original: J.16-J.35; Expansion: K.1-K.18).
[3] Functional Impairment: help with personal care, routine needs or hold a job (Original: N.10-N.12; Expansion: O.16-O.18).
[4] Activity Limitation: >3 months limitation in moderate activity, climbing stairs, or walking one block (Original: N.14 b,c,e; Expansion: O.20 b, c, e).
[5] Pain: moderate, a lot, or very bad excruciating pain (Original: J.36; Expansion: K.19).
[6] Anxiety: medium, a lot, or very many cancer-related anxieties/fears (Original: J.37; Expansion: K.20).
N=10 participants without baseline data were excluded.

Physical Performance/Activity Limitation: All cancers

				Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**25725**	**853**	**3.6**	**1966**	**8.4**	**2440**	**10.4**	**4265**	**17.8**
	Age at baseline	<18	5688	271	5.5	435	8.9	247	5.0	613	12.4
		18-19	2152	78	4.0	178	9.1	177	9.1	277	13.9
		20-24	6024	184	3.4	444	8.1	617	11.3	917	16.4
		25-29	5571	160	3.1	453	8.8	670	13.0	1004	19.0
		30-34	3885	100	2.7	265	7.2	438	11.9	843	22.4
		35+	2405	60	2.6	191	8.3	291	12.6	611	26.0
	Years since diagnosis	5-9	2592	62	4.2	94	6.4	86	5.9	201	13.3
		10-14	8345	272	3.5	571	7.3	607	7.8	1241	15.7
		15-19	8211	279	3.6	685	8.7	862	11.0	1423	17.8
		20+	6577	240	3.7	616	9.6	885	13.8	1400	21.5
	Age at diagnosis	<1	1933	127	6.8	188	10.1	131	7.0	287	15.2
		1-4	8297	336	4.3	726	9.4	718	9.3	1134	14.5
		5-9	5790	191	3.6	449	8.5	603	11.4	883	16.4
		10-14	5453	116	2.3	357	7.2	574	11.6	1047	20.8
		15-20	4252	83	2.3	246	6.7	414	11.3	914	24.1
	Treatment	Surgery only	2169	79	3.8	173	8.3	204	9.8	345	16.3
		Chemotherapy, no radiation	8166	240	3.1	525	6.8	599	7.7	1263	16.1
		Radiation, no chemotherapy	2086	109	5.9	276	14.9	308	16.7	415	21.5
		Chemotherapy and radiation	10806	348	3.6	811	8.5	1054	11.0	1793	18.4
		Unknown	2498	77	3.4	181	8.0	275	12.2	449	19.7
Males	**All cases**		**13753**	**443**	**3.6**	**945**	**7.6**	**1212**	**9.8**	**1897**	**15.0**
	Age at baseline	<18	3065	152	5.8	215	8.3	130	5.0	316	12.1
		18-19	1122	41	4.1	94	9.3	85	8.4	120	11.6
		20-24	3170	94	3.3	216	7.6	313	11.0	397	13.6
		25-29	3091	79	2.8	229	8.0	341	12.0	445	15.3
		30-34	2072	52	2.7	124	6.4	218	11.2	364	18.3
		35+	1233	25	2.1	67	5.7	125	10.6	255	21.2
	Years since diagnosis	5-9	1455	34	4.4	50	6.5	42	5.5	102	12.7
		10-14	4468	155	3.7	279	6.8	311	7.5	592	14.1

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

Physical Performance/Activity Limitation: All cancers

				Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
			All cases	N	%	N	%	N	%	N	%
		15-19	4314	146	3.5	327	8.0	424	10.3	594	14.1
		20+	3516	108	3.2	289	8.5	435	12.7	609	17.5
	Age at diagnosis	<1	987	64	6.7	99	10.4	61	6.4	141	14.6
		1-4	4344	175	4.4	348	8.7	359	9.0	504	12.4
		5-9	3263	116	3.9	250	8.5	331	11.2	426	14.2
		10-14	2887	53	2.0	141	5.4	273	10.5	424	16.0
		15-20	2272	35	1.8	107	5.6	188	9.8	402	20.3
	Treatment	Surgery only	1070	48	4.7	93	9.1	107	10.5	152	14.6
		Chemotherapy, no radiation	4299	127	3.1	253	6.2	298	7.3	547	13.3
		Radiation, no chemotherapy	1086	48	5.0	125	13.2	149	15.8	180	18.2
		Chemotherapy and radiation	5825	184	3.6	394	7.8	519	10.2	789	15.2
		Unknown	1473	36	2.7	80	6.1	139	10.6	229	17.2
Females	**All cases**		**11972**	**410**	**3.7**	**1021**	**9.2**	**1228**	**11.1**	**2368**	**21.1**
	Age at baseline	<18	2623	119	5.1	220	9.5	117	5.1	297	12.8
		18-19	1030	37	3.9	84	8.9	92	9.7	157	16.3
		20-24	2854	90	3.4	228	8.7	304	11.6	520	19.4
		25-29	2480	81	3.5	224	9.6	329	14.2	559	23.6
		30-34	1813	48	2.8	141	8.2	220	12.7	479	27.0
		35+	1172	35	3.1	124	11.0	166	14.7	356	31.0
	Years since diagnosis	5-9	1137	28	4.0	44	6.4	44	6.4	99	14.0
		10-14	3877	117	3.2	292	8.0	296	8.1	649	17.5
		15-19	3897	133	3.6	358	9.6	438	11.7	829	21.8
		20+	3061	132	4.4	327	11.0	450	15.1	791	26.1
	Age at diagnosis	<1	946	63	6.9	89	9.7	70	7.7	146	15.9
		1-4	3953	161	4.3	378	10.2	359	9.7	630	16.8
		5-9	2527	75	3.2	199	8.5	272	11.6	457	19.2
		10-14	2566	63	2.7	216	9.3	301	12.9	623	26.1
		15-20	1980	48	2.7	139	7.9	226	12.8	512	28.2
	Treatment	Surgery only	1099	31	2.9	80	7.5	97	9.1	193	18.0
		Chemotherapy, no radiation	3867	113	3.1	272	7.4	301	8.2	716	19.2

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

	All cases	Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
		N	%	N	%	N	%	N	%
Radiation, no chemotherapy	1000	61	6.8	151	16.8	159	17.7	235	25.0
Chemotherapy and radiation	4981	164	3.7	417	9.3	535	11.9	1004	22.0
Unknown	1025	41	4.4	101	10.8	136	14.6	220	23.4

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

Physical Performance/Activity Limitation: All leukemias

				Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**7908**	**199**	**2.8**	**451**	**6.3**	**570**	**7.9**	**983**	**13.3**
	Age at baseline	<18	2236	78	4.1	124	6.6	79	4.2	182	9.6
		18-19	844	33	4.3	61	8.0	66	8.7	95	12.0
		20-24	1970	50	2.7	120	6.5	168	9.1	255	13.5
		25-29	1608	19	1.2	83	5.4	141	9.2	229	14.7
		30-34	847	11	1.4	44	5.5	76	9.5	146	17.6
		35+	403	8	2.1	19	4.9	40	10.3	76	19.0
	Years since diagnosis	5-9	981	16	2.7	24	4.1	24	4.1	56	9.4
		10-14	2637	66	2.6	134	5.4	139	5.6	308	12.2
		15-19	2441	68	2.9	155	6.7	210	9.0	326	13.6
		20+	1849	49	2.7	138	7.6	197	10.9	293	15.9
	Age at diagnosis	<1	242	26	11.2	39	16.8	26	11.2	37	15.8
		1-4	3735	115	3.3	258	7.5	264	7.7	391	11.2
		5-9	1931	37	2.1	78	4.4	129	7.3	235	13.1
		10-14	1313	14	1.2	50	4.2	90	7.5	206	17.0
		15-20	687	7	1.2	26	4.4	61	10.4	114	18.5
	Treatment	Surgery only	3	_	_	_	_	_	_	1	50.0
		Chemotherapy, no radiation	3383	103	3.2	208	6.5	227	7.1	388	11.9
		Radiation, no chemotherapy	4	_	_	_	_	_	_	_	_
		Chemotherapy and radiation	3775	77	2.3	205	6.2	279	8.4	489	14.3
		Unknown	743	19	2.8	38	5.6	64	9.5	105	15.4
Males	**All cases**		**4218**	**101**	**2.6**	**220**	**5.8**	**274**	**7.2**	**413**	**10.6**
	Age at baseline	<18	1222	45	4.4	65	6.4	47	4.7	104	10.2
		18-19	454	18	4.4	33	8.0	34	8.3	42	10.0
		20-24	997	21	2.3	54	5.9	74	8.0	92	9.7
		25-29	870	9	1.1	38	4.6	68	8.3	90	10.7
		30-34	449	5	1.2	20	4.7	31	7.2	51	11.6
		35+	226	3	1.4	10	4.6	20	9.1	34	15.2
	Years since diagnosis	5-9	557	8	2.6	14	4.5	15	4.8	33	10.5
		10-14	1415	42	3.1	69	5.2	73	5.4	149	11.0

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

Physical Performance/Activity Limitation: All leukemias

				Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
			All cases	N	%	N	%	N	%	N	%
		15-19	1252	29	2.4	72	6.0	89	7.5	115	9.3
		20+	994	22	2.3	65	6.7	97	10.0	116	11.8
	Age at diagnosis	<1	113	11	10.0	19	17.3	15	13.6	17	15.3
		1-4	1998	59	3.2	126	6.9	130	7.2	171	9.2
		5-9	1041	25	2.7	39	4.2	61	6.5	103	10.8
		10-14	650	4	0.7	21	3.6	39	6.6	72	12.1
		15-20	416	2	0.6	15	4.2	29	8.1	50	13.4
	Treatment	Surgery only	1	_	_	_	_	_	_	_	_
		Chemotherapy, no radiation	1694	59	3.7	110	6.9	118	7.3	167	10.2
		Radiation, no chemotherapy	3	_	_	_	_	_	_	_	_
		Chemotherapy and radiation	2076	36	2.0	98	5.4	132	7.3	212	11.4
		Unknown	444	6	1.5	12	3.0	24	6.0	34	8.4
Females	**All cases**		**3690**	**98**	**2.9**	**231**	**6.8**	**296**	**8.7**	**570**	**16.4**
	Age at baseline	<18	1014	33	3.7	59	6.7	32	3.6	78	8.8
		18-19	390	15	4.2	28	7.9	32	9.1	53	14.4
		20-24	973	29	3.2	66	7.2	94	10.3	163	17.4
		25-29	738	10	1.4	45	6.4	73	10.4	139	19.3
		30-34	398	6	1.6	24	6.3	45	12.0	95	24.4
		35+	177	5	2.9	9	5.3	20	11.8	42	24.0
	Years since diagnosis	5-9	424	8	2.9	10	3.6	9	3.2	23	8.2
		10-14	1222	24	2.1	65	5.6	66	5.7	159	13.5
		15-19	1189	39	3.4	83	7.3	121	10.7	211	18.0
		20+	855	27	3.2	73	8.7	100	12.0	177	20.8
	Age at diagnosis	<1	129	15	12.3	20	16.4	11	8.9	20	16.3
		1-4	1737	56	3.4	132	8.1	134	8.3	220	13.3
		5-9	890	12	1.5	39	4.7	68	8.3	132	15.7
		10-14	663	10	1.7	29	4.8	51	8.5	134	21.6
		15-20	271	5	2.2	11	4.8	32	13.9	64	26.6
	Treatment	Surgery only	2	_	_	_	_	_	_	1	100.0
		Chemotherapy, no radiation	1689	44	2.7	98	6.1	109	6.8	221	13.7

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

			Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
		All cases	N	%	N	%	N	%	N	%
	Radiation, no chemotherapy	1	_	_	_	_	_	_	_	_
	Chemotherapy and radiation	1699	41	2.7	107	7.0	147	9.7	277	17.6
	Unknown	299	13	4.8	26	9.5	40	14.6	71	25.7

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

Physical Performance/Activity Limitation: ALL

				Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**6646**	**139**	**2.3**	**323**	**5.3**	**438**	**7.2**	**802**	**12.9**
	Age at baseline	<18	1941	49	3.0	83	5.1	60	3.7	151	9.2
		18-19	730	23	3.5	40	6.0	51	7.7	81	11.8
		20-24	1693	35	2.2	84	5.3	130	8.2	217	13.2
		25-29	1338	16	1.3	67	5.2	118	9.2	195	14.9
		30-34	657	10	1.6	35	5.6	56	9.0	112	17.4
		35+	287	6	2.2	14	5.0	23	8.2	46	16.2
	Years since diagnosis	5-9	844	13	2.5	20	3.8	23	4.4	48	9.1
		10-14	2222	47	2.2	95	4.5	105	5.0	255	11.9
		15-19	2024	43	2.2	101	5.2	153	8.0	261	13.1
		20+	1556	36	2.4	107	7.1	157	10.3	238	15.4
	Age at diagnosis	<1	134	9	7.3	17	13.7	14	11.2	21	16.7
		1-4	3322	81	2.6	187	6.1	210	6.9	340	10.9
		5-9	1696	32	2.1	62	4.0	109	7.0	208	13.1
		10-14	1027	12	1.3	38	4.0	70	7.5	157	16.4
		15-20	467	5	1.2	19	4.6	35	8.6	76	18.0
	Treatment	Chemotherapy, no radiation	2699	57	2.2	120	4.6	150	5.8	304	11.6
		Radiation, no chemotherapy	4	_	_	_	_	_	_	_	_
		Chemotherapy and radiation	3306	67	2.3	171	5.9	239	8.2	412	13.7
		Unknown	637	15	2.6	32	5.5	49	8.4	86	14.7
Males	**All cases**		**3576**	**67**	**2.1**	**152**	**4.7**	**204**	**6.3**	**342**	**10.3**
	Age at baseline	<18	1061	27	3.1	39	4.5	34	3.9	87	9.9
		18-19	397	12	3.3	20	5.6	26	7.2	38	10.3
		20-24	858	12	1.5	34	4.2	48	6.0	75	9.0
		25-29	736	8	1.1	34	4.9	60	8.6	80	11.2
		30-34	354	5	1.5	17	5.0	24	7.1	40	11.6
		35+	170	3	1.8	8	4.8	12	7.2	22	13.0
	Years since diagnosis	5-9	480	7	2.5	12	4.3	14	5.0	28	9.9
		10-14	1201	28	2.4	47	4.1	55	4.8	129	11.2
		15-19	1052	17	1.7	44	4.4	60	6.0	92	8.9

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

				Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
			All cases	N	%	N	%	N	%	N	%
		20+	843	15	1.8	49	6.0	75	9.1	93	11.1
	Age at diagnosis	<1	65	3	4.8	8	12.9	8	12.9	10	15.9
		1-4	1769	35	2.2	81	5.0	96	6.0	147	9.0
		5-9	924	23	2.8	32	3.8	49	5.9	93	10.9
		10-14	527	4	0.8	19	3.9	35	7.2	59	12.1
		15-20	291	2	0.8	12	4.7	16	6.2	33	12.4
	Treatment	Chemotherapy, no radiation	1349	32	2.5	62	4.8	70	5.4	132	10.1
		Radiation, no chemotherapy	3	_	_	_	_	_	_	_	_
		Chemotherapy and radiation	1839	30	1.9	79	4.9	116	7.3	182	11.1
		Unknown	385	5	1.4	11	3.2	18	5.2	28	8.0
Females	**All cases**		**3070**	**72**	**2.5**	**171**	**6.0**	**234**	**8.3**	**460**	**15.9**
	Age at baseline	<18	880	22	2.9	44	5.7	26	3.4	64	8.3
		18-19	333	11	3.6	20	6.6	25	8.2	43	13.5
		20-24	835	23	2.9	50	6.4	82	10.4	142	17.5
		25-29	602	8	1.4	33	5.7	58	10.0	115	19.5
		30-34	303	5	1.7	18	6.2	32	11.2	72	24.1
		35+	117	3	2.7	6	5.4	11	9.8	24	20.9
	Years since diagnosis	5-9	364	6	2.4	8	3.3	9	3.6	20	8.1
		10-14	1021	19	2.0	48	4.9	50	5.2	126	12.8
		15-19	972	26	2.8	57	6.2	93	10.0	169	17.6
		20+	713	21	3.0	58	8.3	82	11.8	145	20.5
	Age at diagnosis	<1	69	6	9.7	9	14.5	6	9.5	11	17.5
		1-4	1553	46	3.2	106	7.3	114	7.8	193	13.0
		5-9	772	9	1.3	30	4.2	60	8.4	115	15.7
		10-14	500	8	1.8	19	4.2	35	7.7	98	20.9
		15-20	176	3	2.0	7	4.6	19	12.6	43	27.4
	Treatment	Chemotherapy, no radiation	1350	25	1.9	58	4.5	80	6.2	172	13.2
		Radiation, no chemotherapy	1	_	_	_	_	_	_	_	_
		Chemotherapy and radiation	1467	37	2.8	92	7.0	123	9.4	230	16.8
		Unknown	252	10	4.3	21	9.1	31	13.3	58	24.8

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

Physical Performance/Activity Limitation: AML

				Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**930**	**51**	**5.9**	**107**	**12.4**	**105**	**12.2**	**131**	**14.9**
	Age at baseline	<18	231	27	13.0	36	17.5	17	8.2	22	10.5
		18-19	89	8	9.6	19	22.9	13	15.7	12	14.3
		20-24	199	11	6.0	31	16.9	33	17.9	31	16.9
		25-29	201	2	1.1	10	5.3	16	8.5	21	10.8
		30-34	134	1	0.8	7	5.3	15	11.4	24	18.2
		35+	76	2	2.8	4	5.6	11	15.7	21	28.0
	Years since diagnosis	5-9	85	3	6.1	4	8.2	1	2.0	6	11.5
		10-14	320	18	5.9	33	10.9	28	9.2	39	12.6
		15-19	323	20	6.4	46	14.7	46	14.7	47	15.0
		20+	202	10	5.0	24	12.1	30	15.3	39	19.3
	Age at diagnosis	<1	93	15	16.1	19	20.4	11	11.8	14	15.1
		1-4	315	29	9.7	60	20.3	46	15.5	36	12.0
		5-9	172	3	1.9	14	8.8	15	9.4	20	12.6
		10-14	199	2	1.1	9	4.9	14	7.6	33	17.7
		15-20	151	2	1.5	5	3.8	19	14.6	28	20.1
	Treatment	Surgery only	3	_	_	_	_	_	_	1	50.0
		Chemotherapy, no radiation	558	39	7.4	77	14.6	65	12.3	68	12.8
		Chemotherapy and radiation	296	9	3.3	26	9.7	30	11.2	47	17.2
		Unknown	73	3	4.5	4	6.1	10	15.6	15	22.1
Males	**All cases**		**456**	**28**	**6.7**	**57**	**13.8**	**56**	**13.4**	**48**	**11.3**
	Age at baseline	<18	126	17	15.3	23	21.1	13	11.8	11	9.8
		18-19	45	5	12.5	12	30.0	7	17.5	3	7.3
		20-24	95	6	7.0	17	20.0	22	25.6	13	15.1
		25-29	90	_	_	1	1.2	3	3.5	6	6.8
		30-34	65	_	_	3	4.7	7	10.9	8	12.5
		35+	35	_	_	1	3.2	4	12.9	7	20.6
	Years since diagnosis	5-9	50	1	4.2	2	8.3	1	4.2	3	12.0
		10-14	160	13	8.5	20	13.2	16	10.5	14	9.0
		15-19	149	9	6.1	23	15.9	22	15.1	13	8.8

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

				Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
			All cases	N	%	N	%	N	%	N	%
		20+	97	5	5.3	12	12.8	17	18.1	18	18.6
	Age at diagnosis	<1	40	7	17.5	9	22.5	7	17.5	6	15.0
		1-4	172	21	12.7	39	24.1	30	18.3	15	9.0
		5-9	79	_	_	5	7.1	7	10.0	7	10.0
		10-14	82	_	_	2	2.7	3	4.1	9	12.0
		15-20	83	_	_	2	2.9	9	13.0	11	14.9
	Treatment	Surgery only	1	_	_	_	_	_	_	_	_
		Chemotherapy, no radiation	269	23	9.1	42	16.9	40	15.9	25	9.8
		Chemotherapy and radiation	146	5	3.8	15	11.5	13	10.0	19	14.3
		Unknown	40	_	_	_	_	3	8.8	4	10.8
Females	**All cases**		**474**	**23**	**5.1**	**50**	**11.1**	**49**	**11.0**	**83**	**18.4**
	Age at baseline	<18	105	10	10.3	13	13.4	4	4.1	11	11.3
		18-19	44	3	7.0	7	16.3	6	14.0	9	20.9
		20-24	104	5	5.2	14	14.3	11	11.2	18	18.6
		25-29	111	2	1.9	9	8.7	13	12.7	15	14.2
		30-34	69	1	1.5	4	5.9	8	11.8	16	23.5
		35+	41	2	5.0	3	7.5	7	17.9	14	34.1
	Years since diagnosis	5-9	35	2	8.0	2	8.0	_	_	3	11.1
		10-14	160	5	3.3	13	8.5	12	7.8	25	16.2
		15-19	174	11	6.6	23	13.8	24	14.4	34	20.5
		20+	105	5	4.8	12	11.5	13	12.7	21	20.0
	Age at diagnosis	<1	53	8	15.1	10	18.9	4	7.5	8	15.1
		1-4	143	8	6.0	21	15.7	16	12.0	21	15.7
		5-9	93	3	3.4	9	10.0	8	8.9	13	14.6
		10-14	117	2	1.8	7	6.3	11	10.0	24	21.6
		15-20	68	2	3.3	3	4.9	10	16.4	17	26.2
	Treatment	Surgery only	2	_	_	_	_	_	_	1	100.0
		Chemotherapy, no radiation	289	16	5.8	35	12.6	25	9.0	43	15.4
		Chemotherapy and radiation	150	4	2.9	11	7.9	17	12.3	28	19.9
		Unknown	33	3	9.7	4	12.9	7	23.3	11	35.5

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

Physical Performance/Activity Limitation: All CNS

				Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**4498**	**418**	**10.4**	**884**	**22.0**	**919**	**22.8**	**1003**	**24.6**
	Age at baseline	<18	953	122	16.1	196	25.9	87	11.5	186	24.6
		18-19	376	31	9.4	71	21.5	60	18.3	62	18.5
		20-24	1182	106	9.9	231	21.5	249	23.2	253	23.2
		25-29	1086	88	8.7	228	22.6	293	29.0	259	25.2
		30-34	625	46	7.7	104	17.5	153	25.6	161	26.5
		35+	276	25	9.6	54	20.8	77	29.5	82	30.7
	Years since diagnosis	5-9	464	31	13.7	47	20.7	30	13.2	49	21.1
		10-14	1540	125	8.9	243	17.3	232	16.5	302	21.2
		15-19	1416	129	9.5	311	23.1	317	23.5	323	23.6
		20+	1078	133	12.7	283	27.1	340	32.5	329	31.0
	Age at diagnosis	<1	219	59	29.9	78	39.6	41	20.8	64	32.3
		1-4	1323	156	12.9	309	25.7	253	21.0	315	25.9
		5-9	1407	123	9.6	288	22.6	306	24.0	295	23.0
		10-14	1069	55	5.7	157	16.3	222	23.1	230	23.5
		15-20	480	25	6.3	52	13.4	97	24.8	99	24.1
	Treatment	Surgery only	1275	63	5.2	136	11.2	165	13.6	215	17.4
		Chemotherapy, no radiation	355	44	13.2	70	21.1	56	16.9	73	21.8
		Radiation, no chemotherapy	1170	101	9.7	250	24.1	260	25.1	272	25.6
		Chemotherapy and radiation	1256	176	16.7	347	33.0	332	31.5	346	32.7
		Unknown	442	34	8.7	81	20.7	106	27.2	97	24.4
Males	**All cases**		**2455**	**229**	**10.5**	**454**	**20.9**	**474**	**21.9**	**495**	**22.4**
	Age at baseline	<18	529	73	17.5	106	25.4	50	11.9	99	23.7
		18-19	191	15	9.1	36	22.0	26	16.0	28	16.6
		20-24	634	59	10.5	116	20.6	128	22.8	123	21.5
		25-29	619	42	7.3	123	21.4	154	26.8	131	22.4
		30-34	333	26	8.3	50	16.0	83	26.7	79	24.7
		35+	149	14	10.1	23	16.5	33	23.7	35	24.5
	Years since diagnosis	5-9	264	16	13.3	26	21.7	15	12.5	23	18.3
		10-14	832	77	10.3	137	18.3	128	17.1	159	21.0

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

				Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
			All cases	N	%	N	%	N	%	N	%
		15-19	772	73	10.0	152	20.8	167	22.9	158	21.3
		20+	587	63	11.0	139	24.3	164	28.8	155	26.8
	Age at diagnosis	<1	128	34	28.8	45	38.5	21	17.9	39	33.1
		1-4	699	84	13.3	151	23.8	126	19.9	155	24.3
		5-9	786	71	10.1	162	23.0	165	23.4	149	21.0
		10-14	571	27	5.3	67	13.2	112	22.1	104	20.3
		15-20	271	13	6.2	29	13.9	50	24.0	48	21.4
	Treatment	Surgery only	650	40	6.5	77	12.6	87	14.2	101	16.1
		Chemotherapy, no radiation	191	23	12.9	38	21.5	32	18.1	37	20.8
		Radiation, no chemotherapy	616	45	8.5	113	21.2	123	23.3	119	21.8
		Chemotherapy and radiation	744	104	16.5	188	30.0	177	28.2	182	29.0
		Unknown	254	17	7.6	38	17.1	55	24.7	56	24.8
Females	**All cases**		**2043**	**189**	**10.1**	**430**	**23.2**	**445**	**23.9**	**508**	**27.0**
	Age at baseline	<18	424	49	14.4	90	26.5	37	10.9	87	25.7
		18-19	185	16	9.6	35	21.1	34	20.6	34	20.4
		20-24	548	47	9.2	115	22.5	121	23.6	130	25.1
		25-29	467	46	10.5	105	24.1	139	31.9	128	28.8
		30-34	292	20	7.0	54	19.1	70	24.5	82	28.5
		35+	127	11	9.0	31	25.6	44	36.1	47	37.9
	Years since diagnosis	5-9	200	15	14.0	21	19.6	15	14.0	26	24.5
		10-14	708	48	7.3	106	16.2	104	15.9	143	21.5
		15-19	644	56	9.0	159	25.7	150	24.2	165	26.4
		20+	491	70	14.7	144	30.4	176	36.9	174	35.9
	Age at diagnosis	<1	91	25	31.6	33	41.3	20	25.0	25	31.3
		1-4	624	72	12.6	158	27.8	127	22.2	160	27.8
		5-9	621	52	9.1	126	22.1	141	24.7	146	25.4
		10-14	498	28	6.1	90	19.7	110	24.1	126	27.2
		15-20	209	12	6.5	23	12.8	47	25.7	51	27.4
	Treatment	Surgery only	625	23	3.8	59	9.8	78	12.9	114	18.8
		Chemotherapy, no radiation	164	21	13.5	32	20.8	24	15.5	36	22.9

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

			Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
		All cases	N	%	N	%	N	%	N	%
	Radiation, no chemotherapy	554	56	11.0	137	27.1	137	27.0	153	29.7
	Chemotherapy and radiation	512	72	16.8	159	37.5	155	36.3	164	38.2
	Unknown	188	17	10.1	43	25.4	51	30.5	41	24.0

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

Physical Performance/Activity Limitation: Astrocytomas

				Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**2694**	**256**	**10.4**	**497**	**20.3**	**527**	**21.5**	**599**	**24.1**
	Age at baseline	<18	528	75	17.2	102	23.6	46	10.5	105	24.1
		18-19	215	16	8.2	43	22.2	32	16.5	34	17.1
		20-24	715	65	9.9	127	19.4	140	21.4	154	23.1
		25-29	665	58	9.3	131	21.1	178	28.8	160	25.5
		30-34	387	25	6.8	61	16.6	84	22.8	94	24.9
		35+	184	17	9.7	33	19.1	47	27.0	52	29.1
	Years since diagnosis	5-9	238	18	14.3	25	19.8	19	15.1	24	18.6
		10-14	906	80	9.6	133	16.0	128	15.4	175	20.8
		15-19	831	72	9.0	168	21.2	164	20.6	187	23.3
		20+	719	86	12.4	171	24.7	216	31.2	213	30.1
	Age at diagnosis	<1	151	47	35.6	60	45.5	29	21.8	49	36.8
		1-4	802	89	12.0	160	21.7	147	19.8	185	24.7
		5-9	794	64	8.7	144	19.6	153	20.9	163	22.1
		10-14	642	37	6.2	102	17.2	138	23.4	136	22.7
		15-20	305	19	7.6	31	12.7	60	24.2	66	25.2
	Treatment	Surgery only	1049	50	5.0	101	10.1	126	12.5	174	17.0
		Chemotherapy, no radiation	255	31	13.1	51	21.7	44	18.6	54	22.6
		Radiation, no chemotherapy	730	76	11.7	168	26.1	176	27.3	180	27.4
		Chemotherapy and radiation	374	74	24.1	119	39.0	112	36.7	125	40.8
		Unknown	286	25	9.7	58	22.7	69	27.0	66	25.4
Males	**All cases**		**1409**	**134**	**10.6**	**244**	**19.4**	**260**	**20.7**	**281**	**21.9**
	Age at baseline	<18	279	47	20.5	53	23.2	27	11.7	58	25.2
		18-19	109	5	5.3	22	23.2	13	13.7	14	14.0
		20-24	355	33	10.4	59	18.6	66	20.8	67	20.8
		25-29	372	26	7.6	67	19.5	91	26.7	76	21.8
		30-34	196	14	7.7	29	16.0	45	24.9	45	23.9
		35+	98	9	9.9	14	15.6	18	20.0	21	22.6
	Years since diagnosis	5-9	126	10	15.9	13	20.6	9	14.3	9	13.4
		10-14	479	50	11.7	79	18.5	74	17.2	92	21.1

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

				Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
			All cases	N	%	N	%	N	%	N	%
		15-19	422	34	8.5	71	17.9	78	19.7	80	19.8
		20+	382	40	10.8	81	22.0	99	27.0	100	26.7
	Age at diagnosis	<1	86	25	32.9	32	42.7	15	19.7	30	39.5
		1-4	404	47	12.6	70	18.8	65	17.4	87	23.1
		5-9	422	36	9.4	82	21.5	80	21.0	77	19.9
		10-14	329	17	5.7	46	15.5	70	23.7	59	19.6
		15-20	168	9	6.9	14	10.9	30	23.3	28	20.0
	Treatment	Surgery only	525	32	6.5	58	11.7	68	13.8	79	15.6
		Chemotherapy, no radiation	142	15	11.5	27	20.8	25	19.2	27	20.6
		Radiation, no chemotherapy	371	33	10.3	73	23.0	79	24.9	74	22.6
		Chemotherapy and radiation	212	42	24.1	58	33.5	53	30.6	63	36.4
		Unknown	159	12	8.5	28	20.0	35	24.8	38	26.4
Females	**All cases**		**1285**	**122**	**10.2**	**253**	**21.3**	**267**	**22.4**	**318**	**26.4**
	Age at baseline	<18	249	28	13.5	49	23.9	19	9.2	47	22.8
		18-19	106	11	11.1	21	21.2	19	19.2	20	20.2
		20-24	360	32	9.5	68	20.2	74	21.9	87	25.3
		25-29	293	32	11.5	64	23.1	87	31.5	84	30.1
		30-34	191	11	5.9	32	17.1	39	20.7	49	25.9
		35+	86	8	9.5	19	22.9	29	34.5	31	36.0
	Years since diagnosis	5-9	112	8	12.7	12	19.0	10	15.9	15	24.2
		10-14	427	30	7.4	54	13.4	54	13.4	83	20.4
		15-19	409	38	9.5	97	24.4	86	21.6	107	26.8
		20+	337	46	14.1	90	27.7	117	35.8	113	33.8
	Age at diagnosis	<1	65	22	39.3	28	49.1	14	24.6	19	33.3
		1-4	398	42	11.4	90	24.7	82	22.3	98	26.3
		5-9	372	28	7.9	62	17.6	73	20.7	86	24.4
		10-14	313	20	6.7	56	18.9	68	23.0	77	25.8
		15-20	137	10	8.3	17	14.5	30	25.2	38	31.1
	Treatment	Surgery only	524	18	3.5	43	8.4	58	11.3	95	18.4
		Chemotherapy, no radiation	113	16	15.1	24	22.9	19	17.9	27	25.0

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

			Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
		All cases	N	%	N	%	N	%	N	%
	Radiation, no chemotherapy	359	43	13.1	95	29.2	97	29.7	106	32.0
	Chemotherapy and radiation	162	32	24.1	61	46.2	59	44.7	62	46.6
	Unknown	127	13	11.3	30	25.9	34	29.6	28	24.1

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

Physical Performance/Activity Limitation: Medulloblastoma/PNET

				Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**1040**	**105**	**11.5**	**261**	**28.6**	**259**	**28.3**	**250**	**27.3**
	Age at baseline	<18	246	31	17.5	62	35.0	27	15.3	50	28.6
		18-19	82	8	11.4	16	22.9	15	21.7	18	25.7
		20-24	292	28	10.6	73	27.5	85	32.1	61	23.0
		25-29	252	19	7.9	70	29.2	73	30.2	66	27.0
		30-34	131	14	11.0	29	23.0	44	34.6	41	32.3
		35+	37	5	14.3	11	30.6	15	41.7	14	38.9
	Years since diagnosis	5-9	124	9	18.4	16	32.7	6	12.2	13	27.1
		10-14	355	27	8.4	68	21.1	65	20.2	78	24.1
		15-19	344	34	10.3	92	28.1	101	30.8	83	25.2
		20+	217	35	16.3	85	39.5	87	40.3	76	35.2
	Age at diagnosis	<1	28	7	25.9	9	33.3	7	25.9	9	33.3
		1-4	298	47	17.4	104	38.5	76	28.4	85	31.6
		5-9	422	40	10.8	109	29.7	113	30.6	90	24.3
		10-14	230	9	4.5	31	15.4	51	25.2	52	25.7
		15-20	62	2	4.1	8	16.3	12	24.5	14	28.6
	Treatment	Surgery only	8	1	12.5	3	37.5	4	50.0	4	50.0
		Chemotherapy, no radiation	53	6	11.8	8	15.7	8	15.7	11	21.6
		Radiation, no chemotherapy	208	11	5.9	45	23.8	43	22.9	42	21.9
		Chemotherapy and radiation	694	85	14.1	195	32.6	185	30.8	184	30.7
		Unknown	77	2	3.0	10	14.9	19	28.4	9	13.4
Males	**All cases**		**631**	**67**	**12.1**	**151**	**27.3**	**152**	**27.5**	**142**	**25.6**
	Age at baseline	<18	147	18	16.7	35	32.4	16	14.8	28	26.4
		18-19	47	7	18.9	9	24.3	8	22.2	11	29.7
		20-24	185	20	12.0	43	25.9	52	31.3	38	22.8
		25-29	157	10	6.7	43	28.9	41	27.3	38	25.2
		30-34	73	9	12.7	15	21.1	25	35.2	20	28.2
		35+	22	3	14.3	6	27.3	10	45.5	7	31.8
	Years since diagnosis	5-9	76	4	13.3	10	33.3	2	6.7	9	31.0
		10-14	208	19	10.2	37	19.9	38	20.4	43	23.2

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

				Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
			All cases	N	%	N	%	N	%	N	%
		15-19	217	26	12.4	53	25.5	61	29.3	52	24.6
		20+	130	18	14.1	51	39.5	51	39.5	38	29.5
	Age at diagnosis	<1	16	6	37.5	7	43.8	4	25.0	6	37.5
		1-4	180	28	17.1	59	36.0	48	29.4	47	28.7
		5-9	266	26	11.3	67	29.1	65	28.1	57	24.6
		10-14	132	5	4.4	11	9.6	26	22.8	24	21.2
		15-20	37	2	6.9	7	24.1	9	31.0	8	27.6
	Treatment	Surgery only	5	_	_	2	40.0	2	40.0	3	60.0
		Chemotherapy, no radiation	27	5	18.5	7	25.9	5	18.5	6	22.2
		Radiation, no chemotherapy	116	6	5.8	23	22.1	23	22.1	25	23.6
		Chemotherapy and radiation	436	55	14.5	117	31.0	113	29.9	106	28.1
		Unknown	47	1	2.6	2	5.1	9	23.1	2	5.1
Females	**All cases**		**409**	**38**	**10.5**	**110**	**30.5**	**107**	**29.6**	**108**	**29.8**
	Age at baseline	<18	99	13	18.8	27	39.1	11	16.2	22	31.9
		18-19	35	1	3.0	7	21.2	7	21.2	7	21.2
		20-24	107	8	8.1	30	30.3	33	33.3	23	23.5
		25-29	95	9	9.8	27	29.7	32	34.8	28	30.1
		30-34	58	5	8.9	14	25.5	19	33.9	21	37.5
		35+	15	2	14.3	5	35.7	5	35.7	7	50.0
	Years since diagnosis	5-9	48	5	26.3	6	31.6	4	21.1	4	21.1
		10-14	147	8	5.8	31	22.6	27	19.9	35	25.4
		15-19	127	8	6.7	39	32.8	40	33.3	31	26.1
		20+	87	17	19.5	34	39.5	36	41.4	38	43.7
	Age at diagnosis	<1	12	1	9.1	2	18.2	3	27.3	3	27.3
		1-4	118	19	17.9	45	42.5	28	26.7	38	36.2
		5-9	156	14	10.1	42	30.7	48	34.8	33	23.9
		10-14	98	4	4.5	20	23.0	25	28.4	28	31.5
		15-20	25	_	_	1	5.0	3	15.0	6	30.0
	Treatment	Surgery only	3	1	33.3	1	33.3	2	66.7	1	33.3
		Chemotherapy, no radiation	26	1	4.2	1	4.2	3	12.5	5	20.8

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

			Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
		All cases	N	%	N	%	N	%	N	%
	Radiation, no chemotherapy	92	5	5.9	22	25.9	20	23.8	17	19.8
	Chemotherapy and radiation	258	30	13.5	78	35.3	72	32.3	78	35.1
	Unknown	30	1	3.6	8	28.6	10	35.7	7	25.0

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

				Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**3111**	**32**	**1.2**	**100**	**3.6**	**185**	**6.7**	**501**	**17.5**
	Age at baseline	<18	61	1	2.1	1	2.1	_	_	4	8.3
		18-19	61	1	1.9	2	3.8	2	3.8	6	11.1
		20-24	375	2	0.7	4	1.4	12	4.1	32	10.3
		25-29	798	6	0.9	22	3.2	39	5.7	103	14.4
		30-34	951	13	1.5	32	3.7	69	7.9	169	18.7
		35+	865	9	1.1	39	4.8	63	7.7	187	22.3
	Years since diagnosis	5-9	242	2	1.7	2	1.7	4	3.3	17	12.6
		10-14	946	8	0.9	25	3.0	42	5.0	123	14.0
		15-19	1008	14	1.5	36	3.9	69	7.4	180	18.7
		20+	915	8	0.9	37	4.2	70	8.0	181	20.4
	Age at diagnosis	1-4	82	2	2.6	5	6.4	5	6.5	10	12.5
		5-9	421	3	0.8	7	1.8	26	6.6	43	10.8
		10-14	1120	8	0.8	35	3.5	64	6.3	171	16.4
		15-20	1488	19	1.5	53	4.1	90	7.0	277	20.6
	Treatment	Surgery only	2	_	_	_	_	_	_	1	50.0
		Chemotherapy, no radiation	364	4	1.2	9	2.7	22	6.5	54	15.5
		Radiation, no chemotherapy	652	3	0.5	18	3.1	28	4.9	107	17.3
		Chemotherapy and radiation	1765	21	1.3	60	3.8	112	7.1	279	17.4
		Unknown	328	4	1.4	13	4.6	23	8.1	60	20.7
Males	**All cases**		**1634**	**14**	**1.0**	**35**	**2.4**	**82**	**5.7**	**198**	**13.4**
	Age at baseline	<18	46	_	_	_	_	_	_	1	2.9
		18-19	48	_	_	1	2.4	2	4.8	5	11.4
		20-24	239	2	1.1	4	2.1	9	4.8	24	12.1
		25-29	445	5	1.3	8	2.1	19	5.0	43	10.9
		30-34	482	5	1.1	12	2.7	32	7.3	68	15.1
		35+	374	2	0.6	10	2.9	20	5.7	57	16.0
	Years since diagnosis	5-9	138	2	3.2	2	3.2	3	4.8	8	11.3
		10-14	491	4	0.9	8	1.9	18	4.2	55	12.3
		15-19	537	6	1.2	10	2.0	27	5.5	64	12.6

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

				Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
			All cases	N	%	N	%	N	%	N	%
		20+	468	2	0.4	15	3.3	34	7.6	71	15.7
	Age at diagnosis	1-4	62	1	1.7	4	6.8	5	8.6	8	13.3
		5-9	305	1	0.4	4	1.4	20	7.1	29	10.1
		10-14	581	4	0.8	10	1.9	23	4.4	63	11.7
		15-20	686	8	1.4	17	3.0	34	6.0	98	16.6
	Treatment	Surgery only	2	_	_	_	_	_	_	1	50.0
		Chemotherapy, no radiation	187	3	1.8	5	2.9	12	7.1	19	10.8
		Radiation, no chemotherapy	336	1	0.3	9	3.0	16	5.3	44	13.8
		Chemotherapy and radiation	915	8	1.0	16	2.0	41	5.2	102	12.6
		Unknown	194	2	1.2	5	3.0	13	7.8	32	18.7
Females	**All cases**		**1477**	**18**	**1.3**	**65**	**4.8**	**103**	**7.6**	**303**	**21.8**
	Age at baseline	<18	15	1	7.7	1	7.7	_	_	3	23.1
		18-19	13	1	10.0	1	10.0	_	_	1	10.0
		20-24	136	_	_	_	_	3	2.8	8	7.1
		25-29	353	1	0.3	14	4.5	20	6.4	60	18.7
		30-34	469	8	1.8	20	4.6	37	8.5	101	22.3
		35+	491	7	1.5	29	6.2	43	9.1	130	27.1
	Years since diagnosis	5-9	104	_	_	_	_	1	1.7	9	14.1
		10-14	455	4	1.0	17	4.1	24	5.7	68	15.8
		15-19	471	8	1.8	26	5.9	42	9.5	116	25.3
		20+	447	6	1.4	22	5.1	36	8.4	110	25.2
	Age at diagnosis	1-4	20	1	5.3	1	5.3	_	_	2	10.0
		5-9	116	2	1.8	3	2.7	6	5.4	14	12.4
		10-14	539	4	0.8	25	5.1	41	8.4	108	21.4
		15-20	802	11	1.5	36	5.0	56	7.7	179	23.8
	Treatment	Chemotherapy, no radiation	177	1	0.6	4	2.4	10	5.9	35	20.2
		Radiation, no chemotherapy	316	2	0.7	9	3.3	12	4.4	63	20.9
		Chemotherapy and radiation	850	13	1.7	44	5.6	71	9.0	177	22.2
		Unknown	134	2	1.7	8	6.8	10	8.5	28	23.5

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

				Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**2117**	**31**	**1.6**	**87**	**4.3**	**159**	**7.9**	**290**	**14.3**
	Age at baseline	<18	212	4	2.1	11	5.8	8	4.3	19	10.0
		18-19	132	_	_	4	3.4	4	3.4	13	10.8
		20-24	469	6	1.4	17	3.9	33	7.5	45	10.1
		25-29	572	9	1.6	24	4.4	47	8.6	79	14.3
		30-34	483	8	1.7	20	4.2	49	10.4	80	16.8
		35+	249	4	1.7	11	4.5	18	7.4	54	22.0
	Years since diagnosis	5-9	144	2	2.1	3	3.2	5	5.4	7	7.1
		10-14	671	5	0.8	22	3.4	38	5.9	74	11.5
		15-19	730	14	2.0	36	5.1	69	9.7	103	14.4
		20+	572	10	1.8	26	4.6	47	8.4	106	18.7
	Age at diagnosis	<1	15	_	_	1	7.1	1	7.1	1	7.1
		1-4	347	9	2.7	21	6.2	17	5.0	38	11.2
		5-9	649	7	1.1	21	3.4	43	7.0	78	12.5
		10-14	672	7	1.1	26	4.1	59	9.3	104	16.2
		15-20	434	8	2.0	18	4.5	39	9.7	69	16.9
	Treatment	Surgery only	16	_	_	2	14.3	2	14.3	3	21.4
		Chemotherapy, no radiation	1077	15	1.4	40	3.8	78	7.5	146	13.9
		Radiation, no chemotherapy	38	_	_	_	_	_	_	_	_
		Chemotherapy and radiation	767	10	1.4	34	4.8	63	8.9	110	15.3
		Unknown	219	6	2.9	11	5.2	16	7.5	31	14.6
Males	**All cases**		**1437**	**19**	**1.4**	**44**	**3.2**	**101**	**7.4**	**168**	**12.2**
	Age at baseline	<18	146	3	2.3	5	3.8	5	3.9	10	7.7
		18-19	97	_	_	2	2.3	2	2.3	9	10.0
		20-24	304	4	1.4	10	3.5	19	6.7	21	7.3
		25-29	407	6	1.5	15	3.9	32	8.3	48	12.2
		30-34	319	5	1.6	11	3.6	35	11.4	51	16.3
		35+	164	1	0.6	1	0.6	8	5.0	29	17.9
	Years since diagnosis	5-9	109	1	1.3	2	2.6	3	3.9	6	7.6
		10-14	456	3	0.7	9	2.1	24	5.6	38	8.7

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

				Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
			All cases	N	%	N	%	N	%	N	%
		15-19	480	10	2.1	22	4.7	44	9.4	60	12.7
		20+	392	5	1.3	11	2.9	30	7.8	64	16.5
	Age at diagnosis	<1	5	_	_	_	_	_	_	_	_
		1-4	235	6	2.6	10	4.4	9	3.9	21	9.2
		5-9	451	6	1.4	15	3.5	29	6.8	49	11.3
		10-14	462	5	1.1	14	3.2	40	9.2	58	13.1
		15-20	284	2	0.8	5	1.9	23	8.8	40	15.2
	Treatment	Surgery only	13	_	_	1	9.1	2	18.2	3	27.3
		Chemotherapy, no radiation	728	11	1.6	22	3.1	50	7.2	85	12.1
		Radiation, no chemotherapy	28	_	_	_	_	_	_	_	_
		Chemotherapy and radiation	511	4	0.9	14	3.0	37	7.9	60	12.5
		Unknown	157	4	2.6	7	4.6	12	7.8	20	13.1
Females	**All cases**		**680**	**12**	**1.9**	**43**	**6.7**	**58**	**9.0**	**122**	**18.7**
	Age at baseline	<18	66	1	1.7	6	10.0	3	5.0	9	15.0
		18-19	35	_	_	2	6.7	2	6.7	4	13.3
		20-24	165	2	1.3	7	4.6	14	9.2	24	15.3
		25-29	165	3	1.9	9	5.8	15	9.5	31	19.5
		30-34	164	3	1.8	9	5.5	14	8.5	29	17.7
		35+	85	3	3.7	10	12.2	10	12.2	25	30.1
	Years since diagnosis	5-9	35	1	5.9	1	5.9	2	11.8	1	5.3
		10-14	215	2	1.0	13	6.2	14	6.7	36	17.1
		15-19	250	4	1.7	14	5.8	25	10.3	43	17.6
		20+	180	5	2.8	15	8.5	17	9.6	42	23.5
	Age at diagnosis	<1	10	_	_	1	10.0	1	10.0	1	10.0
		1-4	112	3	2.7	11	9.9	8	7.3	17	15.3
		5-9	198	1	0.5	6	3.2	14	7.4	29	15.3
		10-14	210	2	1.0	12	6.1	19	9.7	46	23.2
		15-20	150	6	4.3	13	9.2	16	11.3	29	20.1
	Treatment	Surgery only	3	_	_	1	33.3	_	_	_	_
		Chemotherapy, no radiation	349	4	1.2	18	5.3	28	8.2	61	17.8

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

			Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
		All cases	N	%	N	%	N	%	N	%
	Radiation, no chemotherapy	10	_	_	_	_	_	_	_	_
	Chemotherapy and radiation	256	6	2.5	20	8.5	26	11.1	50	20.8
	Unknown	62	2	3.4	4	6.8	4	6.8	11	18.6

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

Physical Performance/Activity Limitation: Wilms

				Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**2277**	**22**	**1.0**	**54**	**2.5**	**101**	**4.6**	**252**	**11.4**
	Age at baseline	<18	832	14	1.8	22	2.8	23	2.9	65	8.2
		18-19	305	3	1.0	8	2.7	14	4.7	37	12.3
		20-24	670	2	0.3	11	1.7	37	5.7	73	11.2
		25-29	374	3	0.8	12	3.3	24	6.6	64	17.5
		30-34	77	_	_	1	1.3	2	2.6	12	15.6
		35+	19	_	_	_	_	1	5.6	1	5.3
	Years since diagnosis	5-9	176	1	0.7	2	1.4	4	2.8	13	9.2
		10-14	739	13	1.8	24	3.3	26	3.6	64	8.8
		15-19	759	4	0.5	13	1.8	32	4.3	76	10.2
		20+	603	4	0.7	15	2.5	39	6.6	99	16.6
	Age at diagnosis	<1	331	4	1.3	8	2.5	12	3.8	34	10.5
		1-4	1396	14	1.0	30	2.2	61	4.5	150	11.0
		5-9	468	4	0.9	14	3.2	24	5.4	57	12.8
		10-14	59	_	_	1	1.8	2	3.6	9	16.4
		15-20	23	_	_	1	5.6	2	11.1	2	10.5
	Treatment	Surgery only	35	1	2.9	1	2.9	1	2.9	3	8.6
		Chemotherapy, no radiation	873	10	1.2	23	2.7	26	3.1	74	8.6
		Radiation, no chemotherapy	4	_	_	_	_	_	_	1	25.0
		Chemotherapy and radiation	1155	11	1.0	26	2.4	61	5.5	147	13.3
		Unknown	210	_	_	4	2.0	13	6.4	27	13.2
Males	**All cases**		**1019**	**12**	**1.2**	**25**	**2.5**	**45**	**4.6**	**93**	**9.4**
	Age at baseline	<18	403	8	2.1	9	2.3	8	2.1	29	7.6
		18-19	126	2	1.6	5	4.0	6	4.8	12	9.6
		20-24	285	1	0.4	5	1.8	22	8.0	29	10.4
		25-29	165	1	0.6	5	3.1	8	5.1	18	11.3
		30-34	32	_	_	1	3.1	1	3.1	5	15.6
		35+	8	_	_	_	_	_	_	_	_
	Years since diagnosis	5-9	79	1	1.6	1	1.6	1	1.6	6	9.8
		10-14	333	6	1.9	8	2.5	10	3.1	26	8.0

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

				Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
			All cases	N	%	N	%	N	%	N	%
		15-19	334	4	1.2	7	2.1	16	4.9	28	8.5
		20+	273	1	0.4	9	3.4	18	6.7	33	12.2
	Age at diagnosis	<1	169	3	1.8	5	3.0	6	3.7	13	7.8
		1-4	628	7	1.1	13	2.1	24	3.9	53	8.6
		5-9	192	2	1.1	7	4.0	15	8.5	24	13.4
		10-14	21	_	_	_	_	_	_	2	11.1
		15-20	9	_	_	_	_	_	_	1	14.3
	Treatment	Surgery only	19	1	5.3	1	5.3	1	5.3	1	5.3
		Chemotherapy, no radiation	396	6	1.6	12	3.1	9	2.3	23	5.9
		Chemotherapy and radiation	499	5	1.1	10	2.1	29	6.1	54	11.3
		Unknown	105	_	_	2	2.0	6	6.1	15	14.9
Females	**All cases**		**1258**	**10**	**0.8**	**29**	**2.4**	**56**	**4.6**	**159**	**13.0**
	Age at baseline	<18	429	6	1.5	13	3.2	15	3.7	36	8.8
		18-19	179	1	0.6	3	1.7	8	4.5	25	14.2
		20-24	385	1	0.3	6	1.6	15	4.1	44	11.7
		25-29	209	2	1.0	7	3.4	16	7.8	46	22.4
		30-34	45	_	_	_	_	1	2.2	7	15.6
		35+	11	_	_	_	_	1	10.0	1	9.1
	Years since diagnosis	5-9	97	_	_	1	1.2	3	3.7	7	8.6
		10-14	406	7	1.8	16	4.0	16	4.0	38	9.5
		15-19	425	_	_	6	1.5	16	3.9	48	11.6
		20+	330	3	0.9	6	1.9	21	6.5	66	20.2
	Age at diagnosis	<1	162	1	0.6	3	1.9	6	3.8	21	13.4
		1-4	768	7	0.9	17	2.3	37	5.0	97	13.0
		5-9	276	2	0.7	7	2.6	9	3.4	33	12.3
		10-14	38	_	_	1	2.7	2	5.4	7	18.9
		15-20	14	_	_	1	9.1	2	18.2	1	8.3
	Treatment	Surgery only	16	_	_	_	_	_	_	2	12.5
		Chemotherapy, no radiation	477	4	0.9	11	2.3	17	3.6	51	10.8
		Radiation, no chemotherapy	4	_	_	_	_	_	_	1	25.0

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

			Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
		All cases	N	%	N	%	N	%	N	%
Chemotherapy and radiation		656	6	1.0	16	2.6	32	5.1	93	14.8
Unknown		105	_	_	2	1.9	7	6.8	12	11.7

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

				Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**1954**	**56**	**3.1**	**111**	**6.1**	**115**	**6.3**	**276**	**14.9**
	Age at baseline	<18	957	35	4.0	58	6.6	32	3.7	106	12.0
		18-19	237	7	3.1	17	7.5	16	7.0	32	13.8
		20-24	544	10	1.9	24	4.6	50	9.7	99	18.7
		25-29	172	2	1.2	10	6.1	14	8.6	29	17.2
		30-34	36	_	_	_	_	1	2.9	7	19.4
		35+	8	2	25.0	2	25.0	2	25.0	3	37.5
	Years since diagnosis	5-9	160	4	4.4	8	8.9	3	3.3	14	15.6
		10-14	610	23	3.9	38	6.5	25	4.3	78	13.2
		15-19	639	20	3.2	41	6.6	41	6.6	88	13.9
		20+	545	9	1.7	24	4.5	46	8.7	96	17.7
	Age at diagnosis	<1	993	31	3.2	52	5.3	44	4.5	132	13.4
		1-4	764	22	3.1	53	7.5	58	8.2	117	16.3
		5-9	148	_	_	1	0.9	7	6.3	16	14.0
		10-14	30	1	4.2	3	12.5	3	13.0	5	20.0
		15-20	19	2	16.7	2	16.7	3	25.0	6	46.2
	Treatment	Surgery only	548	10	1.9	21	3.9	18	3.4	54	10.0
		Chemotherapy, no radiation	562	20	3.6	38	6.9	29	5.3	72	13.1
		Radiation, no chemotherapy	138	2	1.6	6	4.7	15	11.9	23	16.9
		Chemotherapy and radiation	532	20	4.4	40	8.8	44	9.7	100	21.6
		Unknown	174	4	2.5	6	3.7	9	5.5	27	16.6
Males	**All cases**		**953**	**22**	**2.5**	**47**	**5.3**	**54**	**6.1**	**118**	**13.1**
	Age at baseline	<18	479	13	3.0	22	5.0	13	3.0	51	11.6
		18-19	104	3	3.0	8	8.0	8	8.0	12	11.9
		20-24	275	4	1.6	12	4.7	23	9.0	40	15.1
		25-29	78	1	1.4	4	5.5	8	11.1	11	14.5
		30-34	14	_	_	_	_	1	7.7	3	21.4
		35+	3	1	33.3	1	33.3	1	33.3	1	33.3
	Years since diagnosis	5-9	75	2	5.0	3	7.5	1	2.5	7	17.5
		10-14	304	8	2.7	13	4.5	12	4.2	38	13.0

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

				Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
			All cases	N	%	N	%	N	%	N	%
		15-19	308	8	2.7	18	6.1	19	6.4	33	10.9
		20+	266	4	1.6	13	5.1	22	8.6	40	15.2
	Age at diagnosis	<1	516	13	2.6	28	5.6	18	3.6	66	12.9
		1-4	344	8	2.5	18	5.7	28	8.9	40	12.5
		5-9	74	_	_	_	_	5	10.0	8	15.1
		10-14	13	_	_	_	_	1	12.5	2	20.0
		15-20	6	1	25.0	1	25.0	2	50.0	2	50.0
	Treatment	Surgery only	263	6	2.3	12	4.7	10	3.9	26	10.0
		Chemotherapy, no radiation	279	7	2.6	17	6.3	12	4.5	29	10.7
		Radiation, no chemotherapy	62	_	_	2	3.6	7	12.7	12	19.4
		Chemotherapy and radiation	259	8	3.7	14	6.5	18	8.3	35	15.8
		Unknown	90	1	1.2	2	2.4	7	8.3	16	19.0
Females	**All cases**		**1001**	**34**	**3.6**	**64**	**6.8**	**61**	**6.5**	**158**	**16.5**
	Age at baseline	<18	478	22	5.0	36	8.2	19	4.3	55	12.5
		18-19	133	4	3.1	9	7.0	8	6.2	20	15.3
		20-24	269	6	2.3	12	4.6	27	10.4	59	22.3
		25-29	94	1	1.1	6	6.5	6	6.6	18	19.4
		30-34	22	_	_	_	_	_	_	4	18.2
		35+	5	1	20.0	1	20.0	1	20.0	2	40.0
	Years since diagnosis	5-9	85	2	4.0	5	10.0	2	4.0	7	14.0
		10-14	306	15	5.1	25	8.4	13	4.4	40	13.5
		15-19	331	12	3.7	23	7.1	22	6.7	55	16.7
		20+	279	5	1.8	11	4.0	24	8.8	56	20.1
	Age at diagnosis	<1	477	18	3.8	24	5.1	26	5.5	66	14.0
		1-4	420	14	3.6	35	8.9	30	7.7	77	19.3
		5-9	74	_	_	1	1.6	2	3.3	8	13.1
		10-14	17	1	6.7	3	20.0	2	13.3	3	20.0
		15-20	13	1	12.5	1	12.5	1	12.5	4	44.4
	Treatment	Surgery only	285	4	1.4	9	3.2	8	2.9	28	10.0
		Chemotherapy, no radiation	283	13	4.7	21	7.6	17	6.1	43	15.4

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

			Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
		All cases	N	%	N	%	N	%	N	%
	Radiation, no chemotherapy	76	2	2.8	4	5.6	8	11.3	11	14.9
	Chemotherapy and radiation	273	12	5.0	26	10.8	26	10.9	65	26.7
	Unknown	84	3	3.8	4	5.1	2	2.5	11	13.9

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

				Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**1760**	**36**	**2.2**	**95**	**5.9**	**133**	**8.3**	**280**	**17.2**
	Age at baseline	<18	341	15	5.0	19	6.4	13	4.4	41	13.7
		18-19	125	2	1.8	13	11.5	9	8.0	18	15.8
		20-24	425	3	0.8	16	4.3	34	9.2	68	17.9
		25-29	393	9	2.5	22	6.1	38	10.4	58	15.5
		30-34	299	5	1.8	14	4.9	21	7.4	56	19.4
		35+	177	2	1.2	11	6.4	18	10.5	39	22.4
	Years since diagnosis	5-9	182	5	4.5	3	2.7	4	3.6	12	10.5
		10-14	521	14	2.9	33	6.9	31	6.5	75	15.4
		15-19	541	8	1.6	22	4.3	37	7.2	92	17.6
		20+	516	9	1.8	37	7.4	61	12.2	101	19.9
	Age at diagnosis	<1	124	7	5.8	10	8.3	7	5.8	18	14.8
		1-4	562	14	2.7	39	7.5	49	9.4	95	18.1
		5-9	397	6	1.6	17	4.6	31	8.5	61	16.4
		10-14	348	3	1.0	15	4.9	22	7.1	45	14.2
		15-20	329	6	2.1	14	4.9	24	8.4	61	20.8
	Treatment	Surgery only	171	3	1.9	8	5.0	9	5.7	28	17.0
		Chemotherapy, no radiation	361	10	2.9	17	5.0	12	3.5	53	15.4
		Radiation, no chemotherapy	63	3	5.5	1	1.8	2	3.6	9	15.5
		Chemotherapy and radiation	974	15	1.7	58	6.6	93	10.7	157	17.7
		Unknown	191	5	2.9	11	6.4	17	9.9	33	19.0
Males	**All cases**		**951**	**19**	**2.2**	**48**	**5.6**	**69**	**8.0**	**126**	**14.4**
	Age at baseline	<18	192	9	5.6	7	4.3	5	3.1	20	12.2
		18-19	66	2	3.3	9	15.0	5	8.3	10	16.4
		20-24	242	1	0.5	9	4.2	22	10.4	39	17.9
		25-29	208	5	2.6	14	7.3	19	9.6	20	10.1
		30-34	159	2	1.3	8	5.3	12	8.0	22	14.5
		35+	84	_	_	1	1.2	6	7.3	15	17.9
	Years since diagnosis	5-9	100	4	7.3	2	3.6	2	3.6	8	13.6
		10-14	288	6	2.3	15	5.7	16	6.1	39	14.6

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

				Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
			All cases	N	%	N	%	N	%	N	%
		15-19	282	5	1.9	13	4.9	20	7.5	37	13.6
		20+	281	4	1.4	18	6.6	31	11.2	42	15.1
	Age at diagnosis	<1	52	3	5.9	2	3.9	1	2.0	6	11.5
		1-4	331	9	3.0	22	7.3	30	9.9	51	16.6
		5-9	225	4	1.9	12	5.8	14	6.8	26	12.5
		10-14	186	2	1.2	9	5.4	15	9.0	20	11.7
		15-20	157	1	0.7	3	2.2	9	6.7	23	16.5
	Treatment	Surgery only	74	1	1.5	1	1.5	2	3.0	7	9.7
		Chemotherapy, no radiation	212	4	2.0	5	2.5	5	2.5	24	11.8
		Radiation, no chemotherapy	32	2	6.9	_	_	1	3.4	4	13.3
		Chemotherapy and radiation	524	9	1.9	36	7.7	53	11.4	75	15.9
		Unknown	109	3	3.1	6	6.3	8	8.4	16	16.3
Females	**All cases**		**809**	**17**	**2.3**	**47**	**6.3**	**64**	**8.6**	**154**	**20.5**
	Age at baseline	<18	149	6	4.4	12	8.8	8	5.8	21	15.4
		18-19	59	_	_	4	7.5	4	7.5	8	15.1
		20-24	183	2	1.3	7	4.4	12	7.5	29	17.9
		25-29	185	4	2.4	8	4.7	19	11.3	38	21.6
		30-34	140	3	2.2	6	4.5	9	6.8	34	25.0
		35+	93	2	2.2	10	11.1	12	13.3	24	26.7
	Years since diagnosis	5-9	82	1	1.8	1	1.8	2	3.6	4	7.3
		10-14	233	8	3.7	18	8.5	15	7.0	36	16.5
		15-19	259	3	1.2	9	3.6	17	6.9	55	22.0
		20+	235	5	2.2	19	8.4	30	13.3	59	25.7
	Age at diagnosis	<1	72	4	5.7	8	11.4	6	8.6	12	17.1
		1-4	231	5	2.3	17	7.8	19	8.8	44	20.1
		5-9	172	2	1.3	5	3.1	17	10.7	35	21.3
		10-14	162	1	0.7	6	4.2	7	4.9	25	17.1
		15-20	172	5	3.3	11	7.3	15	9.9	38	24.7
	Treatment	Surgery only	97	2	2.2	7	7.6	7	7.7	21	22.6
		Chemotherapy, no radiation	149	6	4.3	12	8.5	7	5.0	29	20.6

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

			Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
		All cases	N	%	N	%	N	%	N	%
	Radiation, no chemotherapy	31	1	3.8	1	3.8	1	3.8	5	17.9
	Chemotherapy and radiation	450	6	1.5	22	5.4	40	9.9	82	19.8
	Unknown	82	2	2.6	5	6.6	9	11.8	17	22.4

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

				Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**2100**	**59**	**3.2**	**184**	**10.0**	**258**	**14.0**	**680**	**36.3**
	Age at baseline	<18	96	2	3.6	4	7.1	5	8.9	10	17.9
		18-19	72	1	2.1	2	4.3	6	12.8	14	29.2
		20-24	389	5	1.7	21	7.1	34	11.6	92	30.4
		25-29	568	24	4.7	52	10.3	74	14.6	183	35.5
		30-34	567	17	3.1	50	9.2	67	12.4	212	38.7
		35+	408	10	2.5	55	13.8	72	18.1	169	42.0
	Years since diagnosis	5-9	243	1	1.1	5	5.6	12	13.5	33	32.7
		10-14	681	18	2.9	52	8.4	74	12.0	217	34.8
		15-19	677	22	3.4	71	11.0	87	13.4	235	35.8
		20+	499	18	3.7	56	11.5	85	17.5	195	39.6
	Age at diagnosis	<1	9	_	_	_	_	_	_	1	11.1
		1-4	88	4	5.0	11	13.8	11	13.8	18	22.5
		5-9	369	11	3.3	23	6.9	37	11.1	98	29.3
		10-14	842	28	3.8	70	9.4	112	15.1	277	36.7
		15-20	792	16	2.3	80	11.7	98	14.4	286	41.1
	Treatment	Surgery only	119	2	1.7	5	4.3	9	7.9	40	34.2
		Chemotherapy, no radiation	1191	34	3.1	120	11.0	149	13.7	403	36.4
		Radiation, no chemotherapy	17	_	_	1	7.1	3	21.4	3	21.4
		Chemotherapy and radiation	582	18	3.8	41	8.7	70	14.8	165	34.4
		Unknown	191	5	3.2	17	11.0	27	17.5	69	44.2
Males	**All cases**		**1086**	**27**	**2.9**	**72**	**7.7**	**113**	**12.1**	**286**	**30.1**
	Age at baseline	<18	48	1	4.2	1	4.2	2	8.3	2	8.3
		18-19	36	1	5.3	_	_	2	10.5	2	10.0
		20-24	194	2	1.4	6	4.2	16	11.2	29	19.5
		25-29	299	10	3.9	22	8.6	33	12.8	84	31.8
		30-34	284	9	3.3	22	8.1	23	8.5	85	31.3
		35+	225	4	1.8	21	9.6	37	16.9	84	37.8
	Years since diagnosis	5-9	133	_	_	_	_	2	4.7	11	21.6
		10-14	349	9	3.0	20	6.6	30	9.9	88	28.4

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

				Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
			All cases	N	%	N	%	N	%	N	%
		15-19	349	11	3.3	33	9.8	42	12.5	99	29.3
		20+	255	7	2.8	19	7.6	39	15.6	88	34.9
	Age at diagnosis	<1	4	_	_	_	_	_	_	_	_
		1-4	47	1	2.3	4	9.1	7	15.9	5	11.4
		5-9	189	7	4.1	11	6.6	22	13.1	38	22.5
		10-14	403	11	3.2	20	5.8	43	12.4	103	29.1
		15-20	443	8	2.2	37	9.9	41	11.1	140	36.8
	Treatment	Surgery only	48	_	_	1	2.1	5	10.6	13	27.1
		Chemotherapy, no radiation	612	14	2.5	44	8.0	60	10.9	163	29.1
		Radiation, no chemotherapy	9	_	_	1	14.3	2	28.6	1	14.3
		Chemotherapy and radiation	297	10	4.3	18	7.8	32	13.8	69	29.0
		Unknown	120	3	3.1	8	8.2	14	14.4	40	40.8
Females	**All cases**		**1014**	**32**	**3.5**	**112**	**12.3**	**145**	**15.9**	**394**	**42.7**
	Age at baseline	<18	48	1	3.1	3	9.4	3	9.4	8	25.0
		18-19	36	_	_	2	7.1	4	14.3	12	42.9
		20-24	195	3	2.0	15	10.0	18	11.9	63	40.9
		25-29	269	14	5.6	30	12.0	41	16.4	99	39.3
		30-34	283	8	3.0	28	10.4	44	16.3	127	46.0
		35+	183	6	3.4	34	19.0	35	19.6	85	47.2
	Years since diagnosis	5-9	110	1	2.2	5	10.9	10	21.7	22	44.0
		10-14	332	9	2.9	32	10.2	44	14.0	129	41.1
		15-19	328	11	3.5	38	12.2	45	14.4	136	42.8
		20+	244	11	4.6	37	15.5	46	19.4	107	44.6
	Age at diagnosis	<1	5	_	_	_	_	_	_	1	20.0
		1-4	41	3	8.3	7	19.4	4	11.1	13	36.1
		5-9	180	4	2.4	12	7.3	15	9.1	60	36.4
		10-14	439	17	4.3	50	12.7	69	17.4	174	43.5
		15-20	349	8	2.6	43	13.9	57	18.4	146	46.2
	Treatment	Surgery only	71	2	3.0	4	6.0	4	6.0	27	39.1
		Chemotherapy, no radiation	579	20	3.7	76	14.1	89	16.5	240	44.0

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

			Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
		All cases	N	%	N	%	N	%	N	%
	Radiation, no chemotherapy	8	_	_	_	_	1	14.3	2	28.6
	Chemotherapy and radiation	285	8	3.3	23	9.7	38	15.8	96	39.7
	Unknown	71	2	3.4	9	15.5	13	22.8	29	50.0

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

Physical Performance/Activity Limitation: Ewings

				Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**738**	**22**	**3.6**	**52**	**8.5**	**78**	**12.7**	**183**	**29.3**
	Age at baseline	<18	61	1	2.7	2	5.4	3	8.1	3	8.1
		18-19	36	_	_	_	_	2	10.5	3	15.8
		20-24	170	3	2.3	7	5.5	10	7.8	38	29.2
		25-29	204	10	5.6	21	11.9	30	16.9	55	30.4
		30-34	164	2	1.3	8	5.3	12	7.8	44	28.2
		35+	103	6	5.9	14	13.9	21	20.8	40	39.2
	Years since diagnosis	5-9	104	_	_	1	3.6	_	_	6	20.0
		10-14	247	6	2.8	15	7.0	27	12.5	57	26.0
		15-19	223	9	4.2	20	9.5	26	12.3	64	29.8
		20+	164	7	4.3	16	9.9	25	15.5	56	34.8
	Age at diagnosis	<1	5	_	_	_	_	_	_	_	_
		1-4	54	2	4.2	5	10.4	8	16.7	9	18.8
		5-9	183	5	3.1	7	4.3	12	7.5	39	24.4
		10-14	278	8	3.5	21	9.3	30	13.1	67	28.8
		15-20	218	7	4.0	19	11.0	28	16.2	68	38.0
	Treatment	Surgery only	1	_	_	_	_	_	_	1	100.0
		Chemotherapy, no radiation	210	4	2.0	14	7.0	16	8.0	38	18.9
		Radiation, no chemotherapy	2	_	_	_	_	_	_	_	_
		Chemotherapy and radiation	463	16	4.3	33	9.0	54	14.6	126	33.4
		Unknown	62	2	4.4	5	11.1	8	17.8	18	40.0
Males	**All cases**		**386**	**10**	**3.1**	**24**	**7.5**	**37**	**11.6**	**83**	**25.6**
	Age at baseline	<18	27	_	_	1	5.9	1	5.9	1	5.9
		18-19	20	_	_	_	_	1	12.5	2	25.0
		20-24	88	2	2.9	3	4.3	6	8.7	15	21.7
		25-29	105	4	4.5	8	9.1	13	14.8	24	26.4
		30-34	90	2	2.4	4	4.9	5	6.1	19	22.9
		35+	56	2	3.6	8	14.5	11	20.0	22	39.3
	Years since diagnosis	5-9	56	_	_	_	_	_	_	4	20.0
		10-14	121	2	2.0	5	5.1	9	9.2	22	21.8

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

				Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
			All cases	N	%	N	%	N	%	N	%
		15-19	123	6	5.2	11	9.5	14	12.1	30	25.6
		20+	86	2	2.3	8	9.3	14	16.3	27	31.4
	Age at diagnosis	<1	2	_	_	_	_	_	_	_	_
		1-4	29	1	3.7	3	11.1	6	22.2	4	14.8
		5-9	91	3	3.7	4	4.9	8	9.9	14	17.5
		10-14	147	3	2.5	8	6.6	12	9.9	33	26.6
		15-20	117	3	3.4	9	10.2	11	12.5	32	35.2
	Treatment	Chemotherapy, no radiation	111	2	1.9	7	6.5	7	6.5	21	19.6
		Radiation, no chemotherapy	1	_	_	_	_	_	_	_	_
		Chemotherapy and radiation	237	8	4.4	15	8.2	26	14.2	52	27.7
		Unknown	37	_	_	2	7.1	4	14.3	10	35.7
Females	**All cases**		**352**	**12**	**4.0**	**28**	**9.5**	**41**	**13.8**	**100**	**33.2**
	Age at baseline	<18	34	1	5.0	1	5.0	2	10.0	2	10.0
		18-19	16	_	_	_	_	1	9.1	1	9.1
		20-24	82	1	1.7	4	6.8	4	6.7	23	37.7
		25-29	99	6	6.7	13	14.6	17	19.1	31	34.4
		30-34	74	_	_	4	5.7	7	9.9	25	34.2
		35+	47	4	8.7	6	13.0	10	21.7	18	39.1
	Years since diagnosis	5-9	48	_	_	1	11.1	_	_	2	20.0
		10-14	126	4	3.4	10	8.5	18	15.3	35	29.7
		15-19	100	3	3.1	9	9.6	12	12.6	34	34.7
		20+	78	5	6.7	8	10.7	11	14.7	29	38.7
	Age at diagnosis	<1	3	_	_	_	_	_	_	_	_
		1-4	25	1	4.8	2	9.5	2	9.5	5	23.8
		5-9	92	2	2.5	3	3.8	4	5.0	25	31.3
		10-14	131	5	4.6	13	12.3	18	16.7	34	31.2
		15-20	101	4	4.7	10	11.8	17	20.0	36	40.9
	Treatment	Surgery only	1	_	_	_	_	_	_	1	100.0
		Chemotherapy, no radiation	99	2	2.2	7	7.6	9	9.8	17	18.1
		Radiation, no chemotherapy	1	_	_	_	_	_	_	_	_

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

			Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
		All cases	N	%	N	%	N	%	N	%
Chemotherapy and radiation		226	8	4.3	18	9.7	28	15.0	74	39.2
Unknown		25	2	11.8	3	17.6	4	23.5	8	47.1

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

				Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**1259**	**35**	**3.1**	**125**	**11.0**	**169**	**14.9**	**472**	**41.0**
	Age at baseline	<18	29	1	7.1	1	7.1	2	14.3	5	35.7
		18-19	30	1	4.3	2	8.7	4	17.4	10	41.7
		20-24	199	2	1.4	13	8.9	22	15.1	52	34.0
		25-29	344	14	4.5	30	9.6	42	13.5	126	39.7
		30-34	374	13	3.6	40	11.0	52	14.4	160	44.0
		35+	283	4	1.5	39	14.2	47	17.1	119	42.8
	Years since diagnosis	5-9	132	1	1.8	4	7.0	11	19.6	27	40.9
		10-14	397	11	3.0	35	9.5	45	12.3	151	40.8
		15-19	423	12	2.9	49	12.0	58	14.1	164	39.9
		20+	307	11	3.7	37	12.3	55	18.5	130	42.9
	Age at diagnosis	1-4	25	2	8.3	4	16.7	2	8.3	7	29.2
		5-9	168	6	3.9	15	9.8	25	16.2	57	36.5
		10-14	534	19	3.9	48	9.9	76	15.6	202	41.0
		15-20	532	8	1.7	58	12.4	66	14.1	206	43.2
	Treatment	Surgery only	86	1	1.2	4	4.8	7	8.4	32	38.1
		Chemotherapy, no radiation	957	29	3.3	104	12.0	131	15.1	361	40.8
		Radiation, no chemotherapy	10	_	_	_	_	2	22.2	2	22.2
		Chemotherapy and radiation	83	2	3.0	5	7.6	13	19.7	27	40.3
		Unknown	123	3	2.9	12	11.4	16	15.4	50	47.2
Males	**All cases**		**648**	**17**	**3.0**	**44**	**7.8**	**72**	**12.7**	**195**	**33.7**
	Age at baseline	<18	20	1	16.7	_	_	1	16.7	1	16.7
		18-19	12	1	12.5	_	_	1	12.5	_	_
		20-24	95	_	_	2	3.1	9	14.1	14	20.3
		25-29	183	6	3.8	13	8.2	19	11.9	59	36.2
		30-34	179	7	4.0	17	9.7	18	10.3	63	36.0
		35+	159	2	1.3	12	7.8	24	15.6	58	37.2
	Years since diagnosis	5-9	74	_	_	_	_	1	4.3	7	23.3
		10-14	209	7	3.7	14	7.4	21	11.2	64	33.5
		15-19	211	5	2.4	21	10.2	28	13.6	67	32.5

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.

				Needs Help w/ Personal Care (N.10/O.16)		Needs Help w/ Routine Needs (N.11/O.17)		Cannot Work or Attend School (N.12/O.18)		Performance Limitation [1]	
			All cases	N	%	N	%	N	%	N	%
		20+	154	5	3.4	9	6.0	22	14.8	57	37.7
	Age at diagnosis	1-4	14	_	_	_	_	_	_	1	7.7
		5-9	84	4	5.4	6	8.2	14	18.9	23	30.7
		10-14	246	8	3.7	12	5.6	29	13.4	68	30.8
		15-20	304	5	1.9	26	9.8	29	11.1	103	38.3
	Treatment	Surgery only	30	_	_	1	3.3	5	16.7	10	33.3
		Chemotherapy, no radiation	489	12	2.8	37	8.5	53	12.2	142	32.1
		Radiation, no chemotherapy	6	_	_	_	_	1	20.0	1	20.0
		Chemotherapy and radiation	44	2	6.1	_	_	5	15.2	13	38.2
		Unknown	79	3	4.6	6	9.2	8	12.3	29	43.9
Females	**All cases**		**611**	**18**	**3.2**	**81**	**14.3**	**97**	**17.2**	**277**	**48.4**
	Age at baseline	<18	9	_	_	1	12.5	1	12.5	4	50.0
		18-19	18	_	_	2	13.3	3	20.0	10	66.7
		20-24	104	2	2.4	11	13.4	13	15.9	38	45.2
		25-29	161	8	5.2	17	11.1	23	15.0	67	43.5
		30-34	195	6	3.2	23	12.3	34	18.3	97	51.3
		35+	124	2	1.7	27	22.3	23	19.0	61	50.0
	Years since diagnosis	5-9	58	1	3.0	4	12.1	10	30.3	20	55.6
		10-14	188	4	2.2	21	11.7	24	13.4	87	48.6
		15-19	212	7	3.4	28	13.8	30	14.7	97	47.3
		20+	153	6	4.0	28	18.5	33	22.1	73	48.0
	Age at diagnosis	1-4	11	2	18.2	4	36.4	2	18.2	6	54.5
		5-9	84	2	2.5	9	11.3	11	13.8	34	42.0
		10-14	288	11	4.1	36	13.3	47	17.5	134	49.3
		15-20	228	3	1.5	32	15.6	37	18.0	103	49.5
	Treatment	Surgery only	56	1	1.9	3	5.7	2	3.8	22	40.7
		Chemotherapy, no radiation	468	17	3.9	67	15.4	78	17.9	219	49.7
		Radiation, no chemotherapy	4	_	_	_	_	1	25.0	1	25.0
		Chemotherapy and radiation	39	_	_	5	15.2	8	24.2	14	42.4
		Unknown	44	_	_	6	15.0	8	20.5	21	52.5

CCSS data from the March 2026 data freeze.
Physical performance measures adapted from Ness, et al., Ann Intern Med 2005; 143:639-647.
[1] Performance Limitation was not assessed for participants who died before baseline.
To compute Performance Limitation, each of the 6 questions in N.14/O.20 was assigned a score of 1 to 3, with 1 indicating limited for more than 3 months. The 6 scores were added and dichotomized; a total score less than 16 indicates limitation.
N=10 participants without baseline data were excluded.